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The 2020 Diabetes Poland guidelines  
— summary of the most important changes
Since 2005, the Diabetes Poland (PTD, Polskie Towarzystwo Diabetologiczne) prepares and publishes annually 
its guidelines on the management of diabetic patients. The idea of guideline development was first suggested in 
2004 by Prof. Jacek Sieradzki who was the president of PTD at that time. The first chairperson of the PTD Guideline 
Writing Group was Prof. Władysław Grzeszczak who acted in this capacity in 2005–2011, followed by the next 
president of PTD, in 2011–2015, Prof. Leszek Czupryniak. In 2015–2019, the coordinator of the Recommendations 
Team was prof. Dorota Zozulińska-Ziółkiewicz, plenipotentiary of the Main Board of of the Diabetes Poland for 
Clinical Guidelines.
The guidelines are a product of a team of about 50 experts representing numerous medical specialties. They 
cover multiple key aspects of clinical diabetes care.
Guideline chapters were prepared by teams coordinated by their leaders.
The goal of this expert teamwork and the resulting guideline publication is to improve prevention, diagnosis, 
and management of diabetes and its complications in Poland. The PTD guidelines reflect advances in diabetology, 
including new clinical and experimental study findings, epidemiological observations, and registry data. Thus, 
some modifications and novel aspects appear every year. However, as the guidelines have always been based on 
the principles of evidence-based medicine, only minor changes are required, related to new knowledge from reli-
able research with major implications for clinical practice.
Summary of the most important changes to the 2019 Diabetes Poland guidelines
In Chapter 2, the information has been added that in patients with pre-diabetes (IFG or IGT) weight loss 
should be about 7%, and that the goals of treating concomitant diseases for people with pre-diabetes are the 
same as for the general population.
In Chapter 3, the information about the need to perform in patient treated only with diet a 4-point blood 
glucose profile once a month and single measurements once a week at various times of the day has been removed 
from Table 3.1.
In Chapter 4, a table with glycemic targets for patients with type 1 and type 2 diabetes and for pregnant wom-
en who regularly use continuous glucose monitoring (CGM) or flash glucose monitoring (FGM) has been added. The 
importance of time spent in target glycemia (time in range, TIR) was emphasized. The percentage of blood glucose 
readings in the range of 70–180 mg/dL should be > 70% for people with type 1 and type 2 diabetes. The percent-
age of readings below < 54 mg/dL should be < 1% and the percentage of readings > 250 mg/dL should be < 5%.
In Chapter 5, recommendations for the organization of medical care for patients with diabetes have been 
updated. In the section “Goals of specialist inpatient care”, in the points concerning: treatment of patients with 
newly diagnosed type 1 diabetes and type 2 diabetes with clinical symptoms of hyperglycemia, implementation of 
intensive insulin therapy using a personal insulin pump and/or continuous glucose monitoring system and initia-
tion of insulin therapy in gestational or pre-gestational diabetes previously not treated with insulin, it was noted 
that hospitalization is necessary when the patient’s clinical condition requires it and when appropriate treatment 
cannot be provided on an outpatient basis.
Chapter 6, it has been emphasized that patients with type 2 diabetes should be educated how to control por-
tion sizes and about the proportion of carbohydrates in individual meals and the diet in general. If possible, the 
patient’s diet should be adjusted to the patient’s dietary preferences. Adults, especially those with type 2 diabetes, 
should limit time spent sitting without breaks. An important element of dietary education should be providing 
the patient with practical information in a positive way, enabling the direct application of acquired knowledge in 
everyday life. A daily caloric deficit of 500–750 kcal is considered safe. The quality of dietary fat is more important 
than total amount of fat consumed. Multivitamin supplementation may be necessary for the elderly, vegetarians, 
vegans and people on very low calorie diets.
In Chapter 7, it has been highlighted that depression often coexists with diabetes and significantly increases 
the risk of diabetes complications (evidence level A).
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In Chapter 8, it has been emphasized that the primary goal of educating a patient with diabetes is to prevent 
the acute complications of diabetes: hypoglycemia and hyperglycemia. The authors of the recommendations en-
courage the use of tele-education based on reliable websites and mobile applications. The importance of period 
assessments of patients’ knowledge (feed-back) was also emphasized.
In Chapter 9, it was again emphasized that in patients regularly using continuous glucose monitoring (CGM) 
or flash glucose monitoring (FGM) systems, one of the basic parameters for assessing diabetes control should be 
the time spent in the glycemic target range (time in range) of 70–180 mg/dL, optimally over 70%.
It has been stated that type 1 diabetes patients with hypoglycemic episodes and glycemic fluctuations 
throughout the day can benefit from a combination of CSII and CGM technology in devices that automatically 
suspend insulin delivery in hypoglycemia or imminent hypoglycemia and in hybrid closed loop (HCL) insulin pumps 
that can normalize hyperglycemia to some extent. In addition, the guidelines contain opinions about insulin 
pumps based on open APS (artificial pancreas system) applications, called DIY (Do It Yourself) pumps, thanks to 
which many patients can improve the metabolic control of diabetes. However it should be emphasized that these 
are not certified systems, and their use and the risks associated with it remain within the patient’s responsibility.
It was emphasized that the first SGLT-2 inhibitor was approved for adjunctive therapy in type 1 diabetes. The 
use of SGLT2 inhibitors may improve glycemic control and help reduce weight in patients with type 1 diabetes.
In Chapter 10, it has been highlighted that early combination therapy with metformin and SGLT2 inhibitors 
and/or GLP-1 receptor agonists should be considered in any patient with blood glucose above target range or 
with concomitant conditions — atherosclerotic cardiovascular disease, chronic kidney disease or heart failure 
with impaired ejection fraction. However, metformin is still recommended as the first-line drug in the first step of 
pharmacological treatment, also in patients with diabetes and known cardiovascular disease. This is in line with 
current ADA guidelines (The Standards of Medical Care in Diabetes — 2020) and the updated ADA  / EASD consen-
sus statement on the treatment of type 2 diabetes.
In Chapter 12, recommendations for the treatment of hypertension in pregnant women with diabetes have 
been clarified. Target blood pressure values are: 110–139 mm Hg and 81–85 mm Hg for systolic and diastolic 
blood pressure, respectively. Blood pressure target below 130/80 mm Hg is recommended for pregnant women 
with diabetes and vascular complications. It has also been added that hypertension can be diagnosed based on 
24-hour ambulatory blood pressure monitoring (ABPM).
In Chapter 13, treatment targets for patients with lipid disorders have been changed. Cardiovascular risk 
categories in patients with diabetes have been updated. Target values LDL cholesterol < 55 mg/dL (< 1.4 mmol/L) 
or a reduction in LDL-C by at least 50% is recommended for patients with diabetes at very high cardiovascular 
risk. For patients with diabetes at high cardiovascular risk, maintaining LDL-C level < 70 mg/dL (1.8 mmol/L) or a 
reduction in LDL-C by at least 50% is recommended. Patients at moderate cardiovascular risk (young patients < 35 
years of age with type 1 diabetes, without chronic complications or other cardiovascular risk factors) or patients 
with type 2 diabetes < 50 years of age, with duration of diabetes < 10 years, without other risk factors recom-
mended LDL-C target range < 100 mg/dL (2.6 mmol/L).
In Chapter 15,  diagnostic criteria with severity assessment of diabetic ketoacidosis has been added. In addi-
tion, a recommendation has been added that the use of low molecular weight heparin in prophylactic dose should 
be considered in patients with severe diabetic ketoacidosis.
In Chapter 16, a new concept of ‘chronic coronary syndrome’ (formerly stable ischemic heart disease) has 
been introduced, as recommended by the experts of the European Society of Cardiology in 2019. In addition, 
recommendations for the use of dual antiplatelet therapy were clarified. In the population of patients after per-
cutaneous coronary intervention (PCI), it is recommended to use acetylsalicylic acid at a dose of 75–100 mg/day 
and clopidogrel 75 mg/day as a second drug, and in patients after acute coronary syndrome (ACS) — acetylsalicylic 
acid 75–100 mg/day and prasugrel 10 mg daily once daily or ticagrelor 90 mg twice daily as a second drug.
In Chapter 18, it has been highlighted that in patients with type 2 diabetes mellitus and chronic kidney 
disease, the use of a SGLT2 inhibitors or GLP1-receptor agonists, which are drugs with proven nephroprotective 
effects, should be considered in order to reduce the risk of progression to chronic kidney disease.
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Chapter 19 has been modified to remove the discrepancies between the text and the table regarding the 
ophthalmological examination of patients with type 2 diabetes without diabetic eye disease. It is recommended 
to perform check-ups every 1–2 years.
In Chapter 20, a notion has been added that autonomic neuropathy of the cardiovascular system is an inde-
pendent risk factor for increased mortality in diabetes.
In Chapter 21, a change in the clinical classification of the diabetic foot syndrome was introduced by adding 
the SINBAD classification to the previously used PEDIS classification. The authors also included in this chapter 
the IWGDF risk stratification system that determines the frequency of preventive foot examinations depending 
on the risk of ulcer development. Imaging diagnostics and revascularization should be considered, if there is no 
progress in wound healing within 4 weeks, despite standard management. The goal of revascularization should 
be to restore blood supply to at least one artery, preferably the one supplying the anatomical area of the ulcer. 
Consideration should be given to using TLC-NOSF dressings in uninfected wounds with neuropathic-ischemic 
etiology (but without critical/significant ischemia) that do not heal despite optimal standard care. It has been also 
emphasized that prior to each amputation it is obligatory to assess the blood supply to the limb. 
In Chapter 22, it has been emphasized that good diabetes control in a child cannot be at the expense of 
reduced quality of life. The recommendation regarding the diagnosis of insulin resistance in obese children us-
ing HOMA-IR has been deleted. Assessment of antibodies indicating autoimmune damage to pancreatic b cells 
was recommended only in justified cases. The recommendation regarding the indications for hospitalization in 
the diabetes ward has also been changed, leaving persistent hyperglycemia, glucose fluctuations and recurrent 
hypoglycemia (HbA1c > 7% removed). The table summarizing the recommendations of diabetes care for children 
and adolescents with diabetes was also redrafted. 
In Chapter 23, it has been emphasized that pregnancy planning for women of childbearing age with diabetes 
should be part of standard diabetes care. SGLT-2 inhibitors as well as other oral antidiabetic agents and GLP-1 
receptor agonists should not be used during pregnancy planning and pregnancy. The use of acetylsalicylic acid in 
patients with pre-gestational diabetes has been extended to 36 weeks of gestation. In patients with gestational 
diabetes or with diabetes in pregnancy, maximum blood glucose level at one hour after a meal shoud be less 
than 140 mg/dL (7.8 mmol/L), and it is recommended that blood glucose level at 2 hours after a meal is less than 
120 ml/dL (6.7 mmol/L). The recommended weight gain during pregnancy depends on the initial body weight: in 
overweight women the optimal weight gain is 6.4–11.1 kg, and in patients with obesity — 4.5–9.1 kg.
In Chapter 25 it has been indicated that patients treated with oral antihyperglycaemic agents undergoing 
“one day” procedures do not need to be temporarily treated with insulin if stopping the antihyperglycemic agent 
on the day of surgery does not result in an increase in blood glucose of > 180 mg/dL (10 mmol/L). On the other 
hand, in patients treated with two or three oral anti-hyperglycemic agents who will undergo major surgery with 
an increased risk of hemodynamic instability, it is recommended to suspend current therapy and periodically use 
insulin therapy. Insulin treatment should be continued until the end of hospitalization and not until the wound 
is healed.
In Chapter 26, recommendations for vaccinations have been updated. It has been indicated that non-immune 
patients should be vaccinated against chickenpox (varicella), rubella, mumps and measles as the mentioned diseas-
es may result in serious decompensation of diabetes. If the anti-HBs antibody titer in previously vaccinated subjects 
is < 10 IU/L, revaccination using 1–3 doses is recommended. If a protective antibody titer is not achieved after 3 
doses of the vaccine (4–12 weeks after the last vaccination), no further vaccination is recommended. Vacinations 
should be done before traveling to endemic areas and should be made in accordance with the epidemiological 
recommendations of the destination country.
The title of Chapter 30 has been changed to “Selected special situations and diseases in diabetic patients”. The 
section discussing an important issue of periodontal disease and other oral diseases in patients with diabetes has 
been added. It has been emphasized that dental diseases are more common in patients with diabetes compared 
to the general population. Periodontal disease negatively affects the metabolic control of diabetes and increases 
the risk of its complications. Treatment of periodontal disease improves the metabolic control of diabetes. Every 
patient with diabetes should have a dental examination once a year.
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Table 1. American Diabetes Association evidence-grading system for “Standards of Medical Care in Diabetes”
Level of evidence Description
A Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately  
powered, including:
• Evidence from a well-conducted multicentre trial
• Evidence from a meta-analysis that incorporated quality ratings in the analysis
Compelling nonexperimental evidence, i.e., “all or none” rule developed by the Centre for Evidence-
-Based Medicine at the University of Oxford
Supportive evidence from well-conducted randomized controlled trials that are adequately powered, 
including:
• Evidence from a well-conducted trial at one or more institutions
• Evidence from a meta-analysis that incorporated quality ratings in the analysis
B Supportive evidence from well-conducted cohort studies
• Evidence from a well-conducted prospective cohort study or registry
• Evidence from a meta-analysis of cohort studies
Supportive evidence from well-conducted case-control study
C Supportive evidence from poorly or incontrolled studies
• Evidence from randomized clinical trials with one or more major or three or more minor  
methodological flaws that could invalidate the results
• Evidence from observational studies with high potential for bias (such as case series with comparison 
with historical controls)
• Evidence from case series or case reports
Conflicting evidence with the weight of evidence supporting the recommendation
E Expert consensus or clinical experience
In the 2019 Diabetes Poland Guidelines, Appendices 1, 2 and 6 have also been updated. 
In Appendix 1, a recommendation has been added that in the year preceding the transition from pediatric to 
adult diabetes care, the patient should undergo examinations for chronic diabetes complications and comorbidi-
ties. Minor changes have been made to the Pediatric Diabetes Care Discharge Summary, including the recommen-
dation to attach the last Hospital Discharge Summary Report.
Appendix 2 on medical review and opining in drivers and workers with dysglycemia or diabetes has been re-
viewed and the following changes have been made: the Diabetes consultation card for examining driving licence 
applicants and drivers and the Diabetes consultation card for preventive examinations have been simplified, and 
the content of the annex was updated in accordance with the new ordinance of the Ministry of Health on August 
29, 2019. 
In Appendix 6, a suggestion has been added that different types of insulin pumps should be available in dia-
betes centers, because this will allow patients to choose the pump best suited to their needs. In addition, in the 
indications for reimbursement of the National Health Fund for the purchase of a personal insulin pump for diabetic 
children, adolescents and young adults under 26 years of age, the HbA1c level for people practicing competitive 
sports or regularly undertaking high-intensity physical exercise was changed, from < 9% to < 8.5%.
By making the above changes, in part suggested by the users of these guidelines, the 2020 PTD Guidelines 
Writing Group hopes that they will serve for improvement of medical care for diabetic patients in our country.
We sincerely thank everybody who has contributed to the development of the new edition of PTD guidelines!
 Prof. Irina Kowalska Prof. Dorota Zozulińska-Ziółkiewicz 
 Plenipotentiary of the Board President of the Diabetes Poland
 of the Diabetes Poland for Clinical Guidelines
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Table 1.1. Diagnostic criteria for dysglycemia
Random blood glucose — measured in 
a blood sample collected at any time 
of the day, regardless of the timing of 
the last meal
Fasting blood glucose — measured in 
a blood sample collected 8–14 hours 
after the last meal
Blood glucose at 120 minutes during 
an oral glucose tolerance test (OGTT) 
according to WHO 
Venous plasma glucose level
≥ 200 mg/dL (≥ 11.1 mmol/L) Æ diabetes* 
(if symptoms of hyperglycemia are present, 
such as increased thirst, polyuria, fatigue)
70–99 mg/dL (3.9–5.5 mmol/L) Æ normal 
glucose tolerance (NGT)
100–125 mg/dL (5.6–6.9 mmol/L) Æ im-
paired fasting glucose (IFG)
≥ 126 mg/dL (≥ 7.0 mmol/L) Æ diabetes*
< 140 mg/dL (7.8 mmol/L) Æ normal glu-
cose tolerance (NGT)
140–199 mg/dL (7.8–11.0 mmol/L) Æ im-
paired glucose tolerance (IGT)
≥ 200 mg/dL (≥ 11.1 mmol/L) Æ diabetes*
WHO — World Health Organization
*Diagnosis of diabetes requires one abnormal reading except for fasting blood glucose which requires two abnormal readings. A potential effect of factors 
not related to testing itself should be taken into account when measuring blood glucose (timing of the last meal, exercise, time of the day)
1. Diagnostic criteria for dysglycemia
Diabetes mellitus is a group of metabolic diseases 
characterized by hyperglycemia due to defective se-
cretion and/or action of insulin. Chronic hypergly-
cemia is associated with damage, dysfunction, and 
failure of various organs, in particular eyes, kidneys, 
nerves, heart, and blood vessels.
 I. Symptoms suggesting the presence of diabetes:
— Polyuria;
— Increased thirst;
— Weight loss that cannot be explained by intended 
weight reduction;
— Other, less typical symptoms and signs: fatigue 
and somnolence, purulent skin lesions, and in-
flammatory conditions of the genitourinary tract.
In case of the onset of symptoms random venous 
plasma glucose level should be measured (Table 1.1).
II.  Diagnostic criteria for dysglycemia (Table 1.1): 
— Random venous plasma glucose level measurement 
at the time when symptoms of hyperglycemia are 
identified — values ≥ 200 mg/dL (≥ 11.1 mmol/L) 
are consistent with the diagnosis of diabetes;
— If no symptoms are present or when symptoms are 
present and random blood glucose is < 200 mg/dL 
(< 11.1 mmol/L), fasting blood glucose should be 
measured twice on separate days — diabetes is 
diagnosed if fasting blood glucose on both these 
occasions is ≥ 126 mg/dL (≥ 7.0 mmol/L);
— If no symptoms of hyperglycemia are pres-
ent and random blood glucose is ≥ 200 mg/dL 
(≥  11.1  mmol/L), fasting blood glucose should 
be measured and diabetes is diagnosed if fasting 
blood glucose is ≥ 126 mg/dL (≥ 7.0 mmol/L);
— An oral glucose tolerance test (OGTT) should be 
performed if fasting blood glucose on one or two 
occasions is 100–125 mg/dL (5.6–6.9 mmol/L), or 
impaired glucose tolerance (IGT) or diabetes may 
be reasonably suspected with fasting blood glu-
cose < 100 mg/dL (< 5.6 mmol/L);
— An OGTT should be performed without prior limi-
tations of carbohydrate intake in a fasting, rest-
ed subject after an overnight sleep; the subject 
should remain resting at the site of testing for the 
2-hour period before ingestion of 75 g glucose so-
lution and blood sampling, with all blood glucose 
level measurements performed in venous blood 
plasma in a laboratory;
— If OGTT is to be performed in a subject with pre-
diabetes treated with metformin for that reason, 
the drug should be withdrawn at least one week 
before OGTT;
— OGTT is the preferred method to diagnose IGT. 
Glucose meter measurements should not be used 
for diagnostic purposes.
Most important recommendations
• Blood glucose measurements to allow early diagnosis of prediabetes/diabetes type 2 should be performed in all 
subjects > 45 years of age and younger overweight or obese subjects with at least one additional risk factor for 
diabetes. [B] 
• Women without a prior diagnosis of diabetes should be evaluated for gestational diabetes with oral glucose 
tolerance test with 75 g of glucose performed between 24 and 28 weeks of gestation. [A]
• The diagnosis of diabetes in children during the first 9 months of life requires genetic testing for neonatal dia-
betes. [A]
• In patients with cystic fibrosis, annual oral glucose tolerance test should be performed beyond 10 years of age 
to diagnose diabetes. [A]
6Clinical Diabetology 2020, Vol. 9, No. 1
In the United States and some European countries, 
glycated hemoglobin (HbA1c) was included in the diag-
nostic criteria.
Currently, Diabetes Poland does not recommend mea-
suring hemoglobin A1c (HbA1c) level to diagnose diabetes.
III.  Nomenclature of hyperglycemic states according 
to the World Health Organization (WHO):
— Normal fasting blood glucose: 70–99 mg/dL (3.9– 
–5.5 mmol/L);
— Impaired fasting glucose (IFG): 100–125 mg/dL 
(5.6–6.9 mmol/L);
— Impaired glucose tolerance (IGT): 120-minute blood 
glucose at 120 minutes of OGTT 140–199 mg/dL 
(7.8–11 mmol/L);
— Prediabetes: IFG and/or IGT;
— Diabetes — one of the following criteria:
1. Symptoms of hyperglycemia and random blood 
glucose level ≥ 200 mg/dL (≥ 11.1 mmol/L);
2. Fasting blood glucose ≥ 126 mg/dL (≥ 7.0 
mmol/L) on two occasions;
3. Blood glucose at 120 minutes of OGTT ≥ 200 
mg/dL (≥ 11.1 mmol/L).
IV.  Subjects at risk require screening for diabetes, as 
symptoms of hyperglycemia are absent in more 
than half of them. Testing for diabetes should be 
performed every three years in all subjects > 45 
 years of age. In addition, the following risk groups 
should be tested annually regardless of age:
— Overweight or obese subjects [body mass index 
(BMI) ≥ 25 kg/m2 and/or waist circumference > 80 cm 
(women) or > 94 cm (men)];
— Subjects with a family history of diabetes (in par-
ents or siblings);
— Physically inactive subjects;
— Members of community or ethnic groups charac-
terized by increased rates of diabetes;
— Those with prediabetes identified during previous 
testing;
— Women with a history of gestational diabetes;
— Women who gave birth to an infant with a birth 
weight > 4 kg;
— Subjects with hypertension (≥ 140/90 mm Hg);
— Subjects with dyslipidemia [high-density lipopro-
tein (HDL) cholesterol < 40 mg/dL (< 1.0 mmol/L) 
and/or triglycerides > 150 mg/dL (> 1.7 mmol/L)];
— Women with polycystic ovary syndrome;
— Subjects with cardiovascular disease.
V.	 	 Etiologic	 classification	of	diabetes	 according	 to	
WHO:
1. Diabetes type 1
— Autoimmune;
— Idiopathic.
2. Diabetes type 2
3.	Other	specific	forms	of	diabetes
— Genetic defects of beta cell function;
— Genetic defects of insulin function;
— Exocrine pancreatic diseases;
— Endocrinopathies;
— Drugs and chemicals;
— Infections;
— Rare immunologic forms of diabetes;
— Other genetic syndromes associated with diabetes.
4. Gestational diabetes
Latent autoimmune diabetes in adults (LADA)
The category of autoimmune diabetes type  1 in-
cludes slowly progressing diabetes caused by autoag-
gression. Latent autoimmune diabetes in adults (LADA) 
is a late manifesting autoimmune form of diabetes in 
adults, most commonly diagnosed in patients above 
35 years of age, characterized by clinical insulin inde-
pendence in the first months after the diagnosis, with 
the presence of serum antibodies against glutamic 
acid decarboxylase (anti-GAD65) and/or other anti-islet 
antibodies and a low serum peptide C level. LADA is 
a form of diabetes type 1 with slowly progressive auto-
immune-mediated destruction of beta cells. This diabetes 
subtype is present in 5–10% of subjects with diabe-
tes diagnosed after 35 years of age and categorized as 
diabetes type 2. Clinical manifestations of LADA do not 
always allow a definite diagnosis, presenting diagnostic 
challenges when differentiating with diabetes type 2.
A definite diagnosis of LADA requires identification 
of autoantibodies typical for diabetes type 1, mostly anti- 
-GAD65, and/or a low serum peptide C level.
Monogenic diabetes
Monogenic diabetes amounts to 1–2% of all diabe-
tes cases. It is caused by single gene mutations. Most 
forms are associated with a defect of insulin secretion, 
and the most common ones are maturity-onset diabe-
tes of the young (MODY), mitochondrial diabetes, and 
neonatal diabetes. Taking into account the monogenic 
forms in the differential diagnosis of diabetes may con-
tribute to treatment optimization and proper evaluation 
of prognosis in the patient and his family members. 
A definite diagnosis of monogenic diabetes is a result of 
genetic testing. Patient selection for genetic testing for 
monogenic diabetes and any therapeutic decisions result-
ing from such a diagnosis should be made in centers with 
a large experience in this area.
Neonatal diabetes is defined as the disease onset be-
fore 9 months of age. Genetic testing should be per-
formed in all patients with persistent neonatal diabetes. 
This should include testing for mutations in the KCNJ11 
gene which codes for Kir6.2 protein. Mutations in this 
gene are the most common cause of persistent neonatal 
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diabetes. Regardless of age, most patients with KCNJ11 
gene mutations may be treated with sulfonylureas which 
are effective and safe in this group and thus may be used 
as an alternative to insulin. Further targets for genetic 
testing include mutation in the insulin genes, the ABCC8 
gene coding for SUR1 protein, and the glucokinase gene. 
If a mutation in the ABCC8 gene is identified, sulfonylurea 
treatment may be attempted. Carriers of mutations in the 
insulin gene and a double mutation in the glucokinase 
gene need to be treated with insulin. Decisions regard-
ing search for mutations in other genes should be made 
individually by diabetes specialists (diabetologists) with an 
appropriate experience in the genetics of diabetes.
In families with autosomal dominant early-onset dia-
betes caused by impaired insulin secretion, in most cases 
without obesity, the differential diagnosis should include 
MODY and mutations in the responsible genes should be 
searched for. The most common form of MODY is associ-
ated with HNF1A and glucokinase gene mutations.
Typical clinical presentation of MODY due to a HNF1A 
gene mutation includes:
 1. Early onset of diabetes (typically before 25 years of 
age);
 2. No insulin dependence and ketoacidosis, low insulin 
requirement, detectable peptide C levels despite the 
disease being present for several years or even longer;
 3. Family history of diabetes over at least 2 generations, 
with early-onset diabetes in at least two family mem-
bers. OGTT performed at an early stage of diabetes 
usually shows high postprandial glucose level eleva-
tion with often normal fasting blood glucose;
 4. Absence of autoantibodies typical for diabetes type 1;
 5. Glycosuria higher than expected based on blood glu-
cose levels.
Chronic complications of diabetes develop in a large 
proportion of patients with MODY due to a HNF1A gene 
mutation, and thus optimal disease control should be 
actively pursued early after the disease onset. Sulfonyl-
ureas are the drugs of choice (except for pregnancy or 
the presence of typical contraindications to these drugs). 
If these are not effective, combined therapy with insulin, 
metformin or dipeptidyl peptidase-4 (DPP-4) inhibitors, 
or insulin monotherapy should be considered.
Testing for glucokinase gene mutations is indicated in 
the following situations:
 1. Persistently elevated fasting blood glucose in the 
range of 99–144 mg/dL (5.5–8.0 mmol/L);
 2. An increase in blood glucose during OGTT lower than 
83 mg/dL (4.6 mmol/L);
 3. A family history of diabetes in one of the parents, but 
negative family history does not exclude this form of 
diabetes.
Healthy nutrition with elimination of simple sugars 
is the treatment of choice in glucokinase defects due 
to a single gene mutation; drugs are usually ineffective. 
HbA1c value characteristic for glucokinase defect is not 
higher than 7.5%.
Decisions regarding testing for mutations in other 
genes associated with MODY should be made individu-
ally in centers experienced in such testing.
The most common cause of mitochondrial diabetes 
is the A3243G mutation of the gene coding for leucine 
tRNA. Testing for this mutation should be performed in 
case of maternal transmission of early-onset diabetes 
associated with deafness in some family members. The 
therapeutic approach in mitochondrial diabetes may in-
clude diet and treatment with sulfonylureas or insulin 
depending on the degree of defective insulin secretion. 
Metformin use should be avoided in mitochondrial dia-
betes.
Cystic	fibrosis-related	diabetes	(CFRD)
Diabetes is present in about 20% of adolescents and 40– 
–50% adults with cystic fibrosis. Diabetes associated 
with cystic fibrosis is classified as other specific type 
of diabetes associated with exocrine pancreatic disease, 
characterized by a slow progression and usually remains 
asymptomatic for many years. Diabetic ketoacidosis oc-
curs rarely, most likely due to preserved endogenous 
insulin secretion or concomitant impairment of gluca-
gon secretion. Initially, hyperglycemia is usually seen in 
circumstances that exacerbate insulin resistance, such as 
acute and chronic infections, glucocorticoid therapy, and 
ingestion of large amounts of carbohydrates (intake by 
oral or intravenous route, gastric tube or percutaneous 
gastrostomy).
Insulin therapy is the treatment of choice.
Routine annual testing for diabetes should be per-
formed in generally healthy subjects with cystic fibrosis 
aged > 10 years.
REFERENCES
1. De Franco E, Flanagan SE, Houghton JAL, et al. The effect of early, 
comprehensive genomic testing on clinical care in neonatal dia-
betes: an international cohort study. Lancet 2015; 386: 957–963.
2. Genuth S, Alberti KG, Bennett P, et al. Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus. Follow-up re-
port on the diagnosis of diabetes mellitus. Diabetes Care 2003; 
26: 3160–3167.
3. Metzger BE, Lowe LP, Dyer AR, et al. HAPO Study Cooperative Re-
search Group. Hyperglycemia and adverse pregnancy outcomes. 
N Engl J Med 2008; 358: 1991–2002.
4. Ode KL, Moran A. New insights into cystic fibrosis-related diabetes 
in children. Lancet Diabetes Endocrinol 2013; 1: 52–58.
8Clinical Diabetology 2020, Vol. 9, No. 1
Diabetes type 1
Currently, no effective and clinically useful methods 
exist to prevent diabetes type 1 both in the general popu-
lations and in subjects at risk.
Diabetes type 2
Screening should be undertaken with fasting blood 
glucose measurements or OGTT using 75 g of glucose 
(see Chapter 1). It is also possible to use HbA1c level 
measurements to screen for dysglycemia; however, this 
method is characterized by low sensitivity with respect to 
IFG. Indications for screening — see chap. 1.
I.  Risk factors for diabetes type 2 (see Chapter 1).
II.  Overview of recommendations regarding preven-
tion and delaying development of diabetes:
— Subjects at a high risk of developing diabetes type 2 
should receive appropriate education regarding 
healthy lifestyle (health benefits related to moder-
ate weight reduction and regular physical activity 
at least 150 minutes a week);
— Patients with prediabetes (IFG or IGT) should 
be advised to reduce weight (by about 7%) and 
increase physical activity at least 150 minutes 
a week. Pharmacological prevention of diabetes 
by using metformin should be considered in sub-
jects at a high risk of developing diabetes type 2, 
particularly if IFG or IGT is present;
— All patients benefit from increased physical activ-
ity, regardless of their age; however, it should be 
emphasized that this intervention is most effective 
in people over 60;
— Repeated advice regarding lifestyle changes is of 
paramount importance for the effectiveness of 
prevention;
— It is recommended to monitor patients for other 
cardiovascular disease risk factors (e.g., tobacco 
smoking, hypertension, dyslipidemia) and their 
treatment. The goals of treating concomitant dis-
eases for people with pre-diabetes are the same as 
for the general population;
— Use of diabetogenic drugs should be avoided.
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2. Preventing and delaying development of diabetes
Most important recommendations
• Patients with prediabetes should receive recommendations on healthy lifestyle (weight reduction and maintenance, 
physical activity at least 150 minutes per week) and information regarding the effectiveness of these methods in 
preventing overt diabetes. [A]
• In patients with prediabetes, particularly those with body mass index (BMI) ≥ 35 kg/m2 and below 60 years of 
age, and in women with a history of gestational diabetes mellitus (GDM), pharmacological prevention of diabetes 
with metformin should be considered along with lifestyle modifications. [A]
• Screening should be performed with fasting blood glucose measurements or oral glucose tolerance test. [C]
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Table 3.1. Recommended frequency of self-monitoring of blood glucose
Treatment regimen Frequency of self-monitoring of blood glucose
Multiple (i.e., at least 3 times daily) insulin injections
Intensive insulin therapy, regardless of the diabetes type
Multiple (i.e., at least 4 times daily optimally, not less than 8 
times daily) readings during the day according to the treatment 
regimen and patient needs
Oral hypoglycemic drugs and/or GLP analogs 4-point blood glucose profile (fasting and 2 hours post main 
meals) once a week, once daily at various times of the day
Diabetes type 2 treated with fixed insulin doses 1–2 readings daily plus 4-point blood glucose profile (fasting and 
2 hours post main meals) once a week plus 7-point blood  glucose 
profile once a month
GLP — glucagon-like peptide
Current monitoring and retrospective evaluation of 
blood glucose levels are integral parts of adequate dia-
betes treatment. Appropriate self-monitoring of blood 
glucose (SMBG) requires regular patient education in this 
regard, including evaluation of the ability to use glucose 
meter and interpret SMBG results, i.e. using them for day- 
-to-day modification of nutrition, exercise, and medica-
tion doses. Regular HbA1c level measurements are another 
necessary component of diabetes treatment monitoring.
I. Self-monitoring of blood glucose
Blood glucose self-monitoring is an integral part of 
diabetes treatment.
Patients treated with multiple daily insulin injections 
or continuous subcutaneous insulin infusion (CSII) should 
perform a daily blood glucose profile that includes read-
ings at morning fast, before and 60–120 minutes after 
each main meal, and before bedtime. Frequency and tim-
ing of additional measurements should be set individually.
Use of blood glucose monitoring systems including 
continuous glucose monitoring (CGM) and flash glucose 
monitoring (FGM) to supplement blood glucose self-
monitoring is particularly indicated in patients with labile 
diabetes type 1 with frequent hypoglycemia episodes 
and hypoglycemia unawareness, as it improves treatment 
safety and effectiveness.
3. Blood glucose monitoring
Most important recommendations
• Most patients treated with intensive insulin therapy should perform self-monitoring of blood glucose (SMBG) 
before and after meals, before bedtime, before planned physical activity, whenever hypoglycemia is suspected, 
and before activities associated with particular dangers of hypoglycemia (e.g., driving). [B]
• Within a comprehensive education program, SMBG may guide self-management decisions in patients receiving 
less intensive insulin therapy [B] and patients not treated with insulin. [E]
• Continuous patient education and periodic assessment of proper measurement technique, interpretation of the 
measurement results, and their effect on therapeutic decisions are important when ordering SMBG. [E]
• Continuous glucose monitoring (CGM) combined with intensive insulin therapy is a useful tool to reduce HbA1c 
levels in adult patients (≥ 25 years of age) with diabetes type 1. [A]
• CGM may be a useful tool in patients with hypoglycemia unawareness and patients with recurrent episodes of 
hypoglycemia. [B]
Self-monitoring of blood glucose is also indicated 
to reach therapeutic targets in patients treated with 
single insulin injections, oral antidiabetic agents, diet, 
and prescribed physical exercise (Table 3.1). Regardless 
of the treatment used, all patients should check blood 
glucose levels more frequently in case of feeling unwell 
or a sudden illness.
Proper SMBG requires patient education regarding 
glucose meter use, interpretation of readings, and fur-
ther management steps. For SMBG, it is recommended 
to use glucose meters that display plasma glucose level 
with the declared margin of error of up to 15% for 
glucose levels ≥ 100 mg/dL (5.6 mmol/L) and 15 mg/dL 
(0.8 mmol/l) for glucose levels < 100 mg/dL (5.6 mmol/L). 
Analysis of glucose readings using dedicated computer 
software may be useful in patients performing ≥ 4 mea-
surements daily. Glucose meters and the technique of 
their use by the patients should be checked in case of 
suspected measurement errors and at least once a year 
at the facility where the patient receives outpatient treat-
ment. This assessment should involve measuring glucose 
level in the same material with a glucose meter using 
a comparative method (laboratory method or point of 
care testing (POCT) consistent with the laboratory meth-
od) — the difference in results obtained should not ex-
ceed the above-mentioned margins of error.
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II. Hemoglobin A1c (HbA1c)
Hemoglobin A1c level reflects average blood glu-
cose levels during the period of approximately 3 last 
months, with about 50% of HbA1c currently present in 
blood being formed during the last month before the 
measurement.
Hemoglobin A1c level measurements should be per-
formed annually in patients with stable disease in whom 
the therapeutic targets have been met. In those in whom 
the therapeutic targets have not been met or the treat-
ment has been modified, HbA1c level should be measured 
at least every 3 months.
Hemoglobin A1c level measurements should be per-
formed using analytic methods certified by the National 
Glycohemoglobin Standardization Program (NGSP) 
(http://www.ngsp.org). Point-of-care testing for HbA1c is 
also possible when using methods and analyzers certified 
by NGSP.
It has been suggested that diagnostic laboratories 
report HbA1c levels in SI units (mmol/mol) in addition to 
traditional units.
When interpreting HbA1c levels, interfering factors 
should be taken into account, such as changes in the 
erythrocyte survival time, hemoglobinopathies, and 
chemical hemoglobin modifications which may render 
use of these measurements difficult or impossible.
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I. General considerations
 1. Therapeutic targets in diabetes include target blood 
glucose levels, blood pressure values, lipid profile, 
and body weight.
 2. In older patients and those with comorbidities, who 
are expected to survive for less than 10 years, thera-
peutic targets should be relaxed so as to not compro-
mise patient’s quality of life.
 3. Generally, therapeutic targets and treatment intensifi-
cation should be largely individualized. In all diabetic 
patients, and particularly those with diabetes type 2, 
the following factors should be taken into account 
when setting therapeutic targets: patient’s attitude 
towards treatment and the expected engagement in 
the treatment process (including that of patient’s fam-
ily members, caretakers etc.), the risk of hypoglycemia 
and its possible consequences (more severe in the 
elderly, and in those with preexisting cardiovascular or 
nervous system damage), duration of diabetes, expect-
ed survival, presence of major vascular diabetic com-
plications and significant comorbidities, the degree 
of patient’s education, and the risk-to-benefit ratio 
4. Setting therapeutic targets in diabetes
Most important recommendations
• In diabetic patients, the overall goal of diabetes control is HbA1c level ≤ 7.0% (53 mmol/mol). [A]
• LDL-C level < 55 mg/dL (1.4 mmol/L) or reduction by at least 50% in diabetic subjects at very high cardiovascular 
risk. [B]
• LDL-C level < 70 mg/dL (1.8 mmol/L) or reduction by at least 50% in diabetic subjects at high cardiovascular risk. [A]
• LDL-C level < 100 mg/dL (2.6 mmol/L) in diabetic subjects at moderate cardiovascular risk (young patients < 35 
years of age with diabetes type 1 but without chronic complications and other cardiovascular risk factors) or pa-
tients with type 2 diabetes < 50 years of age, with duration of diabetes < 10 years, without other risk factors. [A]
• The recommended blood pressure goal is < 130/80 mm Hg. [A]
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general therapeutic targets should be aimed for, with 
target HbA1c level ≤ 7%.
III.	Criteria	of	adequate	lipid	profile	control:
— LDL-C level < 55 mg/dL (1.4 mmol/L) or reduction 
by at least 50% in diabetic subjects at very high 
cardiovascular risk. 
— LDL-C level < 70 mg/dL (1.8 mmol/L) or reduction 
by at least 50% in diabetic subjects at high cardio-
vascular risk.
— LDL-C level < 100 mg/dL (2.6 mmol/L) in diabetic 
subjects at moderate cardiovascular risk (young 
patients < 35 years of age with type 1 diabetes 
but without chronic complications and other car-
diovascular risk factors) or patients with type 2 
diabetes < 50 years of age, with duration of dia-
betes < 10 years, without other risk factors. 
— Non-HDL cholesterol level < 85 mg/dL (2.2 mmol/L) 
in diabetic subjects at very high cardiovascular risk;
— Non-HDL cholesterol level < 100 mg/dL (2.6 mmol/L) 
in diabetic subjects at high cardiovascular risk;
— Triglyceride level < 150 mg/dL (< 1.7 mmol/L);
— HDL cholesterol > 40 mg/dL (> 1.0 mmol/L) [in 
women, higher by 10 mg/dL (0.275 mmol/L)].
IV. Criteria of adequate blood pressure control:
— Systolic blood pressure < 130 mm Hg;
— Diastolic blood pressure < 80 mm Hg.
It is recommended that in patients aged < 65 years 
systolic blood pressure should be maintained in the range 
of 120–129 mm Hg.
It is recommended that in patients aged ≥ 65 years 
systolic blood pressure should be maintained in the range 
of 130–140 mm Hg.
Details — see Chapter 12.
Table 4.1. Relation between HbA1c levels and average plasma glucose levels
HbA1c Average plasma  
glucose levels
Average fasting 
blood glucose
Average preprandial  
blood glucose
Average postprandial  
blood glucose
[mg/dL] [mmol/L] [mg/dL] [mg/dL] [mg/dL]
6 126 7.0
< 6.5 122 118 144
6.5–6.99 142 139 164
7 154 8.6
7.0–7.49 152 152 176
7.5–7.99 167 155 189
8 183 10.2
8–8.5 178 179 206
9 212 11.8
10 240 13.4
11 269 14.9
12 298 16.5
Correlation between HbA1c and average plasma glucose levels 0.92 (according to Diabetes Care 2015; 28: 35)
associated with specific therapeutic targets. In some 
circumstances (e.g., in those with advanced complica-
tions and in the elderly), the therapeutic targets should 
be attained gradually, within several (2 to 6) months.
II.   Criteria of adequate blood glucose control (tak-
ing into account the above considerations)
A general target:
HbA1c ≤ 7% (≤ 53 mmol/mol)
Individual targets:
a) HbA1c ≤ 6.5% (≤ 48 mmol/mol)
— Diabetes type 1 [fasting and preprandial  blood 
glucose, including SMBG: 80–110 mg/dL (4.4– 
–6.1 mmol/L); 2-hour post-prandial SMBG 
< 140 mg/dL (7.8 mmol/L)];
— Diabetes type 2 of a short duration;
— In children and adolescents, regardless of the 
diabetes type. When evaluating blood glucose 
profile in relation to target HbA1c, values given 
in Table 4.1 should be consulted, showing mean 
daily blood glucose values and blood glucose 
ranges corresponding to specific HbA1c levels.
b) HbA1c ≤ 8.0% (≤ 64 mmol/mol)
— In patients at an advanced age and/or in diabet-
ics with macroangiopathic complications (pre-
vious myocardial infarction and/or stroke) and/ 
/or multiple comorbidities;
c) HbA1c level < 6.5% (48 mmol/mol) in women with 
prepregnancy diabetes contemplating pregnancy, 
< 6.0 % (42 mmol/mol) in the second and third 
trimester, if it is not associated with an increased 
rate of hypoglycemia.
If a diabetic patient aged > 65 years is expected to 
survive for more than 10 years, gradual attainment of 
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I. Outpatient care
Modern diabetes treatment requires competencies 
regarding treatment, monitoring, and patient educa-
tion to convey appropriate knowledge and motivation to 
comply with treatment recommendations. Cooperation 
between primary care physicians and specialists is also 
required.
II. Goals of primary care
 1.  Health promotion, identification of risk factors, pre-
vention of carbohydrate disorders, education about 
pre-diabetes and type 2 diabetes.
 2.  Diagnosing carbohydrate metabolism disorders.
 3.  Referring patients to a diabetes clinic for chronic 
treatment in the case of:
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5. Organization of care for patients with diabetes
Most important recommendations
• Comprehensive diabetes care requires input of adequately competent physicians, nursing staff, nurses or midwi-
ves engaged in diabetic education, diabetes educators, and dietitians. Care should be patient-centered, taking 
into account individual patient situation, needs, and preferences. Due to multidisciplinary nature of late diabetic 
complications and concomitant conditions, cooperation with other specialists is also necessary. [B]
Table 4.2. Glycemic targets in patients with type 1 and type 2 diabetes and in pregnant women using CGM/FGM on 
a regular basis
Time-in-Range — TIR Time below range — TBR Time above range — TAR
% of readings; 
time per day
Target range % of readings; 
time per day
Below target 
range
% of readings; 
time per day
Above target 
range
Type 1 dia-
betes/type 2 
diabetes
> 70%
> 16 h, 48 min
70–180 mg/dL 
(3.9–10 mmol/L)
< 4%;
< 1 h
< 1%
< 15 min
< 70 mg/dL
(< 3.9 mmol/L)
< 54 mg/dL
(< 3,0 mmol/L)
< 25%
< 6 h
< 5%
< 1 h, 12 min
> 180 mg/dL
(> 10.0 mmol/L)
> 250 mg/dL
(> 13.9 mmol/L)
Elderly/ 
/patients 
with high 
risk of hy-
poglycemia 
> 50%
> 12 h
70–180 mg/dL
(3.9–10 mmol/L)
< 1%;
< 15 min
< 70 mg/dL
(< 3,9 mmol/L)
< 10%
< 2 h, 24 min
> 250 mg/dL
(> 13.9 mmol/L)
Pregnant 
women 
with type 1 
diabetes
> 70%
> 16 h, 48 min
63–140 mg/dL
(3.5–7.8 mmol/L)
< 4%
< 1 h
< 1%
< 15 min
< 63 mg/dL
(< 3,5 mmol/L)
< 54 mg/dL
(< 3,0 mmol/L)
<  25%
< 6 h
> 140 mg/dl
(> 7.8 mmol/L)
Modified from Battelino T et al. Diabetes Care 2019; 42: 1593–1603
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a)  Type 1 diabetes;
b)  Other specific types of diabetes;
c)  Difficulties in determining the type of diabetes;
d)  Any type of diabetes in children and adolescents, 
and in women who are pregnant or planning to 
become pregnant.
 4.  Treatment of pre-diabetes.
 5.  Treatment of type 2 diabetes, including simple insulin 
therapy.
 6.  Referring patients for diabetologist consultations 
(less frequently for chronic treatment) in the case of:
— Failure to achieve therapeutic goals; patients 
should be referred primarily to intensify insulin 
therapy;
— Comorbidities that interfere with treatment;
— Complications of diabetes;
— Complications of pharmacotherapy; 
—  Other special situations.
III. Goals of specialist care (Table 5.1)
 1. Evaluation of treatment effects and setting thera-
peutic targets during annual check-ups in diabetic 
patients managed in the primary care setting.
 2. Managing diabetic patients treated with injected 
agents [insulin, glucagon-like peptide 1 (GLP-1) re-
ceptor agonists].
 3.  Managing diabetic patients treated with continuous 
subcutaneous insulin infusion (CSII).
 4. Performing the differential diagnosis of diabetes 
types, including monogenic diabetes and diabetes 
combined with other diseases.
 5. Diagnosing, preventing and treating long-term com-
plications.
 6. Diabetes education.
 7. Investigating and managing diabetes in pregnant 
women.
 8. Investigating and managing concomitant conditions.
 9.  Performing annual check-ups according to current 
guidelines of Diabetes Poland.
IV. Goals of specialist inpatient care
 1. Cases of newly detected diabetes type 1 and diabetes 
type 2 with symptomatic hyperglycemia, when ap-
propriate treatment cannot be provided on an out-
patient basis.
 2. Acute diabetic complications (hypo- and hyperglyce-
mia, diabetic ketosis and coma).
 3. Exacerbation of chronic complications.
 4. Modifications of the treatment regimen in patients 
in whom therapeutic targets cannot be met during 
outpatient therapy.
 5. Initiation of intensive insulin therapy using a personal 
insulin pump and/or continuous glucose monitoring 
system (CGM), when appropriate treatment cannot 
be provided on an outpatient basis.
 6. Initiation of insulin therapy in gestational diabetes 
and preexisting diabetes previously not treated with 
insulin, when appropriate treatment cannot be pro-
vided on an outpatient basis.
 7. Difficulties with obtaining normoglycemia in preg-
nant patients with preexisting diabetes, when ap-
propriate treatment cannot be provided on an out-
patient basis.
V. Organizational requirements
Specialist diabetes hospital units
A.  Physician personnel — two full-time diabetologists, 
alternatively, in addition to one diabetologist, an inter-
nist with a minimum one-year experience in a diabetes 
word or clinic, or a 2nd year fellow in diabetology.
B.  Nursing staff — a nurse specialized in diabetes care 
or internal medicine or who have completed a “Dia-
betes Educator” course or a qualification course for 
diabetes nurses or minimum a 2-year experience in 
a diabetes word/clinic.
—  one nurse per 10 diabetic beds with duties limited 
to education and care for diabetic patients
C.  Dietician — a full-time dietician, with duties limited 
to diabetes care.
D.  Access to psychologist consultations.
E.  Access to specialist consultations.
F.   Equipment:
— At least two beds for patients with acute meta-
bolic conditions equipped with an ECG monitor, 
a blood pressure monitor, a pulse oximeter, an 
infusion pump, access to oxygen therapy;
— Education room;
— Intravenous infusion pumps; 
—  Equipment for diagnosis and treatment of diabetic 
foot syndrome;
— Access to cardiac [exercise testing, electrocardio-
graphy (ECG), echocardiography, ECG Holter mon-
itoring, ambulatory blood pressure monitoring] 
and vascular (Doppler ultrasonography) investiga-
tions.
Specialist diabetes clinics
A.  The team providing Outpatient Specialist Care to dia-
betic patients includes:
—  A diabetologist or an internist with a minimum 
two-year experience in a diabetes word or clinic, 
or a 2nd year fellow in diabetology;
—  In pediatric diabetology clinic — a diabetologist, 
or pediatric endocrinologist and diabetologist, or 
a pediatrician with a minimum two-year experi-
ence in a pediatric diabetes word or clinic, or 
a 2nd year fellow in diabetology or pediatric en-
docrinology and diabetology;
—  A nurse specialized in diabetes care or who com-
pleted a “Diabetes Educator” course, or a nurse 
specialized in internal medicine or who completed 
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a qualification course for diabetes nurses or mini-
mum a 2-year experience in a hospital diabetes 
word or a specialist diabetes clinic.
—  A full-time dietician with duties limited to diabetes 
education.
—  Access to psychological care in justified individual 
clinical case.
Children and adolescents, pregnant women — see 
relevant chapters.
B.  Equipment in specialist diabetes clinics:
—  Doctors’ offices;
—  A treatment room with a separate part for sam-
pling and performing tests;
—  A nurse’s office intended also for patient educa-
tion, with a dietary education section;
—  Computer equipment that allows retrieval and 
analysis of data from insulin pumps and continu-
ous glucose monitoring systems;
—  Instruments to screen for diabetic foot syndrome 
(128 Hz tuning fork, monofilaments 5 gs, reflex 
hammer);
— A Doppler ultrasound device for the assessment of 
vascular flow.
In addition, access to specialist consultations should 
be provided to periodically assess diabetes complication 
status.
VI. Organization of care for patients with diabetic 
foot syndrome
A.  Referral diabetes foot outpatients clinics
 1.  Personnel requirements:
  Physicians: equivalent of at least 2 full-time positions 
— diabetes specialist with at least one year of docu-
mented experience in the management of patients 
with diabetic foot syndrome;
  Nurses: equivalent of at least 2 full-time positions 
— at least one year of documented experience in the 
management and care of patients with diabetic foot 
syndrome or chronic wounds.
 2. An established organizational pathway allowing pa-
tient hospitalizations in a unit within the same facility 
(medical center) that has a contract for diabetology or 
internal medicine services signed with the Polish Na-
tional Health Fund (NFZ, Narodowy Fundusz Zdrowia).
 3. Access to multidisciplinary care, including surgeon, 
vascular surgeon, or angiology specialist consultations.
 4. Ability to provide intravenous antibiotic therapy.
 5. Access to basic imaging modalities, e.g. X-ray, ultra-
sound (including Doppler studies) and CT and/or MRI.
 6. Access to laboratory and microbiologic testing per-
formed in a medical diagnostic laboratory listed in 
the register of the National Chamber of Laboratory 
Diagnosticians (KRDL, Krajowa Rada Diagnostów 
Laboratoryjnych).
B. Basic care outpatients clinics
 1.  The responsibility of these clinics should include the 
diagnosis and management of diabetes foot syn-
drome along with prevention of ulcerations, infec-
tions, and Charcot neuro-osteoarthropathy compli-
cating diabetes foot syndrome. These clinics should 
cooperate with referral clinics where more severe 
cases are consulted and offered further treatment.
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Table 5.1. Recommendations regarding monitoring in adult diabetic patients
Parameter Comments
Nutritional and therapeutic education At each visit
HbA1c Once a year, more frequently if doubts regarding maintenance of 
normoglycemia or need to verify treatment effectiveness following 
its modifications
Serum total cholesterol, HDL cholesterol, LDL cholesterol, 
 triglycerides
Once a year, more frequently if dyslipidemia
Albuminuria Once a year in patients not receiving an angiotensin-converting 
enzyme inhibitor or an angiotensin receptor blocker (beginning at 
5 years after the diagnosis in diabetes type 1)
Urinalysis (with urine sediment) Once a year
Serum creatinine + estimation of eGFR Once a year (beginning at 5 years after the diagnosis in diabetes 
type 1)
Serum creatinine, Na+, K+, Ca2+, PO4
3– Every six months in patients with elevated serum creatinine
Fundoscopy (with mydriasis) At 5 years after the diagnosis in diabetes type 1, at the time of the 
diagnosis in diabetes type 2 (details see Chapter 19)
eGFR — estimated glomerular filtration rate; HbA1c — hemoglobin A1c; HDL — high-density lipoprotein; LDL — low-density lipoprotein
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6. Behavioral therapy (lifestyle changes)
Most important recommendations
• All diabetic patients should be offered education regarding the general principles of proper diabetes nutrition by 
appropriately trained personnel (physician, dietician, diabetes nurse, diabetes educator) and using various methods 
and techniques, including telemedicine. Detailed nutritional recommendations should be tailored to the needs and 
capabilities of the patient. [A]
• The major macronutrient determining periprandial insulin requirement are carbohydrates. Instruction how to 
estimate carbohydrate content of a meal to optimize insulin dosing should be a key component of dietary educa-
tion in patients with diabetes type 1. Patients with type 2 diabetes should be educated how to control portion 
sizes and about the proportion of carbohydrates in individual meals and in the whole diet. [A]
• There is no single universal diet that would be appropriate for all diabetic patients. The optimal proportions of 
macronutrients for a given patient should be determined individually, taking into account patient’s age, physical 
activity, presence of diabetes complications, concomitant conditions, and patient preferences. [E]
• Due to its pleotropic benefits, physical exercise is an integral part of proper comprehensive diabetes manage-
ment. For optimal effects, exercise should be regular, undertaken at least every 2–3 days but preferably daily. [A]
• Adults, especially those with type 2 diabetes, should limit time spent sitting without breaks. [B]
Behavioral therapy is an indispensable element of all 
patients of all ages diagnosed with diabetes treatment 
(both type 1 and type 2). Proper nutrition and physical 
activity are important in improving the overall patients’ 
health and in the prevention and treatment of chronic 
complications of diabetes. All patients should be edu-
cated on the general principles of proper nutrition in dia-
betes by authorized persons (doctor, dietician, diabetes 
nurse, diabetes educator) by using different methods and 
techniques, including telemedicine. Patient management 
should include therapeutic lifestyle changes encompass-
ing balanced diet, regular physical activity, avoidance of 
tobacco smoking and alcohol use, optimal sleep dura-
tion, and avoidance of stress. Education for therapeutic 
lifestyle, adapted to the needs and possibilities of the 
patient, allows to achieve intended therapeutic target 
and reduces the costs related to the treatment caused by 
diabetic complications.
Dietary recommendations
I. General recommendations
The goals of dietary treatment in diabetic patients are 
to obtain and to maintain:
— Normal (near normal) blood glucose level to pre-
vent diabetic complications;
— Optimal serum lipid and lipoprotein levels;
— Optimal blood pressure values to reduce the risk of 
vascular disease; and
— Desired body weight.
Dietary treatment includes advice on:
— Individually determined energy value of the diet;
— Calorie distribution over individual meals during 
the day;
— Food sources that will provide necessary calories, 
vitamins, minerals, and phytochemicals.
— Products that should be limited.
When planning diet, individual patient nutritional 
and cultural preferences, age, gender, the level of physi-
cal activity, and the economic status should be taken 
into account. It is important that dietary education 
provide patients with practical information that facili-
tates the direct application of acquired knowledge in 
everyday life. Eating meals is an important element of 
patients' quality of life. Information on the diet provided 
to the patient should be as positive as possible, indi-
cating that the diabetic diet provides the opportunity 
to prepare meals according to individual preferences. 
Negative information provided to patients should be 
limited and relate only to situations where the need to 
limit/eliminate some nutrients has been well proven in 
clinical trials.
Nutritional strategy in diabetic patients should in-
clude:
— Evaluation of usual dietary intake;
— Nutritional diagnosis;
— Determination of the goal and plan of the dietary 
intervention;
— Nutritional intervention (individual or group coun-
seling);
— Monitoring of nutrition and evaluation of its ef-
fects;
— Correction of the dietary plan if the therapeutic 
goal has not been reached.
Diabetic patients should be encouraged to adhere to 
the recommendations on healthy nutrition addressed to 
healthy subjects, and additionally to: 
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— Controlling the size of usually consumed portions;
— Monitor carbohydrate intake overall and in indi-
vidual meals;
— Limit intake of foods containing simple absorbable 
carbohydrates, including added sugar and free 
sugars;
— Consume regular meals.
There is no single universal diet that would be appro-
priate for all diabetic patients. Various dietary strategies 
can be used to treat diabetes, e.g. DASH diet, Mediter-
ranean diet, and plant-based diets.
Patients with diabetes type 1 without overweight 
and obesity should avoid consuming easily absorbable 
simple carbohydrates and adhere to an appropriately 
balanced diet. In all cases, the dietary plan and in-
sulin regimen should be individually tailored. Insulin 
therapy should be adjusted to the patient’s dietary 
habits, meal composition (carbohydrate, protein, and 
fat content), lifestyle, and physical activity. When plan-
ning diet, a priority should be given to estimation of 
absorbable carbohydrate content of the meal, e.g. using 
the carbohydrate exchange system. Glycemic index and 
glycemic load values may also be useful when making 
dietary choices.
In diabetic patients in the oldest age groups, dietary 
education should be particularly careful and individual-
ized to provide appropriate protein intake and at the 
same time it should be simple and easily understood by 
patients.
Although carbohydrates are the major macronutrient 
determining periprandial insulin requirement, patients 
with diabetes type 1 should also be educated regarding 
the glycemic effect of protein and fat.
In diabetes type 2, the major goals are not only to 
maintain good metabolic control of the disease but also 
reduce excess body weight and maintain the desired 
body weight. Thus, in addition to the above recom-
mendations, a factor of major importance is the total 
calorie content of the diet which should be adjusted to 
the patient’s age, actual body weight, and the level of 
physical activity, allowing gradual but systematic body 
weight reduction. A reduction in the total calorie in-
take (by 500–1000 kcal/day) should allow gradual but 
systematic body weight reduction (by about 0.5–1 kg/ 
/week); however the optimum weight reduction should 
be at least 7%. A daily caloric deficit of 500–750 kcal is 
considered safe.
Body weight reduction may be achieved by using 
a low-calorie diet with various proportions of macronu-
trients (protein, fat, carbohydrates). However, chronic 
use of very low carbohydrate diets and fasting is not rec-
ommended. All patients with diabetes and overweight/ 
/obesity are advised to control portion sizes.
II.	Specific	recommendations
Diet composition
1. Carbohydrates:
— No sufficient scientific evidence is available to de-
termine single optimal carbohydrate content in 
the diet of diabetic patients; 
— Carbohydrates should provide about 45% of the 
total calorie intake; and if they are consumed in 
the form of low glycemic index and high fiber 
content products, their share in the total calorie 
intake may be even higher (up to 60%). High 
caloric intake from carbohydrates should also be 
a feature of the diet in subjects who are very active 
physically. In contrast, a lower carbohydrate share 
in the total calorie intake (25–45%) may be tempo-
rarily recommended in patients with little physical 
activity if it cannot be significantly increased, e.g., 
due to concomitant conditions;
— The main source of carbohydrates should be whole 
grain cereal products, especially with low glycemic 
index (< 55 IG);
— The major limitation should apply to the intake of 
simple carbohydrates which should be reduced 
to the minimum. It also recommended to reduce 
intake of added and free sugars, the major sources 
of which are primarily sugar and sweets, but also 
honey and fruit juices and drinks;
— Artificial sweeteners may be used in doses recom-
mended by the manufacturers;
— Daily fructose intake should not exceed 50 g. Fruc-
tose use as a replacement for sugar is not recom-
mended;
— Minimum daily dietary fiber intake should be 25 g/ 
/day or 15 g/1000 kcal. Dietary fiber intake should 
be increased by consuming at least 2 portions 
of whole-grain cereal products and 3 portions 
of high-fiber vegetables. If the recommended di-
etary fiber intake cannot be reached, addition of 
fiber supplements, particularly containing soluble 
fibers, should be considered;
— It is reasonable to increase dietary intake of resis-
tant starch.
2. Fats:
— Dietary fat intake should be the same as in healthy 
subjects, providing 25–40% of the total calorie 
intake;
— The quality of dietary fat is more important than 
total amount of fat consumed. Fat composition 
is particularly important with high dietary fat 
intake;
— Saturated fats should provide less than 10% of the 
total calorie intake;
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— Acceptable levels of alcohol intake are ≤ 20 g/day 
of ethanol in women and ≤ 30 g/day in men.
Alcohol should not be consumed by patients with 
dyslipidemia (hypertriglyceridemia), neuropathy, or a his-
tory or pancreatitis.
6. Salt:
— Salt intake from all sources should not exceed 5 g 
per day (2300 mg sodium/day); 
— If reasonable, patients with hypertension may be 
advised more strict salt intake limitations accord-
ing to the DASH diet principles; however data on 
the reduction of sodium supply below 1.500 mg/ 
/day in diabetic patients are ambiguous. 
Dietary recommendations for special patient popula-
tions (e.g., pregnant women, children and adolescents, 
patients with established nephropathy etc.) are provided 
in the relevant chapters. Detailed recommendations on 
the dietary treatment of diabetes are provided in the 
Polish Society of Dietetics guidelines (www.ptd.prg.pl).
Physical exercise
Due to its pleotropic benefits, physical exercise is an 
integral part of comprehensive diabetes management. 
Physical exercise has a beneficial effect on insulin sensi-
tivity, blood glucose control, and lipid profile, promotes 
body weight reduction, and exerts a beneficial effect on 
mood, even with subjects with depression.
I.   General recommendations regarding physical 
exercise:
— Initially, moderate physical activity should be 
recommended, depending on the patient’s ability 
to exercise;
— For optimal effects, exercise should be regular, un-
dertaken at least every 2–3 days, preferably daily;
— Intensive physical activity should be preceded by 
a 5- to 10-minute warm-up and concluded with 
cool-down exercises;
— Physical exercise may increase the risk of acute or 
delayed hypoglycemia;
— Alcohol may increase the risk of hypoglycemia 
after exercise;
— Dehydration should be prevented when exercising 
in high ambient temperatures;
— The risk of foot damage during exercise (particu-
larly with coexisting peripheral neuropathy and 
a reduced pain perception) and the need for ap-
propriate foot care and comfortable shoes should 
be taken into account.
II.  Exercise intensity is determined by the physician 
based on the full clinical picture
The most appropriate form of exercise in patients 
with diabetes type 2 aged > 65 years and/or overweight 
— Monounsaturated fats should provide up to 20% 
of the total calorie intake;
— Polyunsaturated should provide about 6–10% of 
the total calorie intake;
— Cholesterol intake should be limited to ≤ 300 mg/ 
/day, and < 200 mg/dL in patients with dyslipidemia;
— To reduce serum LDL cholesterol level, low glyce-
mic index carbohydrates and/or monounsaturated 
fats should be substituted for saturated fats; 
— In patients with hypercholesterolemia, introduc-
tion of foods providing 2–3 g of plant sterols/ 
/stanols per day may be beneficial.
— Intake of trans fatty acids should be limited to the 
minimum.
—  Vegetable fats are recommended, with the excep-
tion of palm and coconut oil.
3. Proteins:
Dietary protein intake should be individualized. There 
is no evidence of adverse effects of high-protein diets in 
diabetic patients.
— In most diabetic patients, similarly to the general 
population, proteins should provide 15–20% of 
the total calorie intake (about 1–1.5 g/kg body 
weight/day). In patients with diabetes type 2 and 
excessive body weight, a low-calorie diet contain-
ing 20–30% of protein provides greater satiety 
and helps reduce and maintain a healthy body 
weight. In patients with chronic kidney disease, 
protein intake should be about 0.8–1 g/kg body 
weight/day;
— There is no need to limit animal protein intake, 
although substituting plant protein (e.g., soy pro-
tein) for animal protein may be beneficial in some 
patients.
4. Vitamins and microelements:
— Vitamin or microelement supplementation is not 
recommended unless their deficiencies have been 
identified;
— The exceptions are vitamin D3 (supplementation 
according to the recommendations for the general 
population) and folic acid (supplementation at the 
dose of 400 µg in pregnant women) and vitamin 
B12 in patients on long-term metformin therapy 
with confirmed vitamin B12 deficiency;
— Multivitamin supplementation may be necessary 
for the elderly, vegetarians, vegans and people on 
very low calorie diets.
5. Alcohol:
— Alcohol intake is not recommended in diabetic 
patients;
— Patients should be informed that alcohol inhibits 
hepatic glucose release and thus its intake (par-
ticularly without food) may predispose to hypo-
glycemia;
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is brisk walking (until panting) 3–5 times a week (approx. 
150 minutes/week).
Nordic walking is an appropriate form of exercise in 
overweight/obese subjects at any age.
Those without significant contraindications, especially 
in the younger age groups, should be encouraged to in-
creased  physical activity, including sports. Such patients 
require additional education in the effect of glycemic 
induced by different types of physical activity (e.g. aerobic 
exercise, effort resistance, interval).
A simple and effective recommendation is that adults, 
especially those with type 2 diabetes, limit the time spent 
sitting without breaks. Glycemic benefits can be gained by 
avoiding sitting continuously for more than 30 minutes.
III.  Risks of physical exercise in diabetic patients
 1.  Hypoglycemia:
— Blood glucose level should be measured before, 
during, and after exercise;
— Before planned exercise, reduction of rapid/short-
acting insulin dose by 30–50% (depending on indi-
vidual response) should be considered if peak ac-
tion of the drug would coincide with the exercise 
or occur shortly afterwards;
— During treatment with insulin pump, it is recom-
mended to reduce basal insulin rate by 20–80%, 
depending on the intensity and duration of exer-
cise, preferably 2 hours before exercise;
— Before unplanned exercise, an additional portion of 
simple carbohydrates should be consumed (20–30 g 
per 10 minutes of exercise), and a reduction of 
post-exercise insulin dose should be considered;
— Insulin injections into the limbs about to exercise 
should be avoided if exercise commences within 
30–60 minutes after the injection.
 2.  Metabolic decompensation:
— Very intensive, short-lasting exercise (> 90% 
VO2max) and exercise in hypoxic conditions (e.g., 
high-altitude climbing) may lead to hypoglycemia 
and acidosis;
— If blood glucose level exceeds 250 mg/dL (13.9 
mmol/L), urine testing for ketone bodies is indicated 
in patients with diabetes type 1, and strenous exer-
cise should not be initiated if ketonuria is found;
— Patients with diabetes type 2 should consider a si- 
milar limitation if blood glucose level exceeds 300 
mg/dL (16.7 mmol/L);
 3.  In some circumstances, strenuous exercise may have 
a negative effect on the general health status of the 
patient:
— Diabetic proliferative retinopathy — risk of  vitreous 
body bleeding and retinal detachment;
— Diabetic nephropathy — increase in albuminuria/ 
/proteinuria;
— Autonomic neuropathy — risk of orthostatic hypo-
tension;
— Risk of myocardial ischemia.
Tobacco control
 1.  In all current or former smokers, determine:
— Age at which the patient began smoking;
— Duration of smoking;
— Number of cigarettes smoked;
— Any attempts to quit smoking and duration of 
abstinence;
— Duration of current abstinence.
 2.  Counselling:
— Explanation of the risks associated with smoking 
to non-smokers;
— Advice to quit smoking;
— Patient support in the decision to quit smoking;
— Psychological and pharmacological support if 
needed;
— Discussion regarding smoking during each visit;
— If the patient refuses to quit smoking, this should 
be documented in the medical records.
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7. Psychological management in diabetes
Most important recommendations
• The mental condition of the patient should be evaluated at the initiation of diabetes treatment and during each 
subsequent visit. [B] 
• Depression often coexists with diabetes and significantly increases the risk of diabetes complications. [A]
• Diabetic patients should be evaluated for anxiety symptoms, addictions, eating disorders, and cognitive dysfunc-
tion. These conditions may significantly impair their adaptation to the disease. [B]
The mental state of the patient affects nearly all as-
pects of the management. Non-compliance to treatment 
is commonly associated with psychological problems 
which require identification and appropriate psychother-
apeutic interventions. For this reason, education limited 
to providing the patient with information regarding pre-
scribed therapy and other therapeutic recommendations 
is not very effective. The mental state of the patient 
should be evaluated at the treatment initiation and dur-
ing every visit. Use of appropriate questionnaires and 
tests is recommended.
 1.  Psychological support should include:
— Adequate communication with the patient;
— Continuous evaluation (monitoring) of the mental 
state and compliance to treatment, along with 
psychological interventions.
 2.  The goals of individualized approach to the patient 
include:
— Consideration of the patient’s psychosocial status 
and planning treatment which in the patient’s 
opinion may be realistically undertaken in his or 
her life situation (which is of major importance 
for setting the therapeutic plan that will be both 
optimal and realistic);
— Developing motivation to engage in optimal man-
agement;
— Avoidance of frightening the patient with adverse 
consequences of non-compliance to therapeutic 
recommendations which is ineffective and harmful 
in most cases;
— Implementation of effective education based on 
the psychological diagnosis.
3. Evaluation of the psychological/mental state (psycho-
logical diagnosis) in diabetic patients includes the 
following aspects:
I. Social and psychological situation.
II. Patient’s quality of life.
III. Attitudes, beliefs, concerns, and duties related to 
diabetes (unjustified worries and concerns may 
reduce the ability to cope with the disease). Ask 
the following question:
 To what degree do you worry about the future 
and the possibility that severe complications will 
develop: (0) It is not an issue at all; (1) It is a minor 
issue; (2) It is a moderately important issue; (3) It is 
quite an important issue; (4) It is a very important 
issue. A score of 3 or more indicates a high risk of 
developing psychosocial problems.
IV. Sense of control over the disease. Lacking sense 
of control over the disease results in choosing ap-
proaches to cope with the disease-related stress 
that are characterized by avoidance of thoughts 
about the disease and/or reducing emotions pro-
voked by the disease.
V. Evaluation of the ability to cope with the disease 
(a trend to reduce search for the optimal cop-
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ing strategy and focus on solving disease-related 
problems is seen).
VI. Evaluation of depressive symptoms (depression 
often coexists and increases the risk of diabetic 
complications).
A.  Use tools available freely online to screen for depres-
sion: the Well-being index WHO-5, www.who-5.org 
(score < 13 indicates the need to investigate for de-
pression, and score ≤ 7 indicates a high risk of de-
pression) or the Patient Health Questionnaire PHQ-9, 
www.phqscreeeners.com/overview/aspx (score < 5 is 
normal, 5–9 indicates mild depression, 10–14 indicates 
moderate depression, 15–19 indicates moderately se-
vere depression, and 20–27 indicates severe depres-
sion). In the Polish translation, score > 12 indicates 
a high risk of depression episode (sensitivity 82%, 
specificity 89%).
OR
B.  Ask two questions:
Did you often feel depressed or hopeless during the 
last month?
Did you often lack an interest in undertaking various 
activities or a feeling of pleasure during these activities?
A positive answer to one of these questions has 
a sensitivity of 97% and a specificity	of	67% for the 
diagnosis of depression. In these circumstances, the pa-
tient should be referred to a psychiatrist.
VII. Evaluation of anxiety symptoms, addictions, eat-
ing disorders, reduced cognition (these may sig-
nificantly impair adaptation to diabetes).
 4.  Psychological interventions in diabetic patients in-
clude:
— Developing the sense of control over the disease 
by:
• Providing the patient with comprehensible in-
formation regarding the disease and its treat-
ment,
• Collaborative development of therapeutic goals 
and plans which are realistic from the patient’s 
perspective,
• Gradual achievement of therapeutic goals 
(small steps strategy),
• Offering help in case of treatment failures (so 
the patient knows that the physician will help 
him determine the cause of failure without any 
negative attitude);
— Developing and maintaining diabetes coping skills 
focused on solving disease-related problems.
 5.  Clinically severe depression (depressive episode, dys-
thymia) and other mental health problems require 
psychiatric consultation. In case of maladaptation to 
the disease, psychotherapeutic intervention may be 
undertaken by a primary care physician or a specia-
list. Help of a clinical psychologist is necessary in 
more complex cases.
 6.  Teamwork
Cooperation of the whole therapeutic team is an 
important prerequisite of treatment success. Effective 
communication between team members is required. In 
diabetes clinics, a psychologist is a necessary member of 
the specialist therapeutic team.
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8. Therapeutic education
Developed in cooperation with Alicja Szewczyk, MA, National Consultant in Diabetes Nursing
Most important recommendations
• Education is the mainstay of effective diabetes care and prevention. [A]
• All patients with diabetes and their caregivers should participate in diabetes education to acquire knowledge and 
skills regarding diabetes self-management and support initiation and maintenance of constant self-control. [B]
• The main goals of diabetes education are effective self-care, improved metabolic control and quality of life, and 
support for the diabetic patient/his or her caregivers. The effectiveness of education and its programs undergo 
systematic monitoring, evaluation and methodical improvement. [C]
• Diabetes education should be focused on the patient and his or her individual needs. [B]
• A coordinated and unified position of the multidisciplinary diabetes team has a beneficial effect on the metabolic 
control and the psychological aspect of care. [B]
• All patients with diabetes and their caregivers should be provided access to institutionalized therapeutic and 
motivational education, as the basic, general method in their diabetes prevention and treatment plan. [B]
 I. General recommendations
 1. Education is targeted at subjects at an increased risk 
of diabetes, subjects with prediabetes, and those 
treated for diabetes, and their carers and family 
members. Education is a constant, integral, and nec-
essary component of diabetes management during 
each visit. In addition, it should be undertaken in 
a structured way, including education at the time 
of treatment initiation, followed be reinforcements 
based on regular evaluation of the patient’s educa-
tional needs or if requested by the patient, taking 
into account the progress in diabetology and organi-
zational and social improvements.
 2. The educational program should be developed in 
cooperation with the patient and the therapeutic 
team (physician, nurse, diabetes educator, dietitian, 
psychologist) and be closely associated and coordi-
nated with the recommended treatment approach. 
The patient is performing self-care an active member 
of the therapeutic team.
 3. The goal of patient education is to support self-man-
agement and lifestyle modifications based on the 
recommended diet and physical activity. Education 
on obesity and weight control is a particularly impor-
tant issue in diabetes type 2. The primary goal is the 
patient’s ability to avoid the acute complications of 
diabetes: hypoglycemia and hyperglycemia.
 4. Effectiveness of self-management programs has been 
documented. They actively engage participants in the 
learning process, adjusting the content and form to 
the individual situation and personal experiences of 
the participants, and motivate them to set personal 
behavioral treatment targets, developed in coopera-
tion with the physician.
	 II.		Specific	recommendations
 1. Strategies to integrate diabetes therapy and self-care 
with everyday healthy lifestyle are recommended. 
Their goals are to increase patients’ empowerment 
by discovering and using their natural and acquired 
abilities to take responsibility for their own life.
 2. It is recommended to provide individualized education 
along with realization of group educational programs 
(groups of 6–10 people). Education should be provid-
ed by an appropriately trained personnel (physicians, 
diabetes educators, nurses, dieticians). Other members 
of the therapeutic team, representing various medi-
cal professions, should also participate in education. 
Both educational programs for subjects with newly 
diagnosed diabetes and reinforcement programs for 
patients with long-standing diabetes are needed. It is 
necessary to offer education to patients’ family mem-
bers and caretakers particularly of children and elderly 
with diabetes and also to their probation officers.
 3. In education, modern methods of pedagogy for 
youth or the elderly should be used. Recommended 
are electronic communication and tele-education 
techniques, using reliable websites and mobile appli-
cations. The advantages of the online/mobile meth-
ods of therapeutic education in diabetes include: easy 
accessibility, practical aspects, individual interactivity, 
and the fact that it can be used at any time. However, 
the online methods also have some disadvantages, 
such as the lack of personal contact with the educa-
tor and other people with diabetes. Currently, this 
method can only be a supplementary and occasional 
tool. Education must be conducted in a particularly 
clear way due to the issues discussed, the methods 
used and the type of trainees.
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 4. Education should focus on setting individual diabetes 
management goals, taking into account problems spe-
cific for a given person or a given patient group. The 
educational program should include developing skills to 
influence the course of the disease, as the knowledge 
itself is not sufficient for optimal diabetes management.
 5.  Diabetes education in children and adolescents 
should be tailored to their intellectual capabilities, 
age, and needs.
 6.  Therapeutic education should be offered to all elderly 
subjects. Its goals, methods, and skill teaching should 
be adjusted to the intellectual and physical capabili-
ties of the elderly subjects (who may be independent, 
functionally dependent on caregivers, or at the end 
of life). Education should also be targeted at patient’s 
caregivers. The extent of blood glucose monitoring 
should be set at a minimal level. An important aim 
of blood glucose monitoring is to reduce the risk of 
hypoglycemia and severe hyperglycemia and the risk 
of non-diabetic coma in daily geriatric care.
 III.  Framework educational program should include 
the following components:
 1. Support regarding disease acceptance, increasing ap-
propriate motivation for treatment, and increasing 
patient empowerment.
 2. Setting and evaluating individual therapeutic goals 
based on the disease course, prognosis, recommend-
ed treatment, and personal and social situation of the 
patient.
 3. Basic information about the disease and its treatment 
(causes, clinical characteristics, course and prognosis, 
etc.)
 4. Teaching the techniques of systematic self-monitoring 
of blood glucose, ketone bodies, blood pressure etc., 
and how to manage situations when an intervention 
is necessary.
 5. Teaching the techniques of insulin administration 
(factors affecting the rate of insulin absorption, sites 
of insulin administration, appropriate needle length, 
prevention of insulin-induced lipodystrophy).
 6. For patients treated with a personal insulin pump: 
advantages and disadvantages of and indications and 
contraindications to insulin pump therapy, principles 
of programming and modifying basal infusion rate, 
temporary changes of the basal infusion rate, use 
of single, delayed, and combination boluses, use of 
a bolus calculator, setting an infusion system (how 
to choose the injection site), use of CGM and prop-
er interpretation of glucose level readings, what to 
do in case of an insulin pump failure — return to 
treatment using insulin pens, management of initial 
symptoms of ketoacidosis, principles of withhold-
ing insulin infusion in special situations (e.g., sport), 
technical aspects of insulin pump use, calculation of 
carbohydrate and protein-fat exchanges, achieving 
appropriately balanced meal composition, maintain-
ing an electronic self-control diary.
 7. Information about the appropriate use of indepen-
dent and integrated insulin pump integrated with 
continuous glucose monitoring (CGM) system — the 
backward and in real time, about their functions, set-
ting alarms for hypo- and hyperglycemia, dynamics of 
trend changes, and interpretation of CGM results for 
the current therapy.
 8. Information about diagnosing and treating complica-
tions, both acute (hypoglycemia, infections, myocar-
dial infarction, stroke, etc.) and chronic (nephropathy, 
retinopathy, neuropathy, erectile dysfunction, diabetic 
foot), along with their risk factors (hyperlipidemia, hy-
pertension, smoking, etc.) and approaches to prevent 
complications and diseases related to diabetes.
 9. Information about healthy nutrition and its role in the 
management (including practical information about 
carbohydrate content in foods and creating a nutri-
tional plan based on individual habits, needs, and 
therapeutic strategies, etc.).
 10. Information about the effect of physical exercise on 
the regulation of blood glucose (hypo- and hypergly-
cemia, etc.).
 11. Information about managing special situations (trav-
el, contraception, pregnancy).
 12. Information about social rights of diabetic patients 
(work, driving license, insurance, etc.).
 13. Principles of healthcare utilization (visit frequency, 
follow-up evaluations), optimal compliance to treat-
ment recommendations.
 14. Discussion of the importance of psychological prob-
lems in the management of diabetes and opportuni-
ties for specialist care.
 IV.  Organizational recommendations
 1.  Duration of the initial education should be at least 
5 hours in diabetic patients treated with diet or diet 
and oral antidiabetic agents, about 9 hours in pa-
tients treated with insulin, and 9–15 hours in patients 
treated with a personal insulin pump, depending 
on the settings of care (outpatient or inpatients), 
patient situation, and facility resources. Diabetes edu-
cation should be initiated in each patient as early as 
possible after the diagnosis is made and continued 
during further follow-up, for a total of 5–9 hours in 
patients with diabetes type 1 and at least 7–14 hours 
in patients with diabetes type 2. During subsequent 
years, duration of education must depend on the 
knowledge already absorbed by the patient, number 
of previous errors, and the type of developing com-
plications and concomitant disorders.
 2.  For practical purposes, it may be advisable to orga-
nize a "school of diabetes education."
23
2020 Guidelines on the management of diabetic patients
 3.  Education delivered by physicians, nurses, diabetes 
educators, and dieticians should be undertaken in 
parallel to drug treatment, taking into the account 
the above mentioned time constraints, which re-
quires separate funding within specifically defined 
and contracted services.
 4.  Every education program should be based on the 
principle of professional communication between the 
patient and therapeutic team. Its goal is to achieve 
trust, empathy, and motivation for strict compliance 
with therapeutic recommendations.
V. Standard requirements for an education center
 1. Providing an educational room and equipping the 
workplace with material resources necessary to con-
duct education at the level enabling achievement of 
the goals and effects of diabetes education.
 2. Documentation of the educational activities includ-
ing: framework educational program and training 
sessions undertaken with each patient, identification 
of the local education coordinator, and education- 
-related duties of the healthcare personnel and indi-
vidual patient education charts. Periodic assessments 
of patients’ knowledge (feed-back).
 3. Periodic (at least once a year) evaluation of the pa-
tient’s self-management of diabetes.
 4. Providing patients with an opportunity for periodic 
(at least once a year) evaluation of the quality of 
education delivered in a given center.
 5. Improving skills of the personnel delivering education 
(participation in education courses, providing up-to-
date knowledge).
 6. Consideration of patient evaluation of the quality of 
the education delivered.
 7. Determining the way of consulting educational deci-
sions in the therapeutic team and ensuring informa-
tion sharing about therapeutic goals and educational 
progress.
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Most important recommendations
• The recommended treatment approach is intensive insulin therapy using multiple subcutaneous insulin doses or 
continuous subcutaneous insulin infusion (CSII) using a personal insulin pump. [A]
• A key element of therapy for diabetes type 1 is the patient’s ability to modify insulin doses based on carbohydrate 
meal content, baseline blood glucose level, and planned physical activity. Knowledge of the effect of protein and 
fat on blood glucose level is also important for optimization of insulin dosage. [E]
• In patients with diabetes type 1, use of insulin analogs is preferred due to a lower risk of hypoglycemia and bet-
ter quality of life. [A]
• In patients using continuous glucose monitoring (CGM) or flash glucose monitoring (FGM) systems, one of the 
basic parameters for assessing diabetes control should be time spent with blood glucose levels in target range 
(time in range), optimally over 70%. [E]
9. General principles of the management of diabetes type 1
Management of diabetes type 1
—  Insulin therapy is absolutely required in patients with 
diabetes type 1. Insulin therapy should be continued 
even in the remission phase.
—  The recommended treatment approach is intensive 
insulin therapy using multiple subcutaneous in-
sulin doses or CSII using a personal insulin pump. 
A prerequisite for effective treatment is appropriate 
education (as outlined in Chapter 8), allowing self-
adjustments of insulin doses by the patient based on 
systematic BGSM using a glucose meter (as outlined 
in Chapter 3).
—  In patients with diabetes type 1, use of insulin ana-
logs is preferred due to a lower risk of hypoglycemia 
and better quality of life.
—  Optimization of insulin dose is important in insulin 
therapy for diabetes type 1. Long-term use of supra-
physiological amounts of insulin without attempts to 
identify causes of high insulin requirement and treat 
the underlying problem — except for specific situations 
(acute illness, medications increasing insulin require-
ment, stress) — may lead to adverse metabolic conse-
quences including excessive body weight increase.
—  A key element of therapy for diabetes type 1 is the 
patient’s ability to modify insulin doses based on 
meal calorie content (based on calculating carbohy-
drate and protein-fat exchanges) and planned inten-
sity of physical activity.
—  Use of CGM is indicated with recurrent episodes of 
severe hypoglycemia or large circadian variation of 
blood glucose levels. The combination of CSII and 
CGM technologies may be particularly effective in 
insulin pumps that automatically interrupt insulin 
administration in case of hypoglycemia or imminent 
hypoglycemia and in hybrid closed loop (HCL) insu-
lin pumps that can also normalize hyperglycemia to 
some extent.
—  Devices working on a similar principle as HCL are 
pumps based on open APS (artificial pancreas sys-
tem) applications, called DIY (Do It Yourself) pumps. 
Although many patients can significantly improve 
metabolic control thanks to such systems, it should 
be emphasized that these are not certified systems, 
and their use and the risks associated with it remain 
in the patient's responsibility.
—  Reduction of the risk of hypoglycemia and improved 
patient quality of life may also be achieved by the use 
of flash glucose monitoring (FGM).
—  Telemedicine is an important tool to optimize blood 
glucose control.
—  Sodium-glucose transport protein 2 (SGLT-2) inhibi-
tors are drugs that, when combined with insulin ther-
apy, may improve glycemic control and weight re-
duction in type 1 diabetes. It should be emphasized, 
however, only some SGLT-2 inhibitors are registered 
for the supportive treatment of type 1 diabetes. Their 
use may be associated with the risk of normoglyce-
mic ketoacidosis, especially in the case of a significant 
reduction in the daily insulin dose.
Organization of care for patients with diabetes type 1
—  Patients with diabetes type 1 should be cared for 
by a diabetes specialist since the very diagnosis of 
diabetes type 1 and afterwards. Such a management 
approach allows continuous collaboration with an 
education team (as outlined in Chapter 5) and access 
to necessary consultations.
—  New diabetes type 1 cases and difficult-to-treat acute 
diabetes complications require admission to the hos-
pital at diabetes care unit.
Goals of diabetes type 1 management
The goal of diabetes type 1 management is to achieve 
good metabolic control with blood glucose levels as close 
to normal values as possible and HbA1c ≤ 6.5% unless 
associated with episodes of hypoglycemia or reduced 
patient quality of life. In other cases, the therapeutic goal 
should be HbA1c ≤ 7.0%.
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Only such a management approach may prevent 
acute and chronic complications and allow patient to en-
gage in normal, active family, professional, and social life.
In patients who regularly use CGM/FGM, the primary 
therapeutic goal is to achieve a high (over 70%) percent-
age of time spent in the target range defined as blood 
glucose values from 70–180 mg/dL. It should be empha-
sized that one of the treatment priorities should be to 
avoid hypoglycemia (the permissible time spent at values 
lower than 70 and 54 mg/dL is a maximum of 4% and 1% 
of time, respectively). Glucose targets for patients using 
CGM/FGM are summarized in Table 4.2 in Chapter 4 of 
these guidelines.
Early diagnosis of chronic diabetes complications
—  Early diagnosis of diabetes complications is possible 
with screening for nephropathy, retinopathy, and neu-
ropathy. Screening for these complications in patients 
with diabetes type 1 is outlined in Chapters 18–20.
—  In patients with long-lasting diabetes type 1, diabetic 
macroangiopathy manifesting as ischemic heart dis-
ease, cerebrovascular disease, or peripheral arterial 
disease may develop earlier compared to the gen-
eral population. Principles of diagnosing and treating 
ischemic heart disease are discussed in Chapter 16, and 
management of stroke and acute coronary syndrome 
is outlined in Chapters 17 and 16.1, respectively.
Diagnosis and management of acute complications
—  An adequately educated patient with diabetes type 1 
must know how to treat acute mild to moderate hy-
per- and hypoglycemia and should be able to manage 
these conditions independently. More severe con-
ditions require medical intervention as outlined in 
Chapters 14 and 15.
Special situations in subjects with diabetes type 1
—  Patients with diabetes type 1 and good metabolic 
control, treated with intensive insulin therapy, may 
be subjected to one-day surgery (minor surgical pro-
cedures). Other principles of perioperative manage-
ment in patients with diabetes type 1 are outlined in 
Chapter 25.
—  Compared to the general population, diabetes type 1 
is more commonly accompanied by endocrinopa-
thies, in particular autoimmune disease of the thy-
roid (Hashimoto disease, Graves disease) and adrenal 
cortex (Addison disease), celiac disease, vitamin B12 
deficiency anemia (Addison-Biermer anemia), and 
connective tissue disease. These comorbidities may 
significantly worsen the course of diabetes type 1. 
Development of diseases that complicate the meta-
bolic derangements of diabetes requires admission 
to a specialist unit.
—  Obesity with concomitant insulin resistance may be 
present in subjects with diabetes type 1, resulting 
in an increased insulin requirement and worsened 
metabolic control. Diagnosis and management re-
quire specialist investigations and therapy.
—  Eating disorders including bulimia and anorexia are 
increasingly common in young patients with diabetes 
type 1. Diagnosis and management of these condi-
tions require specialist psychiatric treatment in close 
collaboration with a diabetes specialist.
A well-educated patient with diabetes type 1, treated 
with intensive insulin therapy with good metabolic con-
trol, is able to engage in the same physical activity and 
achieve similar professional goals as non-diabetic sub-
jects of similar age.
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Most important recommendations
• Metformin should be the first choice drug when initiating drug therapy of diabetes type 2 unless it is contrain-
dicated or poorly tolerated. [A]
• If monotherapy using maximum recommended or tolerated doses becomes insufficient to achieve or maintain target 
HbA1c level, another oral agent, GLP-1 agonist, or basal insulin should be added. This decision should not be postponed 
by more than 3–6 months. [A]
• The choice of further drugs should be individualized, taking into account their cardiovascular effect, effective-
ness, side effects, the effect on body weight, risk of hypoglycemia, cost, and patient preferences. [E]
• In patients with cardiovascular disease, particularly previous myocardial infarction, drugs with an established 
beneficial effect on the cardiovascular risk should be considered first. In addition to metformin, such effect was 
shown for some SGLT-2 inhibitors and some GLP-1 agonists [A]. Similarly in patients with chronic kidney disease, 
due to the their proven nephroprotective effect, drugs from both these groups should be preferred, in the first 
place the some SLGT-2 inhibitors, if there are no contraindications to their use [A]. Early combination therapy 
with metformin and some SLGT-2 inhibitors and/or GLP-1 receptor agonists should be considered in any patient 
with blood glucose above target range or with concomitant conditions — atherosclerotic cardiovascular disease, 
chronic kidney disease or heart failure with impaired ejection fraction. [A]
• Due to progressive nature of diabetes type 2, insulin therapy is indicated in many patients when the treatment 
is gradually intensified. [B]
12. Riddell MC, Gallen IW, Smart CE et al. Exercise management in 
type 1 diabetes: a consensus statement. Lancet Diabetes Endocri-
nol. 2017; 5: 377–390. 
13. The Diabetes Control and Complications Trial/Epidemiology of Dia-
betes Interventions and Complications Research Group. Retinopathy 
and nephropathy in patients with type 1 diabetes four years after 
a trial of intensive therapy. N Engl J Med 2000; 342: 381–388.
14. The Diabetes Control and Complications Trial Research Group. 
The effect of intensive treatment of diabetes on the development 
Lowering hyperglycemia by comprehensive manage-
ment of diabetes type 2 (in addition to treating hyper-
tension and dyslipidemia, lifestyle changes, antiplatelet 
treatment etc.) is of key importance for preventing and 
delaying progression of chronic complications of diabe-
tes (both macro- and microvascular).
I.   Lowering hyperglycemia occurs by correcting 
pathogenetic mechanisms of diabetes type 2. 
A different therapeutic mechanism of anti-hyper-
glycemic drugs is glucosuric effect. Treatment of 
diabetes type 2 must be gradual and adapted to 
the progressive nature of the disease. If the thera-
py used at a given stage is no longer effective, i.e., 
target HbA1c level cannot be reached, treatment 
should proceed to the next step after 3–6 months.
II.   Management of diabetes type 2
  Step 1. Monotherapy:
— Lifestyle modification (body weight reduction, in-
creasing physical activity to 30–45 minutes/day), 
reduction of meal calorie content in combination 
with treatment with metformin;
— To minimize the risk of adverse effects of metformin, 
mostly gastrointestinal complaints, therapy should 
be started with small doses which are then gradu-
ally increased to the maximum tolerated dose;
— If metformin is not tolerated or contraindicated, 
therapeutic options included sodium-glucose 
cotransporter 2 (SGLT-2) inhibitors, sulfonyl-
urea, incretin-based therapy (DPP-4 inhibitors or 
GLP-1 receptor agonists), peroxisome prolifera-
tor activated receptor gamma (PPAR-g) agonists 
(pioglitazone), and alpha-glucosidase inhibitors 
(acarbose; in such cases, incretins and SGLT-2 
inhibitors should be preferred in obese subjects 
and those at a high risk of hypoglycemia, and 
a PPAR-g agonist should not be used in patients 
with heart failure;
— Therapeutic effectiveness of the oral therapy used 
may be assessed only after several weeks of treat-
ment;
and progression of long-term complications in insulin-dependent 
diabetes mellitus. N Engl J Med 1993; 329: 977–986. 
15. Tauschmann M, Hovorka R. Technology in the management of 
type 1 diabetes mellitus — current status and future prospects. 
Nat Rev Endocrinol. 2018; 14(8): 464–475. 
16. Triolo TM, Armstrong TK, McFann K et al. Additional autoimmu-
ne disease found in 33% of patients at type 1 diabetes onset. 
Diabetes Care 2011; 34: 1211–1121.
10. Oral antidiabetic agents and GLP-1 receptor agonists  
in the management of diabetes type 2
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— Early combination therapy with metformin and floz-
ins and/or GLP-1 receptor agonists should be consid-
ered in any patient with blood glucose above target 
range or with concomitant conditions — atheroscle-
rotic cardiovascular disease, chronic kidney disease 
or heart failure with impaired ejection fraction.
  Step 2. Combined oral or GLP-1 receptor agonist 
therapy:
— Step 2a: Lifestyle modification and adding an 
SGLT-2 inhibitor or incretin-based therapy (DPP-4 
inhibitor or GLP-1 receptor agonist), a sulfonylurea 
or a PPAR-g agonist to metformin. The choice of 
the drug in this step should be made taking into 
account concomitant diseases, first of all the diag-
nosed cardiovascular disease and chronic kidney 
disease, but also the coexistence of obesity, the 
risk of hypoglycemia and the patient's financial ca-
pabilities. In patients with cardiovascular disease, 
priority should be given to drugs with a proven 
beneficial effect on cardiovascular risk. This effect 
has been demonstrated for some SGLT-2 inhibitors 
and some GLP-1 receptor agonist. In patients with 
chronic kidney disease, including those with de-
creased glomerular filtration rate and/or increased 
urinary protein excretion, drugs from both these 
groups should be preferred — in the first place 
flozins, if there are no contraindications to their 
use, followed by GLP-1 receptor agonists — due to 
their proven nephroprotective effect. SGLT-2 inhib-
itors are also preferred in patients with heart fail-
ure. Similarly, GLP-1 receptor agonists and SGLT-2 
inhibitors are preferred in diabetic patients with 
obesity. In patients with high risk of hypoglycemia 
adding a GLP-1 receptor agonist, a SGLT-2 inhibi-
tor, a DPP-4 inhibitor or a PPAR-gamma agonist 
should be considered. Due to lack of reimburse-
ment of novel antihyperglycemic drugs in Poland, 
sulfonylureas and PPAR-gamma agonists acarbo-
ses are the most economically available drugs.
— Step 2b: Lifestyle modification and three-drug ther-
apy including metformin (in all cases) and two other 
agents with different mechanisms of action from 
the following classes: SGLT-2 inhibitors, GLP-1 recep-
tor agonists, sulfonylureas, a-glucosidase inhibitors 
(acarbose), DPP-4 inhibitors and PPAR-g agonist. The 
choice of drugs in this step should be based on the 
same premises as in the step 2a and on the general 
principles of combining antihyperglycemic agents.
Figure 10.1. A practical management algorithm for diabetes type 2
Incretin-based therapy*, i.e. a gliptin or glucagon-like peptide 1 (GLP-1) receptor agonist; drugs should be used according to SmPC. SU — sulfonylurea,  
alifestyle modification is recommended in each step of treatment
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It also possible to add basal insulin to metformin, 
i.e. switching from Step 1 directly to Step 3 treatment, 
bypassing Steps 2a and 2b.
  Step 3. Lifestyle modification and simple insulin 
therapy [mostly with basal insulin (NPH insulin, long-
acting insulin analog); various regimens — see Chap - 
ter 11], possibly with continuation of metformin and 
other oral drugs or GLP-1 receptor agonist, particu-
larly with continuing overweight.
  Step 4. Lifestyle modification and complex insulin 
therapy, possibly with continuation of metformin 
and other oral drugs (gliptins, pioglitazone, flozins, 
acarbose) or GLP-1 receptor agonist, particularly with 
continuing excessive body weight (see Chapter 11).
 III.  Agents used for the treatment of diabetes type 2 
are listed in Table 10.1. Their effect on non-glycemic 
parameters (i.e., cardiovascular risk, body weight, 
risk of hypoglycemia, lipid parameters, etc.) should 
be taken into account when selecting and combin-
ing drugs, with due attention paid to treatment in-
dividualization (see Chapter 4.I.3). Data from large 
randomized clinical trials indicate a reduction of total 
and cardiovascular mortality with the use of GLP-1 
agonists and SGLT-2 inhibitors.
IV.  Practical algorithm of drug treatment for diabetes 
type 2 is shown in Figure 10.1.
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Most important recommendations
• In patients with diabetes type 1, insulin therapy is the only treatment approach. Intensive insulin therapy with 
multiple injections or CSII is recommended, using insulin pens or personal insulin pump. [A]
• In patients with diabetes type 1, insulin analogs are preferred due to a lower risk of hypoglycemia. [A]
• Diabetes type 2 is a progressive disease. Increasing underlying pathophysiologic disturbances, particularly the 
beta cell defect, result in a need for gradual treatment intensification, including initiation of insulin therapy. [B]
11. Insulin therapy
I.   Indications for initiating insulin therapy in diabe-
tes type 2:
— Newly diagnosed diabetes (with an option to re-
turn to the typical treatment algorithm and with-
drawal of insulin therapy):
• Blood glucose ≥ 300 mg/dL (16.7 mmol/L) with 
concomitant clinical symptoms of hyperglycemia;
— Treatment ineffectiveness without use of insulin 
(HbA1c above target despite intensified behavioral 
therapy).
II.   Indications for switching from previous antihyper-
glycemic therapy (using oral  antihyperglycemic 
agents, in some cases in combination with a GLP-1 
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receptor agonist) to combined therapy including 
insulin if blood glucose remains uncontrolled:
— Continuing hyperglycemia as confirmed on several 
occasions;
And
— Unsuccessful attempts to eliminate potentially cor-
rectable causes of hyperglycemia, such as:
• Dietary errors;
• Too low physical activity;
• Irregular intake of oral antihyperglycemic 
agents (poor compliance);
• Infections;
• Inadequate doses of oral agents.
III.   Indications for initiating insulin therapy regard-
less of blood glucose levels:
— Pregnancy;
— Autoimmune-mediated diabetes in adults (type 1/ 
/LADA);
— Diabetes associated with cystic fibrosis;
— Reasonable patient’s request.
In overweight or obese patients with LADA, metfor-
min use combined with insulin therapy is beneficial.
IV.   Indications for temporary insulin therapy:
— Diabetes decompensation due to transient causes 
(infection, trauma, glucocorticoid therapy, etc.);
— Surgical procedure (see Chapter 25);
— Stroke (see Chapter 17);
— Percutaneous coronary intervention (PCI);
— Acute coronary syndrome;
— Other acute illness requiring admission to an in-
tensive care unit.
V.   Insulin therapy algorithm in diabetes type 2
 1.  Long-acting insulin (isophane — NPH or long-acting 
insulin analog) in one daily injection:
— With morning hyperglycemia — in the evening; 
use of long acting analogues reduces the risk of 
nocturnal and severe hypoglycemia;
— With fasting and daytime hyperglycemia — in the 
morning (consider multiple injections of a short/ 
/rapid-acting insulin if postprandial hyperglycemia 
is noticed).
In selected cases, when initiation of insulin therapy 
was long overdue, resulting in severe hyperglycemia and 
HbA1c levels much above the therapeutic target, initia-
tion of mixed insulin therapy or intensive insulin therapy 
should be considered as the initial treatment option, 
particularly in relatively young patients with long life 
expectancy. Currently, no convincing evidence exists for 
better effectiveness or safety of mixed human insulins or 
insulin analogs. The choice of a particular insulin prepara-
tion should be made individually, taking into account pa-
tient’s preferences regarding the number of daily meals.
 2.  Initial dose is 0.1–0.2 unit/kg or 10 units.
 3.  Oral antihyperglycemic agents and injectable incretin-
based therapies may be used according to the regis-
tration in subjects treated with insulin:
— Metformin therapy should be continued in all pa-
tients, if tolerated and not contraindicated;
— In case of concomitant overweight or obesity, com-
bined therapy with metformin and a SGLT-2 inhibi-
tor or an incretin-based therapy (DPP-4 inhibitor or 
GLP-1 receptor agonist) should be preferred;
— With normal body weight, combination with a sul-
fonylurea may be considered.
Figure 11.1. A practical algorithm for insulin therapy in diabetes type 2. Models of initiation and intensification of insulin therapy
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 4.  Blood glucose control should be evaluated within 
4–5 days, with gradual dose increments by 2–4 units 
based on SMBG readings until adequate control.
 5.  If daily basal insulin requirement is > 0.3–0.5 unit/kg 
body weight and glycemia is poorly controlled, treat-
ment intensification may be considered using mixed 
insulin or biphasic insulin analog; it may also be con-
sidered to supplement long-acting insulin (adminis-
tered once or twice daily) with a short-acting insulin/ 
/rapid-acting insulin analog administered at 1–3 
meals (basal-plus insulin regimen, intensive insulin 
therapy). Discontinuation of insulin secretagogues 
should be considered.
 6.  If large daily insulin doses are used (> 100 units), in-
dicating insulin resistance, causes of the latter should 
be considered and the possibility of adverse effects 
should be taken into account.
An attempt to reduce the degree of insulin resistance 
by a 72- to 96-hour continuous subcutaneous or intrave-
nous insulin infusion is recommended.
Intensive insulin therapy
Intensive insulin therapy is undertaken based on simi-
lar principles in all types of diabetes, using multiple daily 
insulin injections, or by CSII using a personal insulin pump.
I. Principles of intensive insulin therapy:
— Daily SMBG;
— Self-adjustment of insulin doses or administering 
additional insulin doses depending on blood glucose 
readings, energy requirement, and physical activity;
— Precise definition of target blood glucose levels;
— Appropriate therapeutic and nutritional education 
and patient motivation;
— Possibility of a rapid patient contact with the ther-
apeutic team;
— In diabetes type 2, CSII using a personal insulin 
pump is not a routine treatment approach.
II. Algorithms of multiple insulin injections:
— Short-acting insulin or rapid-acting insulin analog 
before meals; and
— Isophane insulin (NPH) or long-acting insulin ana-
log to provide constant basal insulin levels admin-
istered before bedtime and/or in the morning.
In some cases of diabetes type 2 with normal fasting 
blood glucose levels, short-acting insulin injections or 
insulin analog at mealtimes may be sufficient.
III. Personal insulin pump treatment algorithm
Therapy with personal insulin pumps should be un-
dertaken in centers experienced in such treatment. This 
approach is used in diabetes type 1 and some other spe-
cific diabetes types (e.g. diabetes associated with cystic 
fibrosis).
 1.  Indications:
— Need for small insulin doses (e.g., in children);
— Recurrent, unpredictable hypoglycemia episodes;
— Hypoglycemia unawareness;
— Irregular lifestyle and meals;
— Early-morning hyperglycemia;
— Pregestational diabetes mellitus which is difficult 
to control with multiple insulin injections;
— Patient preference if costs incurred by this treat-
ment approach are accepted.
 2.  Contraindications:
— Low intellectual or educational level of the patient;
— Lack of patient compliance;
— No contact with a specialist clinic.
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• The general blood pressure target in patients with diabetes is < 130/80 mm Hg (in patients aged > 65 years it 
is < 140/80 mm Hg). [A]
• The treatment of hypertension should be initiated with the combination of two drugs: an angiotensin conver-
ting enzyme inhibitor (ACEI) or an AT1 angiotensin receptor antagonist with a calcium antagonist or a thiazide/ 
/thiazide-like diuretic [A]
• Pharmacological treatment of hypertension should be continued without interruption, because it is the only way 
to reduce cardiovascular risk. [A]
• In the treatment of hypertension patients with diabetes should strive not only to achieve the target blood pres-
sure, but also to maintain or restore normal diurnal variation in blood pressure assessed by 24-hour monitoring, 
especially in pregnant women with diabetes. [B]
In patients with diabetes, initiation of drug treatment 
is recommended if blood pressure is above 140/90 mm Hg. 
The goal of treatment is to reduce the global cardio-
vascular event risk by lowering systolic blood pressure 
below 140 mm Hg; targeting systolic blood pressure in 
patients under 65 years of age to 130 mm Hg (and if the 
treatment is well tolerated — below 130 mm Hg due to 
benefits associated with the stroke risk reduction). The 
optimal diastolic blood pressure is below 80 mm Hg. 
Hypertension can be diagnosed based on 24-hour auto-
matic blood pressure monitoring (ABPM).
I. Principles of blood pressure measurement
Blood pressure should be measured during each vis-
it, also in the standing position to evaluate orthostatic 
blood pressure falls. Home blood pressure measurements 
are recommended in all patients with the diagnosis of 
hypertension. In patients with systolic blood pressure 
≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg, 
measurement should be repeated on another day, and 
out-of-office blood pressure measurements should be 
recommended. Systolic blood pressure ≥ 140 mm Hg or 
diastolic blood pressure ≥ 90 mm Hg during repeated 
measurements confirms the diagnosis of hypertension. 
In case of diagnostic uncertainties, 24-hour ambulatory 
blood pressure measurement (including evaluation of 
night-time blood pressure values) is useful, along with 
home blood pressure measurements performed by the 
patient.
II. Principles of antihypertensive therapy:
—  When striving to achieve the above goals of treat-
ment of hypertension in diabetic patients, it is 
necessary to avoid lowering the systolic blood 
pressure below 120 mm Hg, and in patients with 
chronic kidney disease — below 130 mmHg;
—  Diastolic blood pressure should not be lowered 
below 70 mm Hg;
— Drug treatment should be combined with lifestyle 
changes in all patients with hypertension;
— As a general rule, treatment should be initiated 
with the combination of two drugs: an angioten-
sin converting enzyme inhibitor (ACEI) or angio-
tensin receptor antagonist AT1 with a calcium an-
tagonist or thiazide/thiazide-like diuretic; however, 
if specific comorbidities are present (e.g., ischemic 
heart disease or chronic kidney disease) the com-
bination of two drugs may be different;
— Considering the above recommendation, it is ad-
visable to use single-pill combinations to improve 
compliance;
— The presence of proteinuria does not change pre-
defined blood pressure goal;
— A combination of an ACEI and a beta-blocker 
is commonly used in patients with hypertension 
and cardiac disease (ischemic heart disease, heart 
failure);
— Combinations of drugs with similar mechanisms 
of action are of little value, as the blood pres-
sure-lowering effect is less than additive or an 
increased risk of adverse effects exists;
— A drug from another class should be added if tar-
get blood pressure has not been reached despite 
two-drug treatment (one of the drugs used should 
be a diuretic);
— In case of a non-dipping nocturnal blood pressure 
pattern or a morning blood pressure surge, modi-
fication of the timing of antihypertensive drug 
administration should be considered;
— Long-acting antihypertensive drugs which allow 
24-hour blood pressure control with once daily 
dosing should be preferred;
— Serum creatinine, potassium, and glomerular fil-
tration rate (GFR) should be monitored during 
treatment with ACEI, ARB, renin inhibitors, and 
diuretics;
12. Treatment of hypertension in diabetic patients
33
2020 Guidelines on the management of diabetic patients
— In patients aged > 65 years, blood pressure should 
be lowered gradually to avoid treatment complica-
tions;
—  In very elderly patients (> 80 years) or with frailty 
syndrome it is reasonable to start antihypertensive 
therapy with monotherapy.
III. Choice of blood-pressure lowering drugs
An effective treatment resulting in normalization of 
blood pressure is more important for the prevention of 
cardiovascular complications than the choice of drugs:
— Renin-angiotensin-aldosterone (RAA) system in-
hibitors should be preferred if albuminuria/pro-
teinuria is present;
— Combined treatment with ACEI and ARB is contra-
indicated;
— Combined treatment may include drugs from the 
above listed and other drug classes, taking into 
account the principles of combining antihyperten-
sive drugs;
— Drug treatment of hypertension in patients with 
concomitant renal dysfunction — see Chapter 18;
— In patients aged > 55 years with concomitant 
cardiovascular risk factors, treatment with ACEI 
should be considered to reduce the cardiovascular 
risk regardless of blood pressure values;
— ACEI or ARB is recommended in normotensive sub-
jects with urinary albumin-to-creatinine ratio ≥ 30 
mg/g to prevent and delay progression of diabetic 
kidney disease;
— In patients with ischemic heart disease, previous 
myocardial infarction, or heart failure, beta-block-
ers and ACEI are reasonable as first-choice drugs 
to reduce mortality risk;
— Use of nonselective beta-blockers should be avoid-
ed with concomitant peripheral arterial disease;
— In case of coexistence of peripheral arterial dis-
ease, taking non-selective b-bleckers should be 
avoided;
— Thiazide/thiazide-like diuretics should be used 
in patents with GFR ≥ 30 mL/min/1.73 m2, while 
a loop diuretic should be used if GFR is < 30 mL/ 
/min/1.73 m2.
Clinical studies indicate that use of at least three 
different antihypertensive drugs is necessary to reach 
therapeutic goals in the majority of patients. Often, this 
requires use of other drug classes in addition to those 
listed above (including alpha-blockers, centrally-acting 
drugs, and vasodilators).
Resistant hypertension, which requires multiple drug 
therapy, is common in diabetes. In this situation, the 
use of spironolactone should be considered. Testing for 
obstructive sleep apnea should be considered in diabetic 
patients with resistant hypertension.
Principles of diabetes management in children and 
adolescents, pregnant women and those contemplating 
pregnancy, and patients above 65 years of age — see 
Chapters on respective subjects. 
IV. Management of hypertension in pregnant women
Target blood pressure values in pregnant women with 
diabetes are: 110–139 mm Hg and 81–85 mm Hg for 
systolic and diastolic blood pressure, respectively. Blood 
pressure target below 130/80 mm Hg is recommended 
for pregnant women with diabetes and vascular com-
plications.
In pregnant women with non-severe hypertension, 
oral drugs of choice are (in the order given) methydopa, 
labetalol, and calcium antagonists. In life-threatening 
situations, the preferred drugs are labetalol and nitro-
glycerin (administered parenterally). If these are not avail-
able, parenteral hydralazine may be used, although an 
increase in the rate of adverse effects in the perinatal 
period has been reported.
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• LDL-C level < 55 mg/dL (1.4 mmol/L) or reduction by at least 50% in diabetic subjects at very high cardiovascular 
risk. [B]
• LDL-C level < 70 mg/dL (1.8 mmol/L) or reduction by at least 50% in diabetic subjects at high cardiovascular risk. [A]
• LDL-C level < 100 mg/dL (2.6 mmol/L) in diabetic subjects at moderate cardiovascular risk (young patients < 35 
years of age with diabetes type 1 without chronic complications and other cardiovascular risk factors or patients 
with type 2 diabetes < 50 years of age, with duration of diabetes < 10 years, without other risk factors). [A]
The main goal is to reduce LDL cholesterol level, while 
non-HDL cholesterol level is a secondary therapeutic tar-
get. Complete normalization of the atherogenic lipid 
profile after achieving target LDL cholesterol level, i.e. in-
creasing HDL cholesterol level and decreasing triglyceride 
level, may be associated with beneficial effects.
Diabetic patients with vascular complications (previous 
myocardial infarction, acute coronary syndrome, coronary 
revascularization or other revascularization procedures, 
stroke, transient ischemic attack, aortic aneurysm, and 
peripheral arterial disease) or other target organ damage 
(proteinuria or microalbuminuria, impaired renal function 
— GFR < 30 mL/min/1.73 m2, left ventricular hypertrophy, 
retinopathy, neuropathy) or with at least three major risk 
factors (age, hypertension, dyslipidemia, smoking, obesity) 
or early onset and long-term of type 1 diabetes (> 20 
years) should be considered at very high cardiovascular 
risk. Patients without chronic diabetes complications who 
have additional cardiovascular risk factor are at high car-
diovascular risk. In young patients with type 1 diabetes 
< 35 years or type 2 diabetes < 50 years, with diabetes 
duration < 10 years and without other cardiovascular risk 
factors, the risk is moderate. When assessing cardiovas-
cular risk, the following tests are helpful: resting ECG, ul-
trasound examination of carotid/femoral arteries to detect 
the presence of atherosclerotic plaques, and ankle-brachial 
index (ABI). The presence of atherosclerotic plaques in 
the carotid and/or femoral arteries found by ultrasound 
examination may be considered a risk-modifying factor.
I. Diagnosis of lipid disorders
History should include:
— Assessment of nutrition and alcohol intake;
— Assessment of physical activity — type and dura-
tion of activity;
— Presence of cardiovascular disease: ischemic heart 
disease, cerebrovascular disease, and peripheral 
arterial disease;
— Evaluation for thyroid, liver, and kidney disease to 
exclude secondary hyperlipidemia;
— Family history of lipid disorders, cardiovascular 
disease, hypertension, and diabetes in first-degree 
relatives.
Use of drugs that may increase lipid levels. Recommen-
ded levels of lipid parameters are presented in Table 13.1.
In patients with diabetes and cardiovascular disease 
further decrease in LDL-C level is associated with greater 
reduction of the risk of cardiovascular events.
Table 13.1. Cardiovascular risk categories and LDL-C and non-HDL-C target levels
Cardiovascular 
risk categories
Criteria Target levels of LDL-C and non-HDL-C
Very high Patients with diabetes and cardiovascular disease 
OR target organ damage*
OR 3 or more main cardiovascular risk factors**
OR early-onset and long-duration (> 20 years) type 1 diabetes
LDL-C < 1.4 mmol/L (55 mg/dL) or 50% 
reduction in LDL-C (IB)
Non-HDL-C < 2.2 mmol/L (85 mg/dL) (IB)
High Patients with diabetes duration ≥ 10 years, without target organ 
damage* plus additional risk factors 
LDL-C  < 1.8 mmol/L (70 mg/dL) or 50% 
reduction in LDL-C (IA)
Non-HDL-C < 2.6 mmol/L (100 mg/dL) (IB)
Moderate Young patients with type 1 diabetes aged < 35 years or type 2 dia-
betes aged < 50 years, with diabetes duration < 10 years, without 
other risk factors
LDL-C < 2.6 mmol/L (100 mg/dL) (IA)
*Target organ damage include: proteinuria or microalbuminuria, impaired renal function (GFR < 30 mL/min/1.73 m2), left ventricular hypertrophy, retinopathy, 
and neuropathy
**The main cardiovascular risk factors are: age, hypertension, dyslipidemia, smoking, obesity
11. Wright JT Jr, Williamson JD, Whelton PK et al. SPRINT Re- search 
Group. A randomized trial of intensive versus standard blood-
-pressure control. N Engl J Med 2015; 373: 2103–2116.
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control in type 2 diabetes. N Engl J Med 2014; 371:1392–1406.
13. Treatment of dyslipidemia
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LDL cholesterol level may be estimated using the 
Friedewald formula if triglyceride level is < 400 mg/dL 
(< 4.5 mmol/L) and LDL cholesterol level cannot be di-
rectly measured:
LDL cholesterol [mmol/L] = total cholesterol [mmol/L] – 
– HDL cholesterol [mmol/L] – triglycerides/2.2 [mmol/L]
HDL-C:
— No target level but values > 1.0 mmol/L (> 40 
mg/dL) in men and > 1.2 mmol/L (> 45 mg/dL) in 
women indicate a lower cardiovascular risk.
Triglycerides:
— No target level but values < 1.7 mmol/L (< 150 
mg/dL) indicate a lower cardiovascular risk.
II. Lipid level monitoring
 1.  Diabetes type 2
— Lipid parameters should be measured at the time 
of the diagnosis of diabetes, with follow-up mea-
surements annually or more frequently, depending 
on the measured levels;
— If lipid parameters are above the normal values, these 
should be re-checked every 8–12 weeks after treat-
ment initiation until the desired levels are reached;
— If lipid parameters are within the desired range, 
follow-up measurements should be performed an-
nually.
 2.  Diabetes type 1 (see also the respective chapter on 
diabetes type 1):
— If lipid levels indicate low risk, lipid parameters 
should be re-checked every 2–5 years, depending 
on the presence of other risk factors for cardiovas-
cular disease.
III. Treatment of dyslipidemia in diabetic patients
 1.  Lifestyle changes:
— Increase in physical activity;
— Body weight reduction in overweight and obese 
subjects;
— Cessation of tobacco smoking;
— Diet with a reduction of saturated fat intake to 
< 10% of the total calorie intake, reduced cho-
Figure 13.1. An algorithm for managing dyslipidemia in diabetes. TG — triglycerides; HDL-C — high-density lipoprotein chole-
sterol; LDL-C — low-density lipoprotein cholesterol
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lesterol (< 300 mg/day or < 200 mg/day with 
increased LDL cholesterol levels), and maximum 
reduction of trans fat intake; intake of n-6 polyun-
saturated fatty acids should be 4–8% of the total 
calorie intake, and intake of n-3 polyunsaturated 
fatty acids should be 2 g of linolenic acid and 200 
mg/day of very long-chain fatty acids;
— In hypertriglyceridemia, reduction of obesity, 
reduced alcohol intake, reduced mono- and di-
saccharide intake (reduction of fructose intake), 
reduced saturated fat intake, adding monounsatu-
rated fats to diet, and reduction of carbohydrate 
intake are all of major importance.
 2.  Tight glycemic control
Tight glycemic control is of major importance for con-
trolling dyslipidemia, in particular hypertriglyceridemia.
 3.  Drug treatment
Statins are first-line drugs in the treatment of diabetic 
dyslipidemia.
Drug treatment, mostly with statins, is used in:
— In diabetic patients with concomitant cardiovascu-
lar diseases;
— In diabetic patients with chronic kidney disease or 
other organ damage, or the presence of 3 or more 
major risk factors;
— In diabetic patients without concomitant cardiovas-
cular disease but with ≥ 1 cardiovascular risk factor.
In type 1 diabetes, statins are recommended in pa-
tients at high or very high cardiovascular risk.
Statin therapy may be considered in patients with 
diabetes type 1 aged ≤ 30 years with documented tar-
get organ damage and/or LDL-C level ≥ 100 mg/dL (2.6 
mmol/L). Women with diabetes can use statins unless 
they are planning a pregnancy.
In asymptomatic patients with type 1 diabetes, the 
use of statins can be delayed to 30 years of age, if they 
have no organ damage, especially microalbuminuria.
Statin treatment is contraindicated during pregnancy 
and breastfeeding. Statins should not be recommended for 
women of childbearing potential unless using effective con-
traception. In addition, the use of statins is contraindicated 
in people with transaminase levels greater than 3 times the 
upper limit of normal and in patients with creatine kinase 
level greater than 4 times the upper limit of normal.
— In diabetic patients with concomitant hypertriglyc-
eridemia > 2.3 mmol/L (> 200 mg/dL) persisting 
despite attainment of the target LDL cholesterol 
level using a statin, an increase in statin dose 
should be considered to reduce non-HDL choles-
terol level which is a secondary therapeutic target. 
Combination treatment with a fibrate should be 
considered in selected cases;
 4.  Combined therapy. Consideration should be given to 
intensifying statin therapy prior to introducing com-
bination therapy.
— In statin-treated patients with diabetes type 2 in 
whom triglyceride level is > 2.3 mmol/L (> 200 mg/ 
/dL) and HDL cholesterol level is < 0.9 mmol/L (< 35 
mg/dL), adding a fibrate to a statin is associated with 
an additional reduction of cardiovascular events;
— Combined statin and ezetimibe treatment was as-
sociated with further LDL cholesterol level lower-
ing and a reduction in the cardiovascular event 
rate compared to statin monotherapy. Ezetimibe 
may thus be of use in patients in whom recom-
mended LDL cholesterol lowering has not been 
attained using a maximum tolerated statin dose 
or statin treatment is not tolerated.
Combined treatment with statins and other lipid-
lowering drugs (ezetimibe, PCK9 inhibitors, fenofibrates) 
may be useful to achieve target lipid parameters in dia-
betic patients but no large clinical trials have been con-
ducted to confirm efficacy and safety of such treatment.
PCSK9 inhibitors that significantly reduce LDL-C may 
be useful in diabetic patients with concomitant familial 
dyslipidemia, recurrent cardiovascular events and elevated 
LDL-C levels despite the addition of a second lipid-lowering 
drug or statin intolerance to the maximum statin dose (IA).
Combined therapy (mostly with statin + fenofibrate) 
is associated with an increased risk of abnormal liver 
function tests, myositis, and rhabdomyolysis, particularly 
with concomitant chronic kidney disease and use of high 
drug doses.
 5.  Management of severe hypertriglyceridemia
A clinically significant risk of acute pancreatitis oc-
curs with triglyceride levels > 10 mmol/L (> 880 mg/dL). 
Hypertriglyceridemia underlies about 10% of acute pan-
creatitis cases, but pancreatitis may develop already with 
triglyceride levels > 5 mmol/L (> 440 mg/dL).
 Recommended management includes:
— Hospital admission in case of acute pancreatitis;
— Strict control of triglyceride levels:
• Reduction of the total calorie intake and fat 
intake (to 10–15% of the total calorie intake),
• Complete abstinence from alcohol,
• Therapy with fibrates.
In diabetic patients who are not treated with insulin, 
insulin therapy should be started to achieve optimal 
blood glucose control, most commonly using intravenous 
insulin pump. This approach allows reduction of triglyc-
eride levels within 2–5 days.
Principles of diabetes management in children and 
adolescents, pregnant women and those contemplating 
pregnancy, and patients above 65 years of age — see 
Chapters on respective subjects.
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• Each patient with diabetes should be asked for the symptoms and frequency of hypoglycemia at each visit. [C]
• Each patient at a high risk of clinically significant hypoglycemia (< 54 mg/dL; i.e. < 3.0 mmol/L) should be 
prescribed glucagon. Family members, caregivers, and teachers involved with diabetic children and adolescents 
should be aware how to administer glucagon. [E]
• Modification of diabetes treatment should be considered if episodes of severe hypoglycemia and hypoglycemia 
unawareness occur. [E]
• When treating hypoglycemia in a conscious patient (with blood glucose level ≤ 70 mg/dL; i.e. 3.9 mmol/L), the 
key intervention is to administer orally 15 g of glucose or other simple carbohydrates. If repeated blood glucose 
measurement after 15 minutes still indicates hypoglycemia, the treatment should be repeated. When hypogly-
cemia resolves, the patient should consume a snack/meal to prevent recurrent hypoglycemia. [E]
• In insulin-treated diabetic patients with hypoglycemia unawareness or an episode of severe hypoglycemia, the 
therapeutic goal should be to maintain somewhat higher blood glucose levels for at least several weeks in order 
to restore at least partial hypoglycemia awareness and prevent future episodes of hypoglycemia. [A]
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14. Hypoglycemia
I.		 	 Definition	of	hypoglycemia.	Hypoglycemia	is	diag	- 
nosed when blood glucose level falls below 70 
mg/dL (3.9 mmol/L) regardless of clinical symp-
toms which may occur only with lower blood 
glucose levels in some patients, particularly 
those with long-standing diabetes type 1 pres-
ent for many years. Blood glucose level of 70 mg/ 
/dL (3.9 mmol/L) should be considered an alert 
level that requires carbohydrate consumption 
or	modification	of	blood	glucose-lowering	drug	
doses regardless of the presence or absence of 
symptoms of hypoglycemia, to prevent further 
reduction	of	blood	glucose	level.	This	justifies	set-
ting the threshold for imminent hypoglycemia at 
70	 mg/dL	 (3.9	 mmol/L).	 Clinically	 significant	
hypoglycemia	 should	 be	 defined	 as	 blood	 glu-
cose	 level	 <	 54	 mg/dL	 (3  mmol/L).	 Symptoms	
of hypoglycemia may also develop with high-
er	 blood	 glucose	 levels	 even	>  100 mg/dL	 (5.6	
mmol/L), if a rapid decrease in blood glucose has 
occurred. So called hypoglycemia unawareness, 
defined	 as	 unawareness	 of	 pathologically	 low	 
(≤ 70 mg/dL, i.e. ≤ 3.9 mmol/L) blood glucose 
levels,	 is	 a	 significant	 complication	 of	 frequent	
hypoglycemia episodes.
  Classification of hypoglycemia according to the Inter-
national Hypoglycemia Study Group, 2017 (Tab. 14.1).
Severe hypoglycemia is an episode requiring help of 
another person to administer carbohydrates, glucagon, 
or initiate other measures. Exact blood glucose values 
during the episode may be not available but resolution 
of symptoms following administration of glucose and/or 
glucagon is considered a sufficient proof that the episode 
was caused by low blood glucose levels.
Recurrent severe hypoglycemia: two or more epi-
sodes of severe hypoglycemia during last 12 months.
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Table	14.1.	Hypoglycemia	classification	by	the	International	Hypoglycemia	Study	Group,	2017
Level Blood glucose level 
threshold
Comments
Alert glucose level  
(level 1)
≤ 70 mg/dL (≤ 3.9 mmol/L) Blood glucose level requiring treatment with simple carbohydrates
Indication for an adjustment of blood glucose lowering agent doses
Clinically important  
hypoglycemia  
(level 2)
< 54 mg/dL (< 3.0 mmol/L) Sufficiently low blood glucose level to indicate  
clinically important hypoglycemia
Severe hypoglycemia  
(level 3)
No specific value Hypoglycemia associated with severe cognitive impairment requiring 
external assistance for recovery
II. General considerations
 1.  Diabetic subjects should not be automatically consid-
ered at risk of hypoglycemia and thus handicapped in 
terms of employment and the social status.
 2.  Risk of hypoglycemia is increased in the following 
situations:
— Insulin use as monotherapy or in combination 
with other antidiabetic agents;
— Sulfonylureas use as monotherapy or in combina-
tion with other antidiabetic agents;
— Inappropriate dosing of the above mentioned 
agents in the settings of increased physical activ-
ity, reduced calorie intake or alcohol consump-
tion;
— Aiming for rapid HbA1c level normalization;
— Coexistence of other diseases that promote hypo-
glycemia (e.g. renal failure, hypothyroidism, adre-
nal insufficiency, eating disorders, diseases with 
impaired intestinal absorption).
 3.  Hypoglycemia may be directly life-threatening in 
some situations (the elderly, patients with ischemic 
heart disease)
III. Management of hypoglycemia unawareness:
— Patient and family member education regarding 
identification of subtle and atypical prodromes of 
hypoglycemia;
— Consideration of this problem during professional 
activities and driving;
— Treatment modifications leading to a significant 
reduction of hypoglycemia episodes as the only 
approach to improve hypoglycemia awareness;
— Frequent SMBG, and consideration of CGM or 
FGM if available.
IV.  Management of recurrent hypoglycemia episodes 
includes thorough evaluation of patient’s habits 
and current treatment of diabetes and other con-
ditions,	and	modification	of	diabetes	therapy	to	
minimize the risk of hypoglycemia (e.g., by re-
ducing insulin dose before anticipated physical 
exercise, switching to another insulin type, etc.).
V. Acute management of hypoglycemia
 1.  In a conscious patient:
— Oral administration of 15 g of glucose and re-evalu-
ation of blood glucose level after 15 minutes. If hy-
poglycemia persists, another 15 g of carbohydrates 
should be administered orally and blood glucose 
level should be measured again after 15 minutes;
— If there is a risk of recurrent hypoglycemia, e.g. af-
ter erroneous administration of excessive dose of 
insulin, after alcohol consumption, after prolonged 
exercise, it is recommended that, in addition to the 
above described intervention complex carbohydrates 
should be consumed (depending on blood glucose) 
and blood glucose level should be monitored.
 2.  In an unconscious patient or a person with impaired 
consciousness and unable to swallow:
— Intravenous administration of 20% dextrose solu-
tion (0.2 g dextrose/kg body weight) followed 
by infusion of 10% dextrose with monitoring of 
blood glucose level;
— If intravenous access is difficult, administer 1 mg 
of glucagon intramuscularly or subcuteneously 
(0.5 mg in children < 6 years of age);
— Upon return of consciousness, if there is a risk of re-
current hypoglycemia, oral administration of 10–20 g 
of carbohydrates and blood glucose monitoring;
— In patients with diabetes treated with insulin or 
sulfonylureas, hypoglycemia lasting many hours 
may occur that sometimes requires prolonged glu-
cose infusion;
— If severe hypoglycemia occurs, hospital admission 
should be considered due to a life-threatening 
condition associated with a risk of irreversible le-
sions in the central nervous system particularly if 
there is a risk of recurrent hypoglycemia.
 3.  In patients receiving intensive insulin therapy using in-
sulin analogs or a personal insulin pump, management 
of hypoglycemia usually includes only administration 
of 15 g of glucose orally and rechecking blood glucose 
level after 15 minutes. If blood glucose level continues 
to be low, glucose should be re-administered and 
blood glucose level rechecked after further 15 minutes 
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(the 15/15 rule). If oral intake of simple carbohydrates 
is not possible during personal insulin pump treat-
ment, interruption of basal insulin infusion and re-
peated blood glucose measurements are indicated.
 4.  In patients treated with long-acting insulins (human 
or insulin analogs) a possibility of delayed recur-
rent hypoglycemia after initial successful treatment 
should be taken into consideration.
Most important recommendations
• No large randomized studies are available to support various therapeutic regimens for acute hyperglycemia. 
Management of diabetic ketoacidosis according to the established regimen is associated with reduced treatment 
duration. [C]
• In diabetic ketoacidosis, crystalloids are preferred over colloids to replace body fluid deficit. [C]
• Continuous intravenous infusion is the preferred method of insulin administration in acute hyperglycemic con-
ditions, and the initial dose (bolus) should be calculated on the basis of the patient’s current body mass rather 
than baseline blood glucose levels. [C]
• Acute hyperglycemic conditions, and particularly diabetic ketoacidosis, require potassium supplementation with 
monitoring of serum potassium level. [C]
• Bicarbonate administration is not recommended in diabetic ketoacidosis if blood pH is > 6.9. [B]
I.	Classification
 1.  Diabetic ketoacidosis (mortality: 0.2–2%; mortality 
risk is increased in patients with recurrent episodes 
of diabetic ketoacidosis).
 2.  Hyperglycemic hyperosmolar state (mortality — 
about 15%).
 3.  Lactic acidosis (mortality — about 50% according to 
the historical data but currently depends to a large 
degree on the experience of the treating center, the 
severity of the underlying disease, and concomitant 
conditions).
II. Diabetic ketoacidosis
 1.  Causes:
— Interruption or errors of insulin therapy;
— Too late diagnosis of diabetes type 1;
— Alcohol abuse;
— Acute inflammation (e.g., bacterial, viral, and fun-
gal infections);
— Pregnancy;
— Other.
 2.  Diagnosis: see Table 15.1.
Laboratory criteria of diabetic ketoacidosis:
— Blood glucose usually > 250 mg/dL (> 13.9 
mmol/L), blood glucose values may be lower in 
patients treated with SGLT-2 inhibitors;
— Blood pH < 7.3;
— Serum bicarbonate level < 15 mmol/L;
— Presence of ketone bodies in urine or serum;
— Anion gap: Na+ (mmol/L) – [Cl– (mmol/L) + HCO3
– 
(mmol/L)] > 12 (measured and not corrected so-
dium level is used in this formula).
 3.  Differential diagnosis:
— Fasting ketosis;
— Alcohol-induced ketoacidosis [blood glucose level 
rarely > 250 mg/dL (13.9 mmol/L), serum bicar-
bonate level usually ≥ 18 mmol/L];
— Metabolic acidosis with anion gap > 20 mEq/L 
(ethylene glycol, methanol, paraldehyde, or salicy-
late poisoning);
— Lactic acidosis (blood lactate level may also in-
crease in ketoacidosis);
— Other comatose conditions leading to hyperglyce-
mia and ketosis, or the latter accompanied by e.g., 
stroke or uremic coma.
 4.  Monitoring of ketoacidosis:
— Evaluation of blood pressure, heart rate, breathing 
rate, and the degree of consciousness: every 1–2 
hours;
— Fluid balance: every 1–2 hours;
— Body temperature measurements: every 8 hours;
— Blood glucose measurements: every hour;
— Serum or plasma sodium and potassium measure-
ments: every 4 hours [corrected serum sodium 
level should be calculated using the formula: mea-
sured serum Na+ + 2.0 mmol/L per each 100 mg/dL 
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15. Management of acute diabetes complications due to hyperglycemia
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(5.6 mmol/L) of blood glucose level above 100 mg/dL 
(5.6 mmol/L)];
— If serum potassium > 5.5 mmol/L when potassium 
is not supplemented: serum potassium measure-
ment after 2 hours, and after normalization — 
 every 4 hours;
— Blood gases: every 4 hours;
— Baseline blood and/or urine ketones.
 5.  Management:
 A.  Patient hydration:
— Water deficit (on average 100 mL/kg body weight) 
should be corrected intravenously within 24–48 
hours with monitoring of the patient’s cardiovas-
cular status:
• 1000 mL 0.9% saline within first hour,
Followed by:
• 500 mL/h 0.9% saline for 4 hours,
Followed by:
• 250 mL/h 0.9% saline until normalization of 
acid-base balance,
• When blood glucose is reduced below 250 mg/dL 
(13.9 mmol/L), add 5% dextrose infusion at 
100 mL/h; if dextrose infusion is added after 
24 hours of fluid therapy, decrease the rate of 
0.9% saline infusion to 150 mL/h,
• In situations associated with increased energy 
requirement (e.g., ketoacidosis associated with 
infection, hyperthyroidism, pregnancy), it is rec-
ommended to substitute 10% dextrose for 5% 
dextrose, administered at the rate of 70 mL/hour;
•  In patients with low body weight (< 50 kg), 
rehydration should be carried out according to 
pediatric recommendations (Figure 22.1).
 B.  Correcting hyperglycemia:
— Intravenous insulin therapy:
• Initial insulin bolus 0.1 unit/kg body weight,
• Followed by intravenous insulin infusion at 0.1 
unit/kg body weight/hour with blood glucose 
monitoring,
• The rate of infusion should be adjusted de-
pending on current blood glucose level, mea-
sured every hour,
• Hourly blood glucose level reduction should be 
not higher than 100 mg/dL (5.6 mmol/L),
• If plasma glucose level does not fall by 50–70 
mg/dL (2.8–3.9 mmol/L) from the baseline value 
during the first hour, increase (usually double) 
the rate of intravenous insulin infusion until con-
stant blood glucose level reduction by 50–70 
mg/dL (2.8–3.9 mmol/L) per hour is reached.
 C.  Correction of electrolyte disturbances:
— Potassium deficit in a person with ketoacidosis is 
3–5 mmol/kg body weight;
— Potassium supplementation should be carried out 
according to the following principles:
Serum potassium level:
• K+ > 5.5 mmol/L Æ do not administer KCl;
• K+ 5.0–5.5 mmol/L Æ 5–10 mmol KCl per hour;
• K+ 4–5 mmol/L Æ 10–15 mmol KCl per hour;
• K+ 3–4 mmol/L Æ 15–20 mmol KCl per hour;
• K+ < 3 mmol/L Æ stop insulin infusion and ad-
minister 25 mmol KCl per hour.
Potassium supplementation > 15 mmol/h should be 
administered via a central venous line or to two periph-
eral veins.
 D.  Bicarbonate administration — consider only if arte-
rial blood pH ≤ 6.9 (in small doses, not more than 
1 mmol/kg body weight); increased lactate level in 
ketoacidosis (which is often associated with mild lac-
tate level elevation due to tissue ischemia) is not an 
indication for bicarbonate administration.
 E. Low-molecular-weight heparin — consider prophylac-
tic dose in patients with severe DKA.
 6.  Treatment adverse effects:
— Hypokalemia related to insulin administration and 
correction of acidosis with bicarbonates;
— Hypernatremia, mostly related to inappropriate 
administration of sodium bicarbonate (np. pulmo-
Table 15.1 Diagnostic criteria with severity assessment of diabetic ketoacidosis
Diabetic ketoacidosis
Mild Moderate Severe
Plasma blood glucose [mg/dL]* > 250 > 250 > 250
Blood pH 7.25–7.30 7.00–7.24 < 7.00
Blood NaHCO3 level [mEq/L] 15–18 10–15 < 10
Presence of ketone bodies in urine** Yes Yes Yes
Presence of ketone bodies in serum** Yes Yes Yes
Serum osmolality [mOsm/kg] Variable Variable Variable
Anion gap*** > 10 > 12 > 12
Mental status Conscious Conscious/confused Stupor/coma
**Does not apply to patients treated with SGLT2 inhibitors (flosin) whose blood glucose may be lower (euglycemic diabetic ketoacidosis) 
**Method using nitroprusside 
***According to the formula: Na+ (mEq/l) – [Cl– (mEq/l) + HCO3– (mEq/L)]
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nary edema, cerebral edema; intravenous mannitol 
infusion at 1–2 g/kg body weight during 20 min-
utes is recommended in case of cerebral edema;
— Hyperglycemia caused by interruption of intrave-
nous insulin administration following initial im-
provement, without early initiation of subcutane-
ous insulin treatment;
— Hypoglycemia due to overly intensive insulin therapy;
— Hyperchloremia due to administration of excessive 
amounts of saline.
 7.  Complication of diabetic ketoacidosis:
— Hypovolemic shock;
— Acute renal failure
— Cerebral edema, more commonly in children.
 8.  Management of acute ketoacidosis in children — see 
Figure 22.1.
III. Hyperglycemic hyperosmolar state
 1.  Causes:
— Most commonly develops due to a delayed diag-
nosis or inadequate treatment of diabetes type 2, 
in the course of stroke, or myocardial infarction, 
following consumption of large amounts of alco-
hol, use of some diuretics, in patients with chronic 
kidney disease, mental health problems, and evi-
dence of infection.
 2.  Diagnosis
Laboratory diagnostic criteria of a hyperglycemic 
hyper osmolar state:
— Blood glucose > 600 mg/dL (> 33.3 mmol/L);
— pH > 7.30;
— Serum bicarbonate level > 15.0 mmol/L;
— Hypernatremia: corrected serum sodium level (cal-
culated using the formula given above) ≥ 150 
mmol/L;
— Serum ketone bodies: absent/trace;
— Effective plasma osmolality > 320 mOsm/kg H2O.
Effective plasma osmolality (mOsm/kg H2O) =  
= 2 [Na+ (mmol/L)] + blood glucose (mmol/L)  
{2 [measured Na (mEq/L)] + [blood glucose  
(mg/dL)]/18}
Normal plasma osmolality is 280–300 mOsm/kg H2O.
 3.  Differential diagnosis:
— Ketoacidotic coma;
— Comatose states due to central nervous system 
disease;
— Uremic coma;
— Coma due to poisoning.
 4.  Management
The approach to management is similar to the man-
agement of diabetic ketoacidosis, except for bicarbonate 
administration:
— Blood glucose lowering (similar insulin doses as in 
the management of diabetic ketoacidosis);
— Normalization of plasma osmolality (with gradual 
reduction by no more than 3 mOsm/kg H2O per 
hour);
— Subcutaneous administration of a low molecular 
weight heparin;
— Correction of water and electrolyte deficits:
• Water deficit is much larger than in patients 
with diabetic ketoacidosis;
— Use of a hypotonic multi-electrolyte solution 
(0.45% saline or hypotonic multi-electrolyte so-
lution), followed by normal saline when plasma 
osmolality has been normalized, with monitoring 
of the patient’s cardiovascular status.
• The rate of saline infusion is determined based 
on serum sodium level and plasma osmolality;
— Monitor blood glucose every hour and electrolytes 
every 4–6 hour.
IV. Lactic acidosis
 1.  Causes:
— Type A is due to cardiogenic shock, massive bleeding, 
septic shock, acute or chronic respiratory failure (it is 
not characteristic for diabetes) but three fourths of 
diabetic patients die due to cardiovascular causes; 
this condition may also occur in diabetic patients.
— Type B is due to causes other than hypoxemia. It 
develops in patients with diabetes, liver disease, 
malignancies, and following ingestion of ethanol, 
biguanides, salicylates, and methanol.
 2.  Laboratory diagnostic criteria:
— Moderately elevated blood glucose (but may also 
be normal);
— Reduced blood pH (< 7.30), bicarbonate level 
< 10 mmol/L, anion gap > 16 mmol/L;
— Lactate level > 5 mmol/L;
— Normal serum sodium level (may be reduced in 
alcohol abuse);
— Usually increased serum potassium level.
 3.  Management:
— Includes the following measures:
• Preventing and counteracting shock (correction 
of hypovolemia, vasoconstrictors in moderate 
doses),
• Counteracting hypoxemia and hypoxia,
• Reducing excessive lactate production (glucose 
and insulin infusion with blood glucose moni-
toring),
• Alkalinization by administration of sodium bi-
carbonate (requirement: base excess × 0.3 × 
body mass in kg),
• In some cases, renal replacement therapy may be 
required (biochemical and/or clinical indications).
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Most important recommendations
• Acetylsalicylic acid and statin are recommended [A], and ACE inhibitor should be considered [C] in diabetic  
patients with ischemic heart disease, if not contraindicated.
• Life-long beta-blocker therapy is recommended after myocardial infarction. [B]
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16. Diagnosis and management of ischemic heart disease  
 in diabetic patients
Ischemic heart disease (IHD) is the major cause of 
mortality among diabetic patients. Diagnosis and man-
agement of IHD and heart failure in this patient popula-
tion are the same as in subjects without dysglycemia.
I.   Differences in the clinical course of IHD in dia-
betic patients indicate the need for follow-up 
assessment of risk factors in this population at 
least once a year.
II.   Indications for diagnostic, functional, and ana-
tomic investigations to diagnose IHD and stratify 
risk in diabetic patients (a cardiology consulta-
tion) (Figure 16.1):
 1.  Presence of typical or atypical cardiovascular symp-
toms or signs.
 2.  Abnormal resting ECG.
 3.  Concomitant atherosclerotic lesions in carotid or pe-
ripheral arteries.
 4.  Planned intensive physical exercise in subjects > 35 
years of age who previously lived a sedentary lifestyle.
 5.  Diabetes type 1 for > 15 years.
 6.  Presence of at least two risk factors for IHD in addi-
tion to diabetes:
— Dyslipidemia (see Chapter 4);
— Hypertension;
— Smoking;
— Family history of premature atherosclerosis;
— Albuminuria;
— Autonomic neuropathy.
III.  Management of stable IHD (chronic coronary syn-
drome, according to new terminology proposed 
by the European Society of Cardiology [ESC]) in 
diabetic patients.
 1.  Initiation of a healthy lifestyle (see Chapter 6).
 2.  Lipid-lowering therapy to achieve therapeutic targets 
(see Chapter 4).
 3.  Reduction or elimination of risk factors for IHD:
— Blood pressure normalization (see Chapter 12);
— Treatment of dyslipidemia (see Chapter 13).
 4.  Drug therapy for IHD in diabetes
— Antiplatelet therapy:
• Acetylsalicylic acid should be also used in patients 
> 40 years of age with diabetes type 1 or 2 and 
an increased cardiovascular event risk (IHD risk 
> 5% during 10 years). Effectiveness of ace-
tylsalicylic acid in the primary prevention in 
diabetic patients at low cardiovascular risk has 
not been established.
• The recommended acetylsalicylic acid dose is 
75–100 mg/day,
• If acetylsalicylic acid is contraindicated, clopi-
dogrel 75 mg/day may be beneficial although 
new antiplatelet agents (i.e., prasugrel and ti-
cagrelor) are currently preferred due to their 
higher effectiveness; if these are unavailable, 
clopidogrel is recommended,
• In patients after a percutaneous coronary in-
tervention (PCI), dual antiplatelet therapy 
with acetylsalicylic acid 75–100 mg/day and 
clopidogrel 75 mg/day is recommended. In pa-
tients after ACS — acetylsalicylic acid 75–100 
mg/day and prasugrel 10 mg/day once daily 
as a second drug. If this therapy is not avail-
able, clopidogrel 75 mg/day is recommended 
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as the second antiplatelet agent. Duration 
of dual antiplatelet therapy depends on the 
presentation of IHD and the type of the im-
planted stent. Recommended treatment du-
ration is one month after the procedure in 
stable IHD treated with a bare metal stent 
(BMS), and 6–12 months after implantation of 
a drug-eluting stent (DES). In all patients after 
an acute coronary syndrome, dual antiplatelet 
therapy for 12 months is recommended;
— Cardioselective beta-blockers or combined alpha1- 
and beta-adrenergic blockers.
— RAA system inhibitors.
If drug treatment is not successful, coronary revascu-
larization should be considered.
Exercise testing and other functional (stress) tests 
are used to confirm the diagnosis, document ischemia, 
stratify risk, and guide selection of treatment modali-
ties and evaluate their effectiveness. Exercise ECG is 
still most easily available and thus most commonly per-
formed but its sensitivity and specificity for diagnos-
ing ischemia is limited, particularly in women. Other 
functional (stress) tests include stress echocardiography, 
myocardial perfusion scintigraphy, magnetic resonance 
imaging (MRI), and positron emission tomography 
(PET). Among anatomical methods, invasive coronary 
angiography remains the gold standard, although mul-
tidetector computed tomography (MDCT) may also be 
useful. Diabetic patients are usually at moderate to high 
coronary artery disease risk. Functional tests are rec-
ommended as first-choice modalities in moderate-risk 
patients, while coronary angiography is the major first-
choice modality in high-risk patients. An advantage of 
MDCT is its high negative predictive value and thus this 
modality is mostly useful to exclude significant coronary 
artery disease. However, it s not recommended in high-
risk patients, as it results in unnecessary contrast agent 
and radiation exposure.
REFERENCES
1. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Black- well 
L et al. Aspirin in the primary and secondary prevention of vascular 
disease: collaborative meta-analysis of individual participant data 
from randomised trials. Lancet 2009; 373: 1849–1860.
2. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, 
Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy 
in 18,686 people with diabetes in 14 randomised trials of statins: 
a meta-analysis. Lancet 2008; 371: 117–125.
3. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of 
a multifactorial intervention on mortality in type 2 diabetes. 
N Engl J Med 2008; 358: 580–591.
4. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL 
cholesterol substantially below currently recommended levels in 
patients with coronary heart disease and diabetes: the Treating 
to New Targets (TNT) study. Diabetes Care 2006; 29: 1220–1226.
5. 2018 ESC/EACTS Guidelines on myocardial Revascularization 
European Heart Journal 2019; 40, 87–165.
Figure 16.1. An algorithm for the diagnosis of and risk stratification in ischemic heart disease (IHD) in diabetic patients. 
ECG — electrocardiogram; MET — metabolic equivalent
44
Clinical Diabetology 2020, Vol. 9, No. 1
16.1.  Management of acute coronary syndromes in diabetic patients  
 — antihyperglycemic therapy
In acute coronary syndromes, normalization of blood 
glucose levels using intravenous insulin infusion is rec-
ommended in order to maintain relative hyperglycemia, 
which should be defined as blood glucose level above 
140 mg/dL (7.8 mmol/L) in subjects with established 
diabetes and above 180 mg/dL (10.0 mmol/L) in sub-
jects without a previous diagnosis of diabetes. Intrave-
nous insulin administration is the only approach that 
allows rapid normalization of blood glucose levels and 
improvement of outcomes following an acute coronary 
syndrome. If possible, a diabetologist should be involved 
in the management of IHD in patients with dysglycemia.
I.		 The	first	day	of	an	acute	coronary	syndrome
 1.  Stop oral antidiabetic agents.
 2.  Measure blood glucose on admission in all patients 
with an acute coronary syndrome.
 3.  If blood glucose is above 140 mg/dL (7.8 mmol/L) in 
subjects with established diabetes or above 180 mg/ 
/dL (10.0 mmol/L) in subjects without a previous diag-
nosis of diabetes, initiate intravenous insulin infusion 
at the rate shown in Table 16.1.1. Recommended 
frequencies of blood glucose measurements during 
daytime: every 1 hour, followed by every 2  hours 
when blood glucose levels become stabilized. Blood 
glucose level should be kept at 100–180 mg/dL (5.6– 
–10 mmol/L) by adjusting appropriately the rate of 
insulin infusion.
 4.  Serum potassium level should be monitored during 
insulin infusion.
Most important recommendations
• On admission, blood glucose level should be measured in patients with an acute coronary syndrome, along with 
HbA1c level in diabetic patients if no current measurement is available. [A]
• Intravenous insulin infusion with target blood glucose levels of 100–180 mg/dL is recommended during the first 
day of an acute coronary syndrome. [C]
If blood glucose increases above 180 mg/dL (10 
mmol/L), temporarily stop intravenous glucose infu-
sion, restarting it when blood glucose falls to 180 mg/dL 
(10 mmol/L), and at the same time increase the rate of 
intravenous insulin infusion.
 5.  If meals are consumed by the patient, add intrave-
nous boluses of a short-acting insulin.
 6.  If diabetic ketoacidosis is present, treat accordingly 
(Chapter 15).
II.  From the second day of an acute coronary syn-
drome until discharge
 1.  Target blood glucose values during glucose-lower-
ing therapy are 100–180 mg/dL (5.6–10.0 mmol/L) 
throughout 24 hours. Thus, treatment must be in-
dividualized, preferably in cooperation with a diabe-
tologist.
 2.  In patients without evidence of acidosis, with dysgly-
cemia diagnosed on the first day of an acute coro-
nary syndrome or with previous successful metformin 
treatment, appropriate diet may allow adequate met-
abolic control of diabetes in this period (Chapter 6). 
In the remaining cases, initiate insulin therapy with 
multiple injections as described earlier (Chapter 11).
 3.  In overweight or obese patients with diabetes type 2, 
metformin may be started before discharge, even as 
early as on the third day after the coronary interven-
tion, if not contraindicated. A reduction in insulin 
dose may be possible after 2–3 days of metformin 
therapy.
Table 16.1.1. Approximate insulin infusion rate in relation to blood glucose level
Blood glucose 10% dextrose [ml/hour] Insulin [unit/hour]
< 100 mg/dL (< 5.5 mmol/L) 50 Stop infusion for 15–30 minutes
100–140 mg/dL (5.5–7.8 mmol/L) 50 0.5–1.0
140–180 mg/dL (6.7–10.0 mmol/L) 50 1.0–2.0
180–250 mg/dL (10.0–13.9 mmol/L) Stop infusion until blood glucose < 180 mg/dL 
(10.0 mmol/L) then 50
2.0–4.0
250–300 mg/dL (13.9–17.4 mmol/L) Stop infusion until blood glucose < 180 mg/dL 
(10.0 mmol/L) then 50
4.0–6.0
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betes, oral glucose tolerance test (see Chapter 1, III, 
Table 16.1.1.) should be performed before discharge. 
A consultation with a diabetologist should be conducted 
if glucose intolerence or diabetes is diagnosed.
Note 2: Metformin should be withdrawn at least 48 
hours before elective diagnostic or therapeutic cardiac 
catheterization/coronary angiography. The drug may be 
resumed 24 hours after coronary angiography.
REFERENCES
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N Engl J Med 2009; 360: 1283–1297.
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III. Following discharge
Metformin should be started in all patients with dia-
betes type 2 after an acute coronary syndrome, unless 
contraindicated or not tolerated.
In patients with diabetes type 2 in whom good meta-
bolic control (see II.1 in this chapter) was achieved at the 
time of discharge and daily insulin requirement does not 
exceed 30 units, it is possible to return to previous glu-
cose-lowering treatment that was used before the acute 
coronary syndrome. In overweight or obese patients with 
diabetes diagnosed during the hospital stay and good 
metabolic control (see II.1) achieved at the time of dis-
charge, with daily insulin requirement not exceeding 30 
units, oral metformin therapy may be used, combined 
with other agents if needed. If good metabolic control 
cannot be achieved or daily insulin requirement exceeds 
30 units, insulin therapy should be continued. Following 
an acute coronary syndrome, each patient with dysglyce-
mia should be urgently referred to a diabetologist.
Note 1: In all patients with an acute coronary syn-
drome, except for those with previously established dia-
Most important recommendations
• Hyperglycemia on admission in the acute phase of stroke is associated with higher mortality, more severe course 
of stroke, and more severe neurological deficit in both diabetic and non-diabetic subjects. [A]
• Available studies do not provide evidence that correction of hyperglycemia in the acute phase of stroke improves 
outcomes. [C]
• Current recommendations regarding correction of hyperglycemia in stroke are based only on expert opinion. [E]
17. Stroke in diabetic patients
Diabetes is a strong risk factor for stroke, both isch-
emic and hemorrhagic.
Elevated blood glucose is seen in as many as 60% of 
patients hospitalized due to an acute stroke. In about 
20% of cases, hyperglycemia occurs in subjects with es-
tablished diabetes, in 16–24% of cases in patients without 
previous diagnosis of diabetes, and in the remaining cases 
it is intermittent hyperglycemia (stress hyperglycemia).
Hyperglycemia in the acute phase of stroke is an 
adverse prognostic factor both in diabetic patients and 
in those without diabetes. Its presence is associated with 
a risk of a larger ischemic area and its hemorrhagic trans-
formation, a more severe course of the condition, and 
a worse prognosis (lower degree of patients’ indepen-
dence and increased early and late mortality). Hyper-
glycemia found on admission often tends to decrease 
gradually and spontaneously within first several hours to 
days after the stroke onset.
Target blood glucose levels in patients with acute 
stroke are similar to that in other severely ill patients 
with hyperglycemia. Insulin therapy should be initiat-
ed if blood glucose is ≥ 180 mg/dL (10 mmol/L), and 
blood glucose should be kept at 140–180 mg/dL (7.8–10 
mmol/L), preferably close to 140 mg/dL (7.8 mmol/L). 
Blood glucose levels below 110 mg/dL (6.1 mmol/L) 
should be avoided to the risk of hypoglycemia.
Insulin should be given intravenously in 0.9% saline 
using a syringe pump, with strict monitoring of blood 
glucose levels. The rate of insulin infusion should be 
modified depending on blood glucose levels measured 
every 1 hour, and every 2 hours after stable blood glucose 
values are obtained. A general algorithm for modifying 
the rate of intravenous insulin infusion depending on 
blood glucose levels is shown in Table 16.1.1. Serum po-
tassium level should be checked 2–3 times a day during 
insulin infusion.
It is not recommended to administer insulin as glu-
cose-insulin-potassium (GIK) infusion. Insulin should not 
be administered subcutaneously during the first two days 
of stroke or longer in unconscious patients.
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Physicians and nursing personnel in the acute stroke 
care unit should be trained in the treatment of hyper-
glycemia using a specified intravenous insulin dosing 
algorithm, with adjustments of the insulin infusion rate 
in relation to blood glucose levels.
When the patient’s condition improves and meals be-
gin to be given orally, intravenous insulin infusion should 
be stopped and subcutaneous insulin dosing should be 
initiated. Withdrawal of intravenous insulin should be 
preceded by subcutaneous administration of a short- 
-acting insulin or rapid-acting insulin analog by about 
1 hour before the planned cessation of intravenous in-
sulin infusion. The recommended treatment regimen 
includes a short-acting insulin or rapid-acting insulin 
analog before meals and long-acting insulin once or 
twice daily. In some cases, it is sufficient to give a short-
acting insulin or rapid-acting insulin analog before meals. 
Insulin should be given before food, with dosing based 
on blood glucose readings immediately before meals.
Due to a high likelihood of diabetes in patients with 
an acute stroke and no previous diagnosis of diabetes, 
investigations for diabetes are needed after the patient’s 
condition has stabilized.
Recommendations regarding management of hyper-
tension and other aspects of care for patients with an 
ischemic stroke are the same as in non-diabetic patients, 
as no evidence is available to indicate benefits from any 
different or specific management of diabetic patients.
Secondary prevention after stroke should be insti-
tuted according to the general recommendations in this 
regard.
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18. Prevention, diagnosis, and treatment of diabetic kidney disease
Most important recommendations
• Screening for increased urinary albumin excretion should be performed annually, beginning at 5 years after the 
diagnosis in patients with diabetes type 1, since the diagnosis in patients with diabetes type 2, and in all patients 
with diabetes and concomitant hypertension. [B]
• Blood glucose levels, blood pressure values, and lipid parameters should be optimized to decrease the risk of 
diabetic nephropathy and/or delay its progression. [A]
• If an increased urinary albumin excretion is found, therapy with ACEI or ARB should be initiated (unless contra-
indicated) as these drugs reduce the risk of progression of diabetic nephropathy. [A]
• Serum creatinine and potassium should be monitored during treatment with ACEI, ARB, and/or a diuretic. [E]
I.   In diabetic patients, urinary albumin excretion, 
serum creatinine, and estimated GFR should be 
determined to detect and evaluate the severity 
of diabetic nephropathy. Albuminuria and esti-
mated GFR are independent predictors of cardio-
vascular and renal risk in diabetic patients.
II.   Screening for albuminuria should be performed 
according to the following principles:
— Testing should be performed annually, begin-
ning at 5 years after the diagnosis of diabetes 
type 1 and at the time of the diagnosis of diabe-
tes type 2;
To evaluate urinary albumin excretion:
— An albumin/creatinine (ACR) ratio should be deter-
mined in a single (spot) urine sample (preferably 
morning urine sample) — for interpretation of the 
results see Table 18.1.
Increased urinary albumin excretion may be diag-
nosed when two positive ACR results are obtained.
III.  Serum creatinine level in diabetic patients should 
be measured at least annually regardless of uri-
nary albumin excretion and used for estimation 
of GFR.
IV.		 	Glomerular	 filtration	 rate	 should	 be	 estimated	
using the CKD-EPI formula:
CKD-EPI formula
GFR = 141 × min (SCr/k, 1)a × max (SCr/k, 1)–1.209 × 
0.993Age × 1.018 (for women)
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Where
SCr — serum creatinine
k = 0.7 for women and 0.9 for men
a = –0.329 for women and –0.411 for men
min = the minimum of SCr/k or 1
max = the maximum of SCr/k or 1
V.			 Stages	of	chronic	kidney	disease	are	defined	 in	
Table 18.2.
VI.  If estimated GFR decreases below 60 mL/min/ 
/1.73 m2 and non-diabetic nephropathy is sus-
pected, a nephrology consultation should be con-
sidered. If estimated GFR decreases below 30 mL/ 
/min/1.73 m2, a nephrology consultation should 
be ordered.
VII. Recommendations for prevention
 1.  Blood glucose, blood pressure, and lipid control 
should be optimized to reduce the risk of nephropa-
thy or delay its progression.
 2.  Tobacco smoking is an independent risk factor for de-
velopment and progression of diabetic nephropathy 
in patients with diabetes type 2.
VIII. Management
 1.  Therapeutic targets for blood glucose, lipid param-
eters, and blood pressure as described in Chapter 4 
should be aimed for to delay progression of diabetic 
nephropathy.
 2.  If albuminuria is found, therapy with ACEI or ARB 
should be initiated (unless contraindicated) as 
these drugs reduce the risk of progression of ne-
phropathy.
 3.  Serum creatinine and potassium should be monitored 
during treatment with ACEI, ARB, and/or a diuretic.
 4.  Combining ACEI with ARB is not recommended.
 5.  Use of a thiazide/thiazide-like diuretic may be consid-
ered with estimated GFR ≥ 30 mL/min/1.73 m2, while 
a loop diuretic should be used with estimated GFR 
< 30 mL/min/1.73 m2.
 6.  Metformin should not be used in patients with eGFR 
< 30 mL/min/1.73 m2. In patients with eGFR 30–59 
mL/min/1.73 m2, metformin doses should be adjusted 
to renal function.
 7. In patients with type 2 diabetes mellitus and chronic 
kidney disease, the use of a sodium glucose 2 co-
transporter inhibitor or glucagon-like receptor ago-
nist, which are drugs with proven nephroprotective 
effects, should be considered. These drugs reduce the 
risk of progression to chronic kidney disease.
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Table 18.3. Recommendations for metformin use based 
on the severity of renal failure (according to Lipska et 
al. Diabetes Care 2011; 34: 1431–1437)
eGFR [mL/min 
per 1.73 m2]
Action
≥ 60 No contraindication to metformin
Monitor renal function annually
45–49 Metformin may be continued
Monitor renal function every 3–6 
months
30–44 Exercise particular caution when using 
metformin
Metformin may be continued in a decre-
ased (by 50%) dose
Monitor renal function every 3 months
Do not start new patients on metformin
< 30 Do not use metformin
eGFR — estimated glomerular filtration rate
Table	18.1.	Definitions	of	abnormal	urinary	albumin	excretion*
Category AER [mg/day] ACR (spot urine sample)  
[mg/day	or	mg/g	creatinine]*
Albumin excretion  
[µg/min] in urine collection
A1 normal to slightly increased albuminuria < 30 < 30 < 20
A2 moderately increased albuminuria 30–300 30–300 20–200
A3 overt proteinuria > 300 > 300 ≥ 200
AER — albumin excretion rate; ACR — albumin/creatinine ratio
*As the amount of albumin excreted with urine per 1 g of creatinine is approximately equal to 24-hour urinary albumin excretion, this approach allows avo-
iding errors of 24-hour urine collection
Table 18.2. Stages of chronic kidney disease
Category Description eGFR [mL/ 
/min/1.73 m2]
G1 Kidney damage* with  
normal or high eGFR
≥ 90
G2 Kidney damage* with mildly 
decreased eGFR
60–89
G3a Moderately decreased eGFR 45–59
G3b Moderately to severely  
decreased eGFR
30–44
G4 Severely decreased eGFR 15–29
G5 End-stage renal failure < 15
eGFR — estimated glomerular filtration rate
*Kidney damage is defined as urinalysis and/or urine sediment abnormalities 
and/or abnormalities in blood markers of kidney damage and/or imaging stu-
dies of the kidneys or urinary tracts persisting for more than 3 months
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Diabetic complications involve nearly all anatomic 
structures of the visual system. The most common 
and most severe complication, with a threat of vi-
sion loss, is diabetic retinopathy and related diabetic 
macular	edema.	Retinopathy	is	a	highly	specific	neu-
rovascular complication of diabetes, both type 1 and 
type 2. Among extraretinal diabetic complications, 
clinically the most important are diabetic cataract 
and secondary (hemorrhagic) glaucoma. The recom-
mendations given below take into account the new 
classification	of	diabetic	retinopathy.
Prevention, diagnosis, and management of diabetic 
retinopathy
I.		 	 Natural	history	and	classification	of	diabetic	reti-
nopathy
 1.  No evidence of diabetic retinopathy.
 2.  Mild non-proliferative diabetic retinopathy (NPDR) — 
presence of microaneurysms only.
 3.  Moderate non-proliferative diabetic retinopathy — 
more advanced changes than in a mild form but less 
advanced than in a severe form.
 4.  Severe non-proliferative diabetic retinopathy:
—  Microhemorrhages (> 20) in 4 retinal quadrants; 
and/or
—  Venous beading in least 2 quadrants; and/or
— Intraretinal microvascular abnormalities in at least 
1 quadrant. 
 5.  Proliferative diabetic retinopathy (PDR) (retinal neo-
vascularization and connective tissue growth) leading 
to vision loss in the mechanisms of:
—  Recurrent bleeding to the vitreous body from the 
retinal neovessels;
—  Retinal detachment due to traction by proliferative 
membranes;
—  Development of glaucoma.
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Most important recommendations
• Optimization of blood glucose levels, blood pressure values, and lipid parameters reduces the risk of development 
and progression of diabetic nephropathy. [A]
• Fundoscopy after mydriasis should be performed no later than 5 years after the diagnosis in adult patients with 
diabetes type 1, and at the time of the diagnosis of diabetes type 2. [B] 
• Retinal laser photocoagulation reduces the risk of vision loss in patients with proliferative retinopathy. [A]
• Intravitreal injections of anti-VEGF agents may improve vision in patients with macular edema. [A]
• Treatment with acetylsalicylic acid used for cardioprotection is not contraindicated in patients with retinopathy 
and does not increase the risk of retinal hemorrhage. [A]
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trol improves kidney outcomes in patients with type 2 diabetes. 
Kidney Int 2013; 83: 517–523.
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19. Diabetic eye disease
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II.	 		Natural	history	and	classification	of	diabetic	mac-
ular edema
 1.  No evidence of diabetic macular edema.
 2.  Mild diabetic macular edema — lesions away from 
the macular center. 
 3.  Moderate diabetic macular edema — lesions close to 
the macular center. 
 4.  Severe diabetic macular edema — lesions involving 
the macular center. 
III.  Risk factors for the development and progression 
of diabetic retinopathy
 1.  Duration of diabetes — the strongest prognostic fac-
tor for the development and progression of diabetic 
retinopathy.
 2.  Poor metabolic control of diabetes:
— Intensive treatment reduces the risk of the devel-
opment and progression of retinopathy in patients 
with diabetes type 1;
— Intensive treatment of diabetes type 2 reduces 
the rate of microangiopathic complications and 
reduction of HbA1c level by 1% is associated with 
a significantly reduced risk of the development of 
microangiopathy.
 3.  Hypertension.
 4.  Lipid disorders.
 5.  Diabetic nephropathy.
 6.  Pregnancy in diabetic women.
 7.  Period of adolescence.
 8.  Surgery for cataract.
 9.  Following kidney and pancreas or kidney transplanta-
tion.
IV.  Diagnosis of diabetic retinopathy
 1.  Assessment of visual acuity.
 2.  Assessment of color identification.
 3.  Fundoscopy (using an ophthalmoscope, always with 
mydriasis).
 4.  Digital color photographs of the eye fundus used 
mostly for screening (they do not replace complete 
ophthalmologic examination).
 5.  Fluorescein angiography of the eye fundus
— Indications:
• Identification of moderate and severe preprolif-
erative retinopathy,
• Identification of early neovascularization foci in 
proliferative retinopathy,
• Evaluation of the effectiveness of laser photo-
coagulation,
• Investigation of unexplained decrease in visual 
acuity.
 6.  Wide-angle scanning laser ophthalmoscopy.
 7.  Optical coherent tomography — major method for 
the diagnosis and monitoring of macular edema.
 8.  Ultrasound — particularly in patients with vitreous 
body hemorrhage.
 9.  Confocal microscopy (evaluation of corneal lesions as 
an early indicator of neuropathy).
V.   Indications for ophthalmologic examination in 
diabetic patients
 1.  Initial examination
— In diabetes type 1 — should be performed within 
5 years after the diagnosis;
— In diabetes type 2 — should be performed at the 
time of the diagnosis or shortly after the diagnosis.
 2.  Follow-up examinations and management:
—  Indicated due to an initially asymptomatic nature 
of retinopathy.
—  Frequency should depend on the degree of sever-
ity of diabetic retinopathy:
• No retinopathy at baseline — every 1–2 years,
• Early non-proliferative retinopathy — every 
6–12 months,
• More severe non-proliferative retinopathy — 
every 3 months,
• Severe non-proliferative retinopathy — urgent 
laser therapy,
• Proliferative retinopathy — urgent laser therapy 
or consideration of other ophthalmologic pro-
cedures (e.g. vitrectomy),
• Diabetic macular edema — urgent laser therapy 
in extrafoveal disease; intravitreal anti-VEGF injec-
tions and possibly laser therapy in foveal disease,
• Following retinal laser treatment — one month 
after the procedure,
• Following vitrectomy — individualized follow-up 
depending on the condition of the eye fundus,
• In pregnant diabetic women — every 1–3 
months throughout the pregnancy depending 
on the condition of the eye fundus,
• In women contemplating pregnancy — before 
conception, with retinal laser treatment at that 
time if needed.
 3.  Urgent indications for ophthalmologic examination:
—  Risk of vision loss:
• Presence of proliferative retinopathy,
• Presence of advanced eye complications (retinal 
neovascularization, vitreous body hemorrhage, 
acute retinal detachment);
—  Presence of changes potentially associated with 
a risk of vision loss:
• Severe non-proliferative retinopathy,
• Non-proliferative retinopathy with diabetic 
macular edema,
• Other difficult-to-interpret abnormalities in the eye 
fundus or unexplained decrease in visual acuity,
• Pregnancy.
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The recommended frequency of ophthalmologic ex-
amination in specific patient groups is summarized in 
Table 19.1. Following these primarily screening recom-
mendations can reduce even several times the risk of 
blindness caused by diabetes.
VI. Screening
Screening for diabetic retinopathy may be performed 
under mydriasis by an ophthalmologist using an ophthal-
moscope or a trained personnel using a fundus-camera 
based on color photographs of the eye fundus. If no retinal 
changes are found during the first two years in patients 
with diabetes type 1, the eye fundus may be subsequently 
assessed every 2 years. In patients with diabetes type 2 
and good metabolic control, if no retinal changes, the eye 
fundus may be assessed every 3 years. This will significantly 
reduce the costs of treatment in diabetic patients.
VII. Management of diabetic retinopathy
 1.  Treatment intensification in patients with poor met-
abolic control of diabetes, intensive treatment of 
hypertension, primarily using ACEI and ARB, and 
treatment of dyslipidemia (fenofibrate, statins). Ace-
tylsalicylic acid used for cardioprotection is not con-
traindicated in patients with retinopathy and does 
not pose a risk of retinal hemorrhage.
 2.  Retinal laser photocoagulation (possible if the optical 
system of the eye is clear):
— Early retinal laser photocoagulation reduces pro-
gression of diabetic retinopathy;
— Types of retinal laser photocoagulation:
• Focal — recommended in early retinopathy and 
extrafoveal diabetic macular edema,
• Grid-type — in diffuse diabetic macular edema,
• Panphotocoagulation — recommended in se-
vere non-proliferative and proliferative retino-
pathy.
 3.  Vitrectomy
—  Indications:
• Vitreous hemorrhages unresponsive to other 
therapies; in such cases, early vitrectomy is in-
dicated (the earlier is the procedure, the better 
are its outcomes),
• Advanced complicated proliferative retinopa-
thy.
 4.  In severe diabetic macular edema, intravitreal injec-
tions of anti-VEGF agents aflibercept, ranibizumab, 
and bevacizumab, optionally in combination with 
retinal laser therapy. Bevacizumab is used off-label 
for this purpose. Intravitreal anti-VEGF agent injec-
tions are recommended as the first-line therapy of 
any diabetic macular edema with foveal involvement.
 5.  Intravitreal or periocular injections of steroids ex-
erting an antiangiogenic and antiedematous effect, 
e.g. triamcinolone, long-acting dexamethasone, or 
extended-release fluocinolone acetonide. 
 6.  In irreversible vision loss, a low vision and blindness 
specialist should be consulted and the patient should 
be referred for blind rehabilitation services.
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Table 19.1. Recommended frequency of ophthalmologic examinations in various patient groups
Initial examination
Diabetes type 1 Diabetes type 2
Initial 5 years after the diagnosis  
(when diagnosed during puberty — shortly after the diagnosis)
At the time of the diagnosis
Follow-up examinations and treatment
Severity of retinopathy Frequency of examinations and treatment
No retinopathy
Early non-proliferative
Preproliferative
Proliferative
Diabetic macular edema:
     extrafoveal
     intrafoveal
Every 1–2 years
Every 6–12 months
At least every 3–6 months
Urgent laser therapy
Urgent laser therapy
Intravitreal anti-VEGF injections + laser therapy
Follow-up after ophthalmologic procedures in special situations
After laser treatment
After vitrectomy
Pregnant women
Women planning pregnancy
Uncontrolled diabetes, hypertension or proteinuria
Depending on the condition of the eye fundus
Depending on the condition of the eye fundus
Every 1–3 months depending on the condition of the eye fundus
Before conception; laser therapy at that time
Every 1–6 months regardless of fundoscopy findings
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I.   Diabetic neuropathy causes severe complaints, 
significantly	 reduces	 the	 quality	 of	 life,	 and	 is	
an established risk factor forthe development of 
diabetic foot syndrome and sudden deaths. Auto-
nomic cardiovascular neuropathy is an indepen-
dent risk factor for increased mortality in diabetes.
II.			 Clinical	classification	of	neuropathy:
—  Generalized symmetrical polyneuropathy:
• Chronic sensorimotor peripheral,
• Autonomic,
• Acute sensory;
—  Focal and multifocal neuropathies:
• Involving cranial nerves,
• Involving spinal nerves (thoracic and lumbar),
• Focal limb neuropathies, including compression 
syndromes,
• Proximal motor neuropathy (amyotrophy).
III. Approach to testing for neuropathy:
—  Testing frequency:
• Diabetes type 1 — at 5 years after the diagno-
sis, unless symptoms suggesting neuropathy 
develop earlier,
• Diabetes type 2 — at the time of the diagnosis,
• Evaluation for evidence of diabetic neuropathy 
— at least once a year.
—  Other, non-diabetic etiologies of the peripheral 
nervous system damage should be excluded (fol-
lowing a neurological consultation).
— In doubtful cases neurologist consultation is indi-
cated.
IV. Diagnostic criteria of diabetic neuropathy
Distal symmetric polyneuropathy
 A.  Diagnostic methods:
—  Tactile sensation using a 10 g monofilament 
(Semes-Weinstein 5.07);
—  Vibration sensation using a biothesiometer or 128 Hz 
tuning forks;
—  Pain sensation using a sterile needle;
—  Temperature sensation using a rod with two differ-
ent (metal and plastic) ends;
— Deep tendon reflexes;
— Muscle strength test;
—  Electroneurographic examination.
 B.  Diagnostic principles:
— Symptoms: abnormal sensation, numbness, burn-
ing, tingling, spontaneous pain, muscle jerks and 
cramps, mostly involving feet and calves, persist-
ing for several months (worsened or occurring 
mostly during the night; exercise does not cause 
or worsen symptoms);
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Most important recommendations
• In patients with diabetes type 1, maintaining optimal blood glucose control since the diagnosis is of key impor-
tance for primary and secondary prevention of diabetic neuropathy, both peripheral and autonomic involving 
the cardiovascular system. [A]
• In addition to detailed history, investigation for diabetic neuropathy should include evaluation of thin fiber (pain 
and/or temperature sensation) and thick fiber (vibration sensation) function. Pressure sensation should be evalu-
ated annually in each patient using a 10 g monofilament. The evaluation should be performed at 5 years since 
the diagnosis of diabetes type 1 and at the time of the diagnosis of diabetes type 2. [B]
• Pregabalin, gabapentin, or duloxetine should be considered as first line medications for neuropathic pain in 
patients with diabetes. [A]
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— Signs: reduced muscle power, reduced or absent 
tendon reflexes (knee, ankle), reduced or absent 
vibration, tactile, pain and temperature sensation;
— Peripheral diabetic neuropathy is considered prob-
able based on the presence of 2 out of the follow-
ing 3 components of the clinical examinations: 
symptoms, reduced or absent sensation (touch, 
vibration, pain, and/or temperature) and/or absent 
tendon reflexes; in painful neuropathy, these ele-
ments of the physical examination may be normal.
— Nerve conduction studies (electroneurography) 
may be also necessary to make a definite diag-
nosis of neuropathy in selected patients; this is 
particularly recommended in the following situa-
tions: rapid progression of symptoms, asymmetry, 
predominance of motor neuropathy or a suspicion 
of non-diabetic cause;
— In patients with unclear clinical picture, evalu-
ation of corneal nerve fiber density by confocal 
microscopy or skin biopsy may also be used for the 
diagnosis of thin fiber neuropathy.
Autonomic neuropathy
Autonomic nervous system function is evaluated indi-
rectly based on the analysis of effector organ function in 
response to specific stimuli. Due to a non-specific nature 
of clinical symptoms and signs, the diagnosis should be 
supported by specific tests. It is necessary to exclude 
other disease of the effector organ, take into account 
other organic and functional abnormalities, and exclude 
an effect of the treatment used.
 1.  Cardiovascular system:
Cardiovascular autonomic neuropathy is diagnosed 
based on the results of test evaluating heart rhythm vari-
ability. Autonomic neuropathy is considered as ‘probable’ 
or ‘early’ in the case of one abnormal test result, and as 
‘confirmed’ when the results of two of the tests listed 
below are abnormal:
—  Tests evaluating the parasympathetic nervous sys-
tem:
• Heart rhythm change during deep breathing,
• Heart rhythm change in response to the upright 
posture,
• Heart rhythm change in response to the Val-
salva manoeuver;
—  Tests evaluating the sympathetic nervous system:
• Blood pressure change in response to the up-
right posture,
 2.  Gastrointestinal system:
—  Gastric dysfunction — barium radiography, ra-
dioisotope scanning, electrogastrography (EGG), 
insulin challenge test, manometry;
—  Small intestine dysfunction — no specific diagnos-
tic tests, manometry to identify abnormal intesti-
nal motility;
—  Large intestine dysfunction — barium follow-
-through, manometry;
—  Gall bladder dysfunction — functional ultrasound.
 3.  Genitourinary system
—  Bladder dysfunction — cystometry (evaluation 
of bladder volume before and after micturition); 
bladder sphincter electromyography, uroflow-
metry and urethral pressure profile;
—  Erectile dysfunction — questionnaires [Interna-
tional Index of Erectile Function (IIEF) and its ab-
breviated 5-item version (IIEF-5)], vascular studies 
(Doppler ultrasound), cavernosography, functional 
testing (nocturnal penile tumescence tests).
 4.  Dysfunctional sudomotor function — simple perspi-
ration tests, testing using sophisticated equipment 
(evaluation of sudomotor function using Sudoscan).
 5.  Pupil dysfunction — pupillometry.
V. Management
 1.  Causal treatment of diabetic neuropathy:
—  Optimal metabolic control of diabetes, with par-
ticular attention to avoiding hypoglycemia;
—  Blood pressure and lipid control, smoking cessa-
tion, avoiding alcohol use;
—  Drug therapy: alpha-lipoic acid, benfotiamine, 
ACEI.
 2.  Symptomatic treatment of neuropathic pain in so-
matic diabetic neuropathy:
—  Pregabalin;
—  Serotonin and norepinephrine reuptake inhibitors: 
duloxetine, venlafaxine;
—  Gabapentin;
—  Tricyclic antidepressants (amitriptyline);
—  Tramadol, trapentadol and opioid analgesics (are 
not recommended as a first-line therapy);
—  Topical agents: capsaicin, nitroglycerin;
—  Non-drug treatments: physical therapy, acupunc-
ture.
 3.  Symptomatic treatment of autonomic diabetic neu-
ropathy:
—  Cardiovascular system:
• Cardiac arrhythmia — controlled graded exer-
cise, ACEI, beta-blockers (without intrinsic sym-
pathomimetic activity),
• Orthostatic hypotension — compression cloth-
ing to increase venous return (e.g. compression 
stockings), mineralocorticoids (fludrocortisone);
—  Gastrointestinal system:
• Gastroparesis — diet modification (frequent 
small meals, semiliquid or liquid diet in severe 
dysfunction), prokinetic drugs (cisapride, ito-
pride, erythromycin, trimebutine), acid reducers 
(H2 receptor antagonists, proton pump inhibi-
tors), antiemetics, nasoduodenal tube, surgical 
treatment, gastric electrical stimulation therapy,
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• Intestinal dysfunction — diet modifications 
(consider gluten- or lactose-free diet), chole-
styramine, clonidine, octreotide, antidiarrheals 
(loperamide), pancreatic enzymes, antibiotics;
—  Genitourinary system:
• Bladder dysfunction — avoiding urinary reten-
tion, regular micturition, anticholinergic drugs 
(bethanechol), external bladder massage be-
fore micturition, bladder catheterization (tem-
porary or permanent);
• Erectile dysfunction — phosphodiesterase type 5 
inhibitors (sildenafil, vardenafil, tadalafil), 
central erection stimulants (apomorphine), 
vacuum penile pump devices, intracavernosal 
prostaglandin E1 injections, penile prostheses,
• Female sexual dysfunction — mechanical stimu-
lating devices, topic moisturizers;
—  Dysfunctional perspiration:
• Botulinum toxin, vasodilators, moisturizing 
creams.
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Most important recommendations
• Maintaining optimal blood glucose levels, lipid parameters, and blood pressure values reduces the risk of the 
diabetic foot syndrome. [A]
• Effective treatment of the diabetic foot syndrome may only be provided within multidisciplinary clinics. [B]
• The gold standard for off-loading of non-infected neuropathic foot is total contact cast that includes the foot 
and the lower leg. [A]
• The key interventions in the treatment of the diabetic foot syndrome are surgical wound debridement, systemic 
antibiotic therapy for infections, and vascular interventions for foot ischemia. [A]
Multidisciplinary (reference) diabetes foot clinics 
should be created in regional (voivodship, university) dia-
betologic centers, and basic diabetes foot clinics should 
be created at diabetology clinics to continue care initi-
ated in a multidisciplinary clinic.
Organizational structure and responsibilities in ac-
cordance with the Diabetes Foot Outpatient Treatment 
Sup port Program by the Ministry of Health (http://www.
mz.gov.pl/zdrowie-i-profilaktyka/programy-zdro-
wotne/wykaz-programow/program-wsparcia-ambu-
latoryjnego-leczenia-zespolu-stopy-cukrzycowej/).
I.		 	 Definition. Diabetic foot is a foot infection and/or 
ulceration and/or deep tissue (e.g., bone) destruc-
tion caused by a varying degree of damage to pe-
ripheral nerves and/or pedal vessels. Implied in the 
definition is further categorization of this condition 
into neuropathic, vascular, and mixed diabetic foot.
Investigations in the diabetic foot syndrome in-
clude evaluation for peripheral polyneuropathy, leg isch-
emia, deformations, and other risk factors for foot dam-
age. It is recommended that physicians directly inspect 
patients’ feet during each visit.
II. Risk factors for diabetic foot syndrome:
— Peripheral neuropathy and/or vascular ischemic 
changes within lower limbs;
— Low patient knowledge;
— Long-lasting, poorly controlled diabetes;
— Inappropriate foot hygiene;
— Inappropriate footwear;
— Presence of corns and calluses;
— Foot deformations;
— Increased sole pressure.
Factors contributing to disease recurrences:
— Previous amputations;
— History of ulcerations;
— Neuropathic arthropathy (Charcot foot).
III.	Clinical	classification	of	diabetic	foot	syndrome
The PEDIS (Perfusion, Extent, Depth, Infection, Sensa-
tion) classification, which takes into account both infec-
21. Diagnosis and management of diabetic foot syndrome
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tions and the ischemic factor, (Table 21.1) and SINBAD 
(Table 21.2) classification are recommended. 
IV. Prevention:
— Systematic foot examination; yearly evaluation for 
abnormal sensation (physical examination) and 
ischemia [assessment of dorsalis pedis and poste-
rior tibial artery pulses; consider measurement of 
the ankle-brachial index (ABI)] in all patients; the 
frequency of foot examination should depend on 
the risk of wound development (Table 21.3);
— Regular podiatric care (removal of calluses and 
hyperkeratosis);
— Use of recommended footwear, orthopedic in-
soles, and socks;
— In the case of large deformations of the foot mak-
ing it impossible to fit the standard footwear, it 
is advisable to provide the patient with custom-
made footwear;
— Systematic patient education regarding foot hy-
giene and consequences of absent protective pain 
sensation;
— Education and systematic treatment of other risk 
factors such as smoking, overweight, hyperten-
sion, and dyslipidemia, along with good metabolic 
control of diabetes;
— Early identification and treatment of limb isch-
emia;
— In the absence of ulceration, walking training is 
recommended.
V. Infections in the course of diabetic foot
 1.  The diagnosis is mostly based on the clinical picture 
(the presence of at least two typical symptoms and 
Table	21.1.	The	PEDIS	classification
                           Degree of severity
1 2 3 4
Perfusion Normal: palpable pedal pulses 
or ABI > 0.9
Clinical evidence of impaired 
perfusion: intermittent claudi-
cation, ABI < 0.9,  
TcpO2 30–60 mm Hg
Critical ischemia: resting 
pain, ABI < 0.4,  
TcpO2 < 30 mm Hg
Extent Ulceration size in square centimeters
Depth Superficial ulceration within 
the dermis
Ulceration may involve all soft 
tissues
Penetration to bone: 
osteo lysis in X-ray or posi-
tive probe-to-bone test
Increase of 
infection
No clinical evidence  
of infection
Infection involving the skin and 
subcutaneous tissue, inflam-
mation within 2 cm from the 
margin of the ulceration
Locally severe inflamma-
tion, beyond 2 cm from 
the margin of the ulcer-
ation, but no evidence of 
a systemic infection
Evidence of a systemic  
infection: fever > 38°C,  
heart rate > 90 bpm,  
breath rate > 20/min,  
leukocyte count > 12,000/mm3 
or < 4000/mm3
Sensation No evidence of sensory  
neuro pathy in basic tests  
(using a monofilament and 
tuning forks or Neurotip)
Sensory neuropathy present
ABI — ankle-brachial index; TcpO2 — transcutaneous oxygen pressure
Table	21.2.	SINBAD	Classification
Category Definition Score
Site Forefoot 0
Midfoot and hindfoot 1
Ischemia Pedal blood flow intact: at least one palpable pulse 0
Clinical evidence of ischemia 1
Neuropathy Protective sensation intact 0
Protective sensation lost 1
Infection None 0
Present 1
Area < 1 cm2 0
≥ 1 cm2 1
Depth Ulcer confined to skin and subcutaneous tissue 0
Ulcer reaching muscle, tendon or deeper 1
Total 6
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signs of infection) and not only microbiological test-
ing results.
 2.  Evaluation of the severity of infection (see the PEDIS 
classification).
 3.  Microbiological testing (including antibiotic suscepti-
bility) and its interpretation (colonization, contamina-
tion, infection):
—  It is recommended to collect tissue samples, as-
pirate, or scrapings for culture following wound 
debridement;
—  Testing is necessary if a clinically infected wound is 
present;
—  When evaluating infection, interpretation of the 
culture result is difficult, and it is recommended 
that this evaluation is primarily based on the clini-
cal picture;
—  Blood culture is recommended only in case of sys-
temic evidence of an infection;
—  If there is no or mild clinical wound infection, and 
no antibiotics were used previously, it is accept-
able not to perform culture.
 4.  Evaluation for osteomyelitis (should be performed 
in all cases of an infected ulceration, particularly if 
chronic):
—  Probe-to-bone test;
— Foot radiography (every 3–6 weeks);
— Magnetic resonance imaging (indicated);
— Bone biopsy or bone sample culture and histopa-
thology (indicated); bone biopsy is necessary if 
the diagnosis of osteomyelitis is questionable or if 
there is a need to identify the pathogen;
— Laboratory tests — erythrocyte sedimentation rate 
> 70 mm at one hour indicates an increased likeli-
hood of osteomyelitis, and lower rates indicate 
a lower risk. Evaluation of C-reactive protein 
(CRP) level and leukocyte count may also be use-
ful. A possibility of bone inflammation cannot be 
definitely excluded based on normal laboratory 
test results.
 5.  The nature of the wound (dry or exudative) is the 
primary criterion for the choice of dressing.
A.  Approach to antibiotic therapy
—  Use only for a confirmed infection (do not use 
prophylactically);
—  Do not delay therapy.
—  Initially, use an antibiotic covering the most com-
mon causative bacterial flora (staphylocci and 
streptococci);
—  In grade 4 infections by the PEDIS classification, 
provide coverage also for Gram-negative bacteria 
and anaerobes;
—  Duration of antibiotic therapy — until resolution 
of the infection and not just healing of the ulcer-
ation:
• Grade 2 infection by the PEDIS classification — 
1–2 weeks, in some cases longer (in particular 
in immunocompromised patients and those 
with limb ischemia);
• Grade 3–4 infection by the PEDIS classification 
— 2–4 weeks; 
— Route of administration:
• Intravenous — grade 4 infection by the PEDIS clas-
sification, some cases of grade 3 infection (MRSA, 
P. aeruginosa), intolerance of oral antibiotics;
• Oral — grade 2–3 infection by the PEDIS classifica-
tion, improved grade 4 infections;
• Topical — collagen sponge with gentamycin; use 
of garamycin sponge may be considered;
• Intraarterial — not recommended.
B.   Choice of antibiotics
— Severe infections:
• Intravenous therapy — ciprofloxacin + 
clindamycin, amoxicillin-clavulanate or piper-
acillin-tazobactam, or carbapenem + vancomy-
cin until a MRSA infection is excluded,
• Oral continuation — amoxicillin-clavulanate 
and cotrimoxazole (doubled dose) or cipro-
floxacin 750 mg twice daily or moxifloxacin + 
linezolid,
• MRSA infection: linezolin, vancomycin;
— Less severe infections:
Table	21.3.	Foot	screening	frequency	according	to	the	risk	of	ulcer	(IWGDF	risk	stratification	system)
Category Ulcer risk Characteristics Frequency
0 Very low No loss of protective sensation, no ischemia Once a year
1 Low Loss of protective sensation or ischemia Once every 6–12 months
2 Moderate Loss of protective sensation and ischemia or loss of protective 
sensation + foot deformity or ischemia + foot deformity
Once every 3–6 months
3 High loss of protective sensation or ischemia 
and one or more of the following:
•  history of foot ulcer
•  a lower extremity amputation
•  end-stage renal disease
Once every 1–3 months
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• Usually oral therapy, using similar antibiotics as 
in severe infections, e.g.:
• Gram-positive bacteria: semisynthetic penicil-
lins/first-generation cephalosporins;
• Recent antibiotic therapy, Gram-positive or 
Gram negative bacteria: fluorochinolones, be-
ta-lactams or if allergy to beta-lactams: clinda-
mycin, flurochinolones, cotrimoxazole;
— Management of osteomyelitis (no consensus treat-
ment approach):
• Surgical removal of the affected bone (small 
amputation);
• Antibiotic therapy as in severe infections;
• Monitoring of the treatment effectiveness: lab-
oratory tests (erythrocyte sedimentation rate, 
CRP), foot radiographs.
VI.   Multidisciplinary management of the diabetic 
foot syndrome
Effective treatment of the diabetic foot syndrome 
may only be provided within multidisciplinary clinics. This 
concept encompasses an organizational structure that 
allows patient access to the required specialists knowl-
edgeable and experienced in the treatment of diabetic 
foot syndrome who form a therapeutic team and com-
municate with each other.
The management of the diabetic foot syndrome in-
cludes:
— Metabolic control of diabetes: insulin therapy 
(intensive insulin therapy is preferred), treatment 
with oral antidiabetic agents is acceptable in some 
cases if it allows appropriate metabolic control of 
diabetes and insulin treatment is not required;
— Foot off-loading: appropriate off-loading device 
for the affected foot (temporary footwear to off-
load the forefoot or hindfoot), compensatory 
footwear for the healthy foot, therapeutic insoles, 
crutches, wheelchair, plaster cast, specialized foot-
wear, bedrest. The gold standard for off-loading of 
non-infected neuropathic foot is total contact cast 
that includes the foot and the lower leg, made us-
ing a special technique exclusively by trained per-
sonnel; use of total contact cast requires special 
patient supervision and regular cast exchanges to 
evaluate the limb for the presence of new wounds;
— Antibiotic therapy (oral or intravenous), see above;
— Surgical treatment — removal of necrotic tissues, 
drainage, incisions;
— Intravascular and vascular surgical procedures, hy-
brid procedures (diabetic foot with a predominant 
ischemic etiology — patients with low ABI (< 0.5), 
TcPO2 < 25 mm Hg and/or a history of intermit-
tent claudication should be referred for further 
vascular investigations and to a vascular surgeon 
or angiology specialist. Imaging diagnostics and 
revascularization should also be considered (even 
if the results of the tests mentioned above are 
normal), if, there is no progress in wound healing 
within 4 weeks, despite standard management. Of 
note, limb ischemia may not manifest with typi-
cal pain symptoms in many diabetic patients. 
The goal of revascularization should be to restore 
blood supply to at least one artery, preferably the 
one supplying the anatomical area of the ulcer;
— Podiatric treatment (regular wound care, conven-
tional dressings, and wound moisturizing therapy);
— Traditional wound dressings and therapy provid-
ing a moist wound environment. Consideration 
should be given to using TLC-NOSF dressings in 
uninfected wounds with neuropathic-ischemic 
etiology (but without critical/significant ischemia) 
that do not heal despite optimal standard care;
— Other — hyperbaric chamber (ischemic wounds 
not healing despite standard treatment), nega-
tive-pressure wound therapy (use in parallel with 
standard care should be considered, especially for 
postoperative wounds); medications to improve 
perfusion (ischemic or predominantly vascular eti-
ology); low-molecular-weight heparins (acute isch-
emia, critical limb ischemia); acetylsalicylic acid; 
walking training. Sulodexide treatment may be 
considered; skin transplantation, growth factors, 
human skin preparations, ozonotherapy, and au-
tologous platelet gel are not recommended as an 
alternative to standard care;
—  In selected cases, wound cleaning may be consid-
ered using Lucilia sericata larvae cultured in sterile 
conditions in specialized laboratories.
Each patient with the diabetic foot syndrome should 
receive education regarding ulcer prevention.
Neuropathic osteoarthropathy (Charcot foot)
—  Evaluation:
• The diagnosis is made based on history and 
clinical presentation (unilateral edema, erythe-
ma, increased warmth of the foot, particularly 
if no ulceration is present, in a patient with fea-
tures of diabetic polyneuropathy), after other 
causes have been excluded, particularly deep 
vein thrombosis and gout.
—  Management:
• Acute condition — off-loading for 24 hours 
a day (total contact cast, other forms of off-
loading), bisphosphonate therapy with vitamin 
D and calcium administration may be considered 
(long-term treatment, not always effective);
• Chronic condition — education, foot hygiene, 
special orthopedic footwear with corrective in-
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soles, surgical and orthopedic procedures to cor-
rect deformations (exostectomy, arthrodesis).
Multidisciplinary team management is recommended.
VII. Indications for hospital admission
Acute admissions:
—  Grade 4 infection by the PEDIS classification;
—  Grade 3 infection by the PEDIS classification if 
intravenous antibiotic therapy is needed;
—  All cases of critical limb ischemia.
Elective admissions:
—  No improvement despite 2 months of outpatient 
treatment;
—  Preparation before planned surgery (small am-
putation, skin transplantation, revascularization 
procedures).
VIII. Amputation
Before each amputation, it is obligatory to assess 
the blood supply to the limb.
—  Large amputation (above the ankle) should be 
considered in case of:
• A life-threatening condition due to inflamma-
tion, extensive necrosis (an absolute indication),
• Debilitating, treatment-resistant pain, particu-
larly due to ischemia (a relative indication),
• Loss of the support function of the foot (a rela-
tive indication);
—  Small amputation (below the ankle) should be 
considered in case of:
• Liquefactive necrosis,
• Osteomyelitis involving distal phalanges of the 
foot (avoidance of chronic antibiotic therapy, 
faster healing),
• In dry necrosis, awaiting until autoamputation 
is recommended.
The choice of the level of amputation depends on 
tissue perfusion, and reconstruction and rehabilitation 
possibilities.
Amputation should always spare as much limb as 
possible.
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The following chapter deals with variations from the 
general recommendations related to specific pediatric 
issues.
I. Diabetes types in the pediatric population
 1.  Autoimmune diabetes type 1 is the most common 
form.
 2.  In obese subjects, impaired fasting glucose and/or 
impaired glucose tolerance may develop, followed 
by diabetes type 2. OGTT is recommended every two 
years in children above 10 years of age (or earlier, if 
the puberty has already commenced) with BMI > 95th 
percentile.
 3.  Of note, monogenic diabetes is the second most 
common form of diabetes in the pediatric population 
in Poland. Indications for investigations for mono-
genic diabetes are presented in Chapter 1.
 4.  The number of children with cystic fibrosis and dys-
glycemia or diabetes is increasing. Diabetes in these 
patients is usually asymptomatic. Annual OGTT with 
blood glucose measurements at 30, 60, 90 and 120 
minutes should be performed in children > 10 years 
of age with cystic fibrosis.
 5.  Primary diagnostic work-up for hyperglycemia or re-
vision of the diagnosis always includes testing for 
GADA along with 1–2 from the following antibodies: 
ICA, IA2A, IAA, ZnT8 in justified cases (testing should 
always be performed in a reference laboratory). The 
presence of a high antibody titer or elevated antibody 
titers and/or IFG and/or IGT indicates an active auto-
immune process of pancreatic beta cell apoptosis. 
Because of the significant risk of developing clini-
cally apparent type 1 diabetes, patients require health 
education to prevent ketoacidosis.
 6.  The possibility of a mixed diabetes etiology should 
always be borne in mind.
II. Therapeutic targets
 1.  Prevention of acute and chronic diabetes complica-
tions.
 2.  Achieving and maintaining normal, harmonious phys-
ical development including body height, weight, and 
composition (as evaluated using percentile growth 
charts), and the course of puberty that is appropriate 
for age and gender, and providing an appropriate 
quality of life of the patient and his/her family.
 3.  Therapeutic targets for cardiovascular risk reduction:
—  HbA1c ≤ 6.5% with stable blood glucose levels and 
minimized hypoglycemia episodes, while main-
taining good quality of life;
—  LDL cholesterol < 100 mg/dL (< 2.6 mmol/L);
—  Blood pressure < 90th percentile for age, gender, 
and height (> 16 years of age: < 130/85 mm Hg);
—  BMI < 85th percentile for age and gender;
—  Moderate physical activity > 1 hour per day;
—  Sedentary activities < 2 hours per day;
— Avoiding smoking.
III. Management of diabetes
 1.  Drug therapy
Diabetes type 1 — insulin therapy:
— The approach to insulin therapy should be ad-
justed to individual patient needs and accepted by 
the patient and his/her caregivers;
— Intensive insulin therapy is the treatment of choice, 
either as:
• Continuous subcutaneous insulin infusion (CSII) 
using a personal insulin pump;
• Multiple daily injections using insulin pen nee-
dles with the length of ≤ 6 mm;
— Indications for and contraindications to CSII — see 
respective Chapter;
— Initiation of CSII therapy at the disease onset is 
recommended, particularly in children < 10 years 
of age;
— Bolus calculator function use from the beginning 
of the therapy is advised, as it increases the stabil-
ity of blood glucose values and reduces the risk 
of hypoglycemia; it is necessary to regularly verify 
and modify bolus calculator settings;
22. Diabetes in children and adolescents
Most important recommendations
• Children with diabetes type 1 should be treated with intensive insulin therapy. [A]
• Blood glucose levels should be measured in fasting conditions and before meals, before bedtime, and before, 
during and after exercise if feeling unwell and 1–2 hours after the meal as needed. [B]
• Use of CGM with intensive insulin therapy is effective to lower HbA1c levels in children and adolescents; this  
decreases the risk of hypoglycemia. [B] Insulin pumps with automatic insulin-delivery suspension feature are 
particularly useful in the prevention of hypoglycemia. [B]
• Recommended target HbA1c level in children is ≤ 6.5% with stable blood glucose levels and minimized hypogly-
cemia episodes. [E] Guidelines for assessing CGM parameters can be found in Chapter 4.
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— The choice of rapid-acting and long-acting insulin 
analogs should be individualized based on pa-
tient’s needs, taking into account pharmacologi-
cal differences between various preparations and 
their licensed indications;
— In pediatric patients, daily insulin requirement is 
characterized by a large variability and increases 
significantly in the pubertal period, but it should 
not exceed 1.5 U/kg/day;
— During intensive insulin therapy: the magnitude 
of the basal dose (20–50% of the daily dose) and 
its profile depend on the age of the child and the 
type of insulin pump; 
— Rapid-acting/short-acting insulin is best adminis-
tered 15–20 or 30 minutes before a meal, and the 
ultra-rapid-acting analog — 2 min. before meals; 
consider dose splitting and administering half of 
the dose before a meal and the other half during 
or after a meal, and in exceptional cases adminis-
tering the whole dose after a meal;
Diabetes type 2 — treatment options for this age 
group include insulin, metformin and GLP1 (age limits 
according to SPC).
In the case of:
— Absent symptoms, HbA1c < 9%, and no acidosis, 
drug treatment may be started with metformin;
— Present symptoms and/or HbA1c ≥ 9% and no 
acidosis, initial drug treatment includes metformin 
and basal insulin;
— Ketoacidosis — initial treatment as in diabetes 
type 1.
Monogenic diabetes and diabetes in genetic syn-
dromes — treatment depends on the type of disease (use 
of sulfonylureas is off-label).
Diabetes in cystic fibrosis — see Chapter 1.
2.   Nutrition in diabetic children and adolescents
Basic principles of healthy nutrition in diabetic chil-
dren are the same as in their non-diabetic peers.
It is recommended to maintain normal energy bal-
ance and reduce absorbable carbohydrate intake, maxi-
mally to 45–50% of the daily calorie requirement. Reduc-
tion of simple sugar intake to 10% of the daily calorie re-
quirement and including portions of vegetables in every 
meal is recommended.
3.   Self-monitoring:
— Blood glucose monitoring may be undertaken by 
blood glucose self-monitoring, flash glucose moni-
toring, and real-time continuous glucose monitor-
ing (CGM) generating messages and sound alerts 
without user input; 
— Frequency of blood glucose measurements should 
be individualized — in the case of FIIT not less than 
8 times a day. For this reason, it is advisable to 
use continuous glucose monitoring systems (FGM/ 
/CGM) since the initiation of FIIT.
Blood glucose should be measured in fasting condi-
tions and before meals, 1–2 hours after the meal, before 
bedtime, and before, during and after exercise. Periodic 
evaluation of night-time blood glucose profile is recom-
mended. Patients should be instructed to measure blood 
glucose immediately if feeling unwell.
Use of FGM/CGM requires structured diabetes educa-
tion regarding proper interpretation of current readings 
and blood glucose trends. In patients using real-time 
CGM systems education should be extended to include 
the principles of sensor calibration, appropriate choice 
and programming of messages and alarm limits mes-
sages.
The FGM/CGM systems allow more effective adjust-
ment of insulin doses to blood glucose trends, resulting 
in more stable blood glucose values, a reduced number 
of hypoglycemia episodes, better metabolic control, and 
improved quality of life of patients and their caregivers. 
Real-time CGM is particularly indicated in children < 
10 years of age and in patients with hypoglycemia un-
awareness or frequent nocturnal hypoglycemia. In these 
patient groups, it is recommended to use insulin pumps 
integrated with CGM, with a function of automatic tem-
porary cessation of insulin administration in case of low 
blood glucose values or a risk of hypoglycemia. Only 
permanent use of CGM is effective therapeutically (min. 
70% of the time).
Betahydroxybutyrate testing by a test strip is a more 
sensitive marker of ketonemia than testing for ketones 
in urine.
4.   Therapeutic education 
— Education is a key element of diabetes manage-
ment; it should always be targeted at the patient 
and his/her caregivers;
— Patient and his/her parents/caregivers need initial 
education and regular educational reinforcements 
at least once in 1–2 years;
— Educational methods and programs should be var-
ied and adjusted to the patient’s age, intellectual 
capabilities, and educational tasks of the parents;
— In adolescents and young adults, particular at-
tention should be paid to prevention of chronic 
diabetes complications, contraception, pregnancy, 
and addictions.
— The process of developing self-monitoring skills 
should be gradual; too early or too late placement 
of this responsibility on children and adolescents 
with diabetes is associated with treatment failures;
— Workshops and camps for children, adolescents 
and young adults with diabetes are a useful and 
effective educational tool;
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— Members of the diabetology team who care for 
patients below 18 years of age participating in 
camps without parental attendance must provide 
continuous medical care at these facilities, includ-
ing night duties. Legal and organizational support 
is expected from the administrative units involved 
in care for children with diabetes;
— Initiating and continuing diabetes education is 
a responsibility of the whole therapeutic team, 
with a particular role of a diabetes educator.
 5.  Psychological care
— Continuous psychological care of children, ado-
lescents and young adults with diabetes and their 
families is required since the disease onset;
— Common problems include subclinical and clinical 
depressive syndromes, eating disorders including 
anorexia nervosa (particularly in adolescent girls), 
and other non-specific conditions (eating disor-
ders not otherwise specified, ED-NOS);
— Care should be provided by an experienced psy-
chologist who is well versed with the problems of 
pediatric and adolescent diabetes.
— Screening for depressive disorders should be per-
formed in all patients every 1–2 years, and addi-
tionally in all patients with poor metabolic control 
of the disease.
 6.  Additional remarks
— The whole patient family should be involved in 
the process of treating diabetes in children and 
adolescents, with joint discussions on therapeutic 
targets;
— Patients should be encouraged to be independent 
and take responsibility for their treatment to a de-
gree that is appropriate for their age, intellectual 
development, and emotional maturity;
— Children > 10 years of age should be able to 
measure blood glucose using a glucose meter and 
FGM/CGM, inject insulin using a pen, and change 
infusion sets in personal insulin pumps and FGM/ 
/CGM sensors.
IV. Concomitant conditions in patients with diabetes 
type 1
The most frequent comorbidities include:
— Autoimmune thyroiditis and celiac disease; their 
course is usually oligo- or asymptomatic (e.g., 
increased blood glucose excursions, impaired 
growth);
— IgA deficiency;
— Some concomitant chronic diseases (e.g. epilepsy, 
Asperger disease, mental and intellectual disor-
ders) may be associated with additional require-
ments to be considered when planning diabetes 
therapy.
V. Acute and chronic diabetes complications (see also 
respective chapters)
1. Acute complications:
— In case of blood glucose levels below 70 mg/dL 
(3.9 mmol/L) or clinical symptoms of hypoglyce-
mia, glucose should be administered at about 
0.3  g/kg body weight (dose depends on blood 
glucose values and active insulin), and blood glu-
cose measurement should be repeated after 15 
minutes;
—  Blood glucose levels < 54 mg/dL (3.0 mmol/L) 
indicated clinically significant hypoglycemia;
—  If CGM is used, hypoglycemia is diagnosed if blood 
glucose levels are < 54 mg/dL for > 15 minutes;
— Severe hypoglycemia in children is diagnosed in 
case of altered consciousness and/or seizures;
— Diagnostic criteria for ketoacidosis and hypergly-
cemic hyperosmolar state in children are the same 
as in adults;
— Management of diabetic ketoacidosis in children is 
summarized in Figure 22.1. It is emphasized that 
rehydration can be carried out using either 0.45% 
or 0.9% NaCl;
— Management of hyperglycemic hyperosmolar 
state:
• Fluid therapy: rapid initial infusion ≥ 20 mL/ 
/kg body weight of 0.9% saline, with next doses 
administered until restoration of peripheral tis-
sue perfusion, followed by fluid replacement 
during 24–48 hours using 0.45% saline. The 
optimal rate of serum sodium reduction is 0.5 
mmol/L per hour, and of blood glucose is 50–70 
mg/dL per hour and no more than 90 mg/dL 
per hour. If blood glucose decreases by > 90 
mg/dL per hour, addition of 2.5–5% dextrose 
should be considered after a few initial hours 
of hydration therapy;
• Insulin therapy: insulin should be added if 
blood glucose does not decrease by at least 50 
mg/dL per hour during appropriate fluid thera-
py only; initial insulin dose is 0.025–0.05 unit/ 
/kg/hour, with further adjustment to achieve 
blood glucose reduction at the rate of 50–70 
mg/dL per hour;
• Electrolytes: potassium, phosphorus, and mag-
nesium deficit is higher than in diabetic keto-
acidosis; potassium supplementation should be 
started as soon as renal function and diuresis is 
stabilized; intravenous administration of potas-
sium phosphate and potassium chloride (1:1) 
allows adequate phosphate supplementation; 
phosphate administration may result in hypo-
calcemia; magnesium supplementation should 
be considered in hypomagnesemia;
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Figure 22.1. Management of diabetic ketoacidosis in children; ECG — electrocardiogram; i.v. — intravenous
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— Each center treating children with diabetes should 
develop a protocol for the management of pa-
tients with DKA that specifies the local indications 
for hospitalization in intensive care units (ICUS) 
taking into account diabetes-unit staffing level, 
training of the therapeutic team and access to 
ICUs.
— Indications for treatment in an intensive observa-
tion room within the diabetes unit or in ICU:
•  Severe DKA (pH < 7.1) with long duration of 
symptoms, circulatory disorders, decreased 
level of consciousness;
•  Increased risk of cerebral edema (age < 5 years, 
rapidly developing acidosis, low pCO2, high 
urea nitrogen);
•  Hyperosmolal DKA.
 2.  Chronic complications:
— Regular follow-up evaluations are needed to pre-
vent complications (Table 22.1);
— If any chronic complication is diagnosed, screen-
ing for other abnormalities (e.g., nephropathy, 
retinopathy, neuropathy, and macroangiopathy) 
is necessary;
— With persistent albuminuria, when albumin lev-
el is above the upper limit values, ACEI or ARB 
treatment is indicated to reduce its progression. 
Treatment effectiveness should be monitored with 
follow-up testing for albuminuria;
— ACE or ARB treatment is recommended to normal-
ize blood pressure; treatment effectiveness should 
be constantly monitored, and obtaining noctur-
nal blood pressure reduction is indicated, as con-
firmed by ambulatory blood pressure monitoring 
(ABPM);
— Management of dyslipidemia:
• LDL cholesterol levels > 100 mg/dL (2,6 mmol/L) 
require improvement of blood glucose control 
and lifestyle modifications;
• In children > 8 years of age, if previous at-
tempts at making lifestyle modifications did 
not result in beneficial changes in serum lipids 
or other risk factors for atherosclerosis are pres-
ent, genetic testing for LDL cholesterol receptor 
gene mutations and statin treatment should be 
considered if LDL cholesterol level is > 159 mg/ 
/dL (4.1 mmol/L).
VI. Perioperative management (see respective chapter)
VII. Recommendations regarding diabetes care in chil-
dren and adolescents (Table 22.1)
 1.  General recommendations
—  Every child with new-onset diabetes should be 
admitted to a specialist pediatric diabetes unit, 
and later remain under regular specialist care in 
a pediatric and adolescent diabetes clinic until 
transition to adult diabetes care (for transition see 
Appendix 1);
—  A 24-hour access to diabetes information for pa-
tients and their caregivers should be provided;
—  Admission to a diabetes unit should be always 
considered with disease decompensation (persis-
tent hyperglycemia, blood glucose excursions, re-
current hypoglycemia);
—  In diabetes care, data from the memory of insulin 
delivery devices and glucose monitoring systems 
should be retrieved and interpreted on each hos-
pitalization and diabetologist consultation.
 2.  Therapeutic team
—  Inpatient care — per 10 pediatric diabetes beds: 
physicians (specialist in pediatric diabetes, spe-
cialist in pediatric diabetes and endocrinology, 
if unavailable: pediatrician/endocrinologist with 
an experience in diabetology confirmed by the 
voivodship diabetes consultant in diabetology or 
pediatric endocrinology or diabetology) — two 
full-time posts; nursing personnel devoted exclu-
sively to diabetes education or diabetes educa-
tors — two full-time posts; dietitian (full post), 
psychologist (full post), and a social worker (1/4 
post). In diabetes units with intensive observation 
room a nurse dedicated to this care is required;
—  Outpatient care — per a therapeutic team caring 
for 300 patients: specialist in pediatric diabetes 
(if unavailable: pediatrician), specialist in pedi-
atric diabetes and endocrinology, if unavailable: 
pediatrician/endocrinologist with an experience in 
diabetology confirmed by the voivodship diabetes 
consultant) — one full-time post; nursing person-
nel with duties limited to diabetes care or diabetes 
educators — 1–2 full-time posts; dietician — 1/2 
post; and psychologist — 1/2 post.
 3.  Outpatient visits
—  Unlimited frequency of diabetes visits, recom-
mended frequency every 6–8 weeks, at least 4 
times a year;
—  Recommended mean duration of a visit: 20–30 
minutes for a specialist visit and 30–40 minutes for 
a procedural and diagnostic visit (treatment with 
a personal insulin pump);
—  Educational visits do not always constitute a part 
of a physician consultation and may also be con-
veyed using electronic means;
—  Additional tasks of the therapeutic team include 
organization of care for diabetic children in edu-
cational facilities, organization of educational 
camps/workshops, and preparation of educational 
materials.
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Table 22.1. Recommendations regarding diabetes care in children and adolescents
Therapeutic education targeted at the 
patient and his/her caregivers
At the diagnosis and afterwards as required, at the discretion of the treating physician or 
education nurse
Nutritional education targeted at the 
patient and his/her caregivers 
At the diagnosis and afterwards as required, at the discretion of the treating physician or 
education nurse/dietitian
Psychological care of the patient and his/ 
/her caregivers
At the diagnosis and afterwards as required, at the discretion of the treating physician or 
education nurse or psychologist
Diagnostics to determine the type 
of diabetes
At the diagnosis and revision of the diagnosis: clinical picture; family history; assessment of 
insulin secretion, pancreatic antibodies, insulin sensitivity*; genetic tests *(*when needed)
HbA1c 3–4 times a years, may be measured less frequently in patients who regularly use CGM/ 
/FGM
Serum total cholesterol, HDL cholesterol, 
LDL cholesterol, triglycerides
After stabilization of glycemia, and then, if in normal range, every 2 years in patients older 
than 10 years of age
Abdominal ultrasound At the diagnosis
Body weight and growth monitoring At each visit using percentile charts for age and gender
Monitoring of pubertal development  
using the Tanner scale
At the discretion of the physician, at least annually, assessment of menstrual regularity
Blood pressure During each visit, children < 7 years of age at least twice a year, children > 10 years of age, 
24-hour ambulatory blood pressure monitoring (ABPM) — every 2 years or in the case of 
elevated blood pressure values in random measurements
Investigations for celiac disease According to the respective ESPGNH guidelines, screening every 2 years for the first 10 
years of the disease duration if no clinical symptoms
Evaluation of thyroid function/ 
/investigations for thyroid disease
At the onset of the disease: TSH, FT4, anti-TPO and anti-TG (USG in case of positive  
antibody testing and/or thyroid dysfunction), followed by TSH, anti-TPO and anti-TG every 
2 years (at the discretion of the treating physician)
Screening for chronic complications: 
creatinine, albuminuria, urinalysis 
ophthalmological consultation
After stabilization of glycemia, and then every 2 years in patients older than 10 years of 
age or with diabetes duration of more than 5 years. In the case of abnormal results, the 
frequency of subsequent tests should be individualized according to the patient's needs
Specialist consultations According to general pediatric indication and at revision of the diagnosis
 4.  Outpatient clinic and hospital unit equipment
—  Equipment: automatic syringes, personal insulin 
pumps, glucose meters, CGM systems, ambulatory 
blood pressure monitors, ophthalmoscope, mono-
filaments, food scales, computer equipment to 
retrieve and print data from therapeutic systems;
—  Space and necessary teaching equipment for edu-
cation;
—  Hospital units: ≥ 1 intensive metabolic care bed 
per 10 regular diabetes beds, equipped with pulse 
oximetry and ECG monitor, oxygen source, USG 
machine with vascular flow measurement option.
VIII. A child with diabetes in an educational facility
 1.  Cooperation between the therapeutic diabetes team, 
pedagogical personnel, school nurse, and the patient 
family is needed to ensure child safety at school and 
prevent diabetic patient stigmatization:
—  Following the diagnosis of diabetes, the peda-
gogical personnel should be provided with written 
information about the disease and necessary help 
in life-threatening situations, along with contact 
telephone numbers of the parents, treating physi-
cian, and education nurse;
— Appropriate training of the pedagogical personnel 
regarding diabetes self-management;
— Training of the school nurse regarding the use of 
a glucose meter, insulin pen, or insulin pump;
—  The educational facility should be adequately pro-
vided with glucose and glucagon by the patient’s 
caregivers;
—  Diabetes is not an indication for an individualized 
education plan or exemption from any activities 
(e.g., sport activities or school trips).
 2.  Duties of the pedagogical personnel:
—  Comprehensive help allowing rapid and safe pa-
tient return to the educational facility and full 
integration with peers;
—  Basic knowledge of diabetes self-management;
—  Allowing on-site diabetes self-monitoring in the edu-
cational facilities by patients of all age groups, with 
supervision by the school staff in younger children;
—  Strict cooperation with the therapeutic diabetes 
team and the patient’s caregivers.
IX. Travel
— Responsibilities of the patient and his/her care-
givers include informing the organizer about the 
disease, its management, nutrition, and help in 
acute situations, and providing contact telephone 
numbers of the members of the therapeutic dia-
betes team;
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—  An appropriate certificate in English informing 
about the disease should be prepared before an 
international travel;
—  Insulin, glucagon, glucose, glucose meter with 
reagent strips, equipment for insulin pumps, and 
insulin pens should be appropriately stored and 
placed in the hand-luggage.
X. Choice of future profession
—  Particular attention should be paid to education 
of diabetic patients, and providing them with as 
good education as possible;
—  A task of the therapeutic diabetes team is to help 
the patient with the choice of future profession 
by evaluating his/her health status, presence of 
complications, and intellectual and mental capa-
bilities.
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23. Diabetes and pregnancy
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Pregnancy planning in all women with diabetes has 
a major effect on the course of the disease, reducing 
adverse maternal and fetal/neonatal outcomes.
Diabetes in pregnancy includes:
 1.  Pregestational diabetes mellitus (PGDM) — diabetes 
preexisting in a woman who becomes pregnant (re-
gardless of the diabetes type).
 2.  Hyperglycemia first detected at any time during preg-
nancy.
I. Contraception
Patients should be informed that diabetes itself is not 
a contraindication for hormonal contraception. Patients 
should be evaluated for conventional contraindications 
to hormonal contraception and be offered an opportu-
nity to choose an individually preferred, effective con-
traception method, taking into account the risk associ-
ated with unplanned pregnancy. Intrauterine devices or 
progestogen-only contraceptive pills are recommended 
if the duration of diabetes is > 20 years or neurovascu-
lar complications are present (nephropathy/retinopathy/ 
/neuropathy). Patients who plan a pregnancy should be 
informed that the risk of pregnancy complications in-
creases with the duration of diabetes, presence of target 
organ damage, and worse metabolic control.
Combined oral contraceptives containing less than 35 
µg of ethinylestradiol are recommended due to their mini-
mal effect on carbohydrate and lipid metabolism. Preferred 
progestins include levonorgestrel and norethisterone.
A progestin-releasing IUD is recommended as a con-
traceptive method in obese women > 35 years of age, 
patients with diabetes type 2, and in those with concomi-
tant vascular complications.
II. Model of care for pregnant diabetic women
 1.  During pregnancy planning, pregnancy, and the post-
partum period, all diabetic women should remain un-
der care of an experienced team of diabetologists and 
obstetricians. Women with diabetes type 2 treated 
with oral antidiabetic medications require initiation 
of insulin therapy already when planning pregnancy 
to achieve adequate blood glucose control. It is only 
acceptable to use metformin in women with diabetes 
type 2 in the preconception period if this treatment 
allows adequate metabolic control. SGLT-2 inhibitors 
and GLP-1 receptor agonists are currently not ap-
proved for use during pregnancy and should not be 
used during pregnancy planning.
  Each clinician caring for a woman with diabetes type 
2 should regularly initiate a discussion about her re-
productive plans and inform her about the need for 
pregnancy planning due to complex risk factors for 
adverse obstetric outcomes present in this patient 
population.
 2.  Management aims include:
—  Optimization of diabetes treatment;
—  Evaluation and treatment of diabetic complications;
—  Diabetes education, including nutritional advice;
— Recommendation to stop smoking;
—  Evaluation of thyroid function (to exclude hypo-
thyroidism): the upper limit of the reference range 
for thyroid-stimulating hormone (TSH) should be 
defined as 2.5 µIU/mL in the first trimester and up 
to 3.0 µIU/mL in the second and third trimester;
—  During pregnancy, visits related to diabetes should 
occur at least once a month, and in some cases 
every 2–3 weeks. This is due to, among others, 
changing insulin requirements and the need to 
monitor body weight, renal function, eyesight, 
and blood pressure;
—  In case of gestational hypertension at blood pres-
sure values exceeding 140/90 mm Hg treatment 
should be resumed;
—  In diabetic women with chronic hypertension, tar-
get systolic blood pressure is < 130 mm Hg and tar-
get diastolic blood pressure is < 80 mm Hg (methyl-
dopa is the first-choice drug during pregnancy);
— In women with pre-pregnancy diabetes, acetylsali-
cylic acid at the dose of 1 mg/kg (75–150 mg/day) 
is recommended from 12 to 34 weeks of gestation 
(prevention of preeclampsia).
 3.  Pregnancy is discouraged in diabetic women in the 
following clinical situations:
—  Nephropathy with GFR < 40 mL/min;
—  Treatment-resistant proliferative retinopathy;
—  Cardiac complications:
• Advanced, treatment-resistant ischemic heart 
disease: hypertrophic cardiomyopathy or se-
vere dysfunction of the systemic ventricle (left 
ventricular ejection fraction < 30%, New York 
Heart Association class III/IV), 
• History of peripartum cardiomyopathy with any 
residual left ventricular dysfunction;
—  Autonomic neuropathy involving the cardiac con-
duction system or the gastrointestinal system.
Ultimately, decisions regarding procreation are to be 
made by the patient herself, but the patient must be in-
formed about the health risks of pregnancy in such cases.
Pregnancy does not seem to be associated with a risk 
of post-partum worsening of chronic diabetes complica-
tions. Unless the above listed complications are present, 
women with diabetes are free to plan any number of 
children they wish.
III.		 Diagnostic	criteria	and	classification	of	hypergly-
cemia	first	detected	during	pregnancy
All pregnant women should be evaluated for dys-
glycemia. Initial fasting blood glucose measurement to 
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Figure 23.1. Detection of diabetes during pregnancy. An oral glucose tolerance test (OGTT) with 75 g of glucose is recommen-
ded (one step approach). Note: randomly measured fasting blood glucose in the first trimester > 92 mg/dL but > 125 mg/dL 
may not be used to diagnose diabetes during pregnancy; OGTT is required following appropriate patient preparation
detect gestational hyperglycemia should be ordered early 
during pregnancy, at the time of the first visit to a gy-
necologist. In pregnant women at risk (see Table 23.1), 
a diagnostic test (OGTT with 75 g of glucose) should 
be ordered already at the time of the first visit during 
pregnancy (see Chapter 1). If blood glucose is normal 
(see Figure 23.1), the diagnostic test should be repeat-
ed between 24 and 28 weeks of gestation or in case 
of symptoms suggesting diabetes. Between 24 and 28 
weeks of gestation, single-step diagnostic investigation 
is performed using OGTT with 75 g of glucose. 
Hyperglycemia first detected at any time during preg-
nancy should be diagnosed and categorized using the 
2013 WHO classification:
— Diabetes mellitus in pregnancy — if general condi-
tions for the diagnosis of diabetes are met, i.e.;
• Fasting blood glucose ≥ 7.0 mmol/L (126 mg/ 
/dL), or
• Blood glucose at 2 hours of OGTT with 75 g of 
glucose ≥ 11.1 mmol/L (200 mg/dL), or
• Random blood glucose ≥ 11.1 mmol/L (200 mg/dL) 
associated with clinical symptoms of hypergly-
cemia;
— Gestational diabetes mellitus (GDM) — if at least 
one of the criteria in Table 23.2 is met.
In the postpartum period, blood glucose normalizes 
in most women but all women should be evaluated for 
dysglycemia, as diabetes in pregnancy is a risk factor 
for overt diabetes during later life. An OGTT with 75 g 
of glucose is recommended at 6–12 weeks postpartum, 
followed by fasting blood glucose measurements every 
year. An OGTT with 75 g of glucose should be performed 
before the next planned pregnancy.
IV.  Multidisciplinary, integrated approach to the mana - 
gement of pregestational diabetes mellitus and 
hyperglycemia during pregnancy
Hyperglycemia during pregnancy increases the risk of 
complications in the pregnant woman and the develop-
ing fetus, and also affects further child development. 
Thus, blood glucose values seen in healthy pregnant 
women should be aimed for regardless of the type of 
pregnancy (PGDM or hyperglycemia during pregnancy). 
Currently, the following target self-measured blood glu-
cose values are recommended:
Table 23.1. Risk factors for hyperglycemia during pregnancy
— pregnancy beyond 35 years of age
— history of macrosomia (birth weight > 4000 g)
— previous delivery of a neonate with a congenital anomaly
— history of intrauterine fetal demise
— hypertension
— overweight or obesity
— family history of diabetes type 2
— gestational diabetes during previous pregnancies
— multiparity
— polycystic ovary syndrome
Table 23.2. Diagnostic criteria for gestational diabetes ba-
sed on an oral glucose tolerance test with 75 g of glucose 
according to IADPSG (2010) and WHO (2013)
Measurement Plasma glucose
[mg/dL] [mmol/L]
Fasting 92–125 5,1–6,9
60 minutes ≥ 180 ≥ 10,0
120 minutes 153–199 8,5–11,0
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—  Fasting and before meals: 70–90 mg/dL (3.9–5.0 
mmol/L);
—  Maximum blood glucose level at one hour after 
a meal: < 140 mg/dL (< 7.8 mmol/L), and in pa-
tients with diabetes it is recommended that blood 
glucose level at 2 hours after a meal is < 120 ml/dL 
(< 6.7 mmol/L);
—  Before 2 and 4 AM: 70–90 mg/dL (3.9–5.0 mmol/L).
Pregnant women should perform SMBG after an ap-
propriate training by a nurse experienced in caring for di-
abetic patients. The number and timing of SMBG should 
depend on the severity of dysglycemia and the treatment 
used. CGM may be helpful in women treated with CSII.
HbA1c level in women with PGDM should be mea-
sured every 6 weeks, and values < 6.5% in the first tri-
mester, < 6.0% in the second and third trimester should 
be aimed for. No evidence supports the usefulness of 
HbA1c measurements as a tool to monitor metabolic con-
trol in GDM. It is recommended that in patients using 
CGM, time spent in blood glucose values of > 140 mg/dL 
(7.8 mmol/L) be less than 25% daily, in the range of 
63–140 mg/dL (3.5–7.8) mmol/L) — more than 70% daily, 
values < 63 mg/dL (3.5 mmol/L) — less than 4%, and 
< 54 mg/dL (3.0 mmol/L) — less than 1% daily.
 1.  Nutritional therapy:
— Carbohydrates — 40–50% of the daily calorie in-
take (< 180 g carbohydrates/day); low glycemic 
index carbohydrates are preferred;
— Protein — 30% of the daily calorie intake (1.3 g/kg 
body weight) per day;
— Fats — 20–30% of fats the daily calorie intake 
(saturated < 10%);
— Daily calorie intake depending on body weight, 
height, physical activity and age — the mean dai-
ly calorie requirement is about 30 kcal/kg body 
weight or 1500–2400 kcal;
— Low calorie diet is recommended in overweight 
patients;
— Excessive body weight in pregnant woman is associ-
ated with increased risks of large for gestational age;
— Recommended weight gain depends on baseline 
body weight (6.8–11.4 kg for overweight women 
and 4.5–9.1 kg for women with obesity, up to 18 
kg for patients with BMI < 19.8 kg/m2);
— Use of artificial sweeteners is allowed, except for 
saccharin which crosses the placenta and its effect 
on the developing fetus is not entirely clear (see 
Appendix 5);
— When planning pregnancy, folic acid supplemen-
tation (at least 0.4 mg/day) should be initiated at 
least 6 weeks before conception and continued 
until 12 weeks of gestation.
 2.  Physical exercise:
— Aerobic activity of moderate intensity is recom-
mended unless contraindicated.
 3.  Insulin therapy in PGDM:
— Human insulins have been long used for the treat-
ment of diabetes during pregnancy and their safe-
ty has been established. Safety of insulin analogs 
lispro and glargine has been shown in a number 
of observational studies, and that of aspart and 
determir also in randomized studies;
— Intensive insulin therapy with multiple insulin in-
jections (see Chapter 11);
— Insulin therapy with CSII — rapid-acting insulin an-
alogs are recommended. Patient selection for per-
sonal insulin pump therapy and managing PGDM 
patients using this approach should be undertaken 
in diabetes units experienced in CSII therapy. Treat-
ment should be preferably initiated while planning 
pregnancy or during early pregnancy (before 12 
weeks of gestations), and only exceptionally later 
in those patients in whom adequate metabolic 
control cannot be achieved during treatment with 
multiple insulin injections.
 4.  Insulin therapy in hyperglycemia first detected during 
pregnancy:
— The recommended approach is intensive insulin 
therapy with multiple insulin injections or using 
a personal insulin pump;
— Insulin requirement is sharply reduced postpartum 
and insulin therapy may be withdrawn in most 
patients with GDM.
 5.  Oral antidiabetic agents are currently not recom-
mended for the treatment of diabetes during preg-
nancy due to the fact that they pass through the 
placenta. Randomized studies are available indicating 
their negative long-term effect on the development 
of the offspring. In women treated with oral anti-
diabetic agents, initiation of insulin therapy while 
planning pregnancy or as early as possible after the 
diagnosis of pregnancy is recommended.
 6.  Educational system:
— Clinical issues — instruction provided by a physi-
cian, nurse, or dietitian knowledgeable in personal 
insulin pump therapy;
— Technical issues regarding the use of a personal insu-
lin pump — instruction provided by a nurse or physi-
cian certified as a technical instructor or an employee 
of the company producing personal insulin pumps;
— Education program is undertaken according to the 
training card which serves to document the course 
of treatment;
— Education program may be undertaken in outpa-
tient and/or inpatient settings;
— Treatment initiation is possible when the patient 
absorbs basic clinical and technical knowledge re-
garding CSII (understanding the therapeutic prin-
ciples and technical details of using main insulin 
pump functions).
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 7.  Breastfeeding should be widely promoted and rec-
ommended in women with PGDM and DGM unless 
contraindicated for other reasons.
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Most important recommendations
• When initiating diabetes treatment in subjects above 65 years of age, therapeutic targets should be set individu-
ally depending on the health status of the patient, his or her cognitive function, and socioeconomic status. [C]
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24. Diabetes in the elderly
I.   The prevalence of diabetes in the elderly (subjects 
> 65 years of age) may be as much as 25–30%.
II.   Symptoms of hyperglycemia in patients > 65 
years of age may be less evident than in younger 
subjects, leading to a delayed diagnosis.
III.  Expected survival time is much reduced in diabetic 
patients at an advanced age, and thus it should be 
remembered while planning the therapy that pre-
venting complications that develop after several 
years of the disease becomes less important than 
in younger subjects.
IV.   Management goals in diabetic patients > 65 ye-
ars of age:
—  The major management goal in the elderly diabet-
ic patients is to improve or at least preserve their 
previous quality of life. Avoiding hypoglycemia 
while reducing the symptoms of hyperglycemia is 
of key importance;
—  If a diabetic patient > 65 years of age does not 
have significant complications or comorbidities, 
diabetes control should be gradually instituted 
with the target HbA1c level of ≤ 7%;
—  In patients at an advanced age with long-standing 
diabetes and significant macroangiopathic compli-
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cations (previous myocardial infarction or stroke), 
the target HbA1c level is ≤ 8.0%;
—  Investigating for diabetic complications, prevent-
ing their progression, and recommending appro-
priate therapy;
—  Management of concomitant conditions to re-
duce functional impairment and improve the 
quality of life.
V.   Physical exercise — following initial determination 
of the individual risk and patient’s exercise tolerance, 
outdoor exercise characterized by gradual onset and 
termination should be recommended, with avoid-
ance of straining and breath-holding exercises and 
due attention to the risk of trauma, in particular the 
risk of developing diabetes foot syndrome.
VI.   Nutritional recommendations — general recom-
mendations apply; no age-specific recommenda-
tions; diet modifications are of little effectiveness 
due to long-lasting dietary habits.
VII.   Oral antihyperglycemic agents:
—  Metformin — see Chapter 10, section II (stage 1 
treatment of diabetes type 2); consider concomi-
tant conditions and an increasing risk of metabolic 
acidosis; particular attention is required in patients 
with estimated GFR < 60 mL/min/1.73 m2;
—  Sulfonylureas — treatment should be initiated 
with low doses due to a risk of hypoglycemia;
—  DPP-4 inhibitors, GLP-1 receptor agonists, alpha-
glucosidase inhibitor, PPAR-g agonist, SGLT-2 in-
hibitors — no specific contraindications exist to 
the use of these agents in patients > 65 years of 
age; these agents may be particularly useful in this 
age group due to a minimal risk of hypoglycemia. 
Do not use the PPAR-g agonist in patients with 
even mild heart failure.
VIII. Insulin therapy:
—  No specific indications and contraindications exist 
regarding insulin therapy in the elderly;
—  If indicated, insulin therapy should not be delayed;
—  Insulin preparations characterized by the lowest 
risk of hypoglycemia should be selected when ini-
tiating or modifying insulin therapy;
—  Age > 65 years is not a contraindication to inten-
sive insulin therapy;
—  In some very elderly patients (> 80 years of age), it 
may be effective to use low doses of a short-acting 
insulin or rapid acting analogous of insulin before 
main meals without basal long-acting insulin;
—  If meal size is unpredictable (e.g. patients with poor 
appetite or advanced dementia), rapid-acting insu-
lin analogs administered directly after the meal in 
a dose adjusted to the meal size may be indicated.
IX. Diabetes education — should be targeted to both 
patients and their caregivers.
X. Antihypertensive therapy:
—  Age is not a criterion when selecting antihyperten-
sive drug classes;
—  Benefits of antihypertensive therapy in patients 
> 65 years of age are similar compared to those 
in younger subjects.
XI.  Lipid-lowering therapy:
—  Although direct evidence are lacking, it may be 
concluded that benefits of lipid-lowering therapy 
seen in both primary and secondary prevention in 
younger subjects may also be extended to patients 
> 65 years of age.
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Most important recommendations
• Elective surgery in diabetic patients should be delayed if HbA1c level is > 8.5%. [C]
• In patients treated with insulin before surgery, insulin therapy must not be interrupted preoperatively, and tem-
porary insulin treatment should be initiated in most patients with diabetes type 2 who have been treated with 
oral antidiabetic drugs. [B]
• In critically ill diabetic patients receiving parenteral feeding, intravenous insulin should be administered at doses 
guided by blood glucose levels. [C] 
• Blood glucose monitoring in the perioperative period in diabetic patients reduces the risk of complications and 
mortality. [B]
• Target blood glucose levels in the perioperative period are 100–180 mg/dL. [C]
I. Investigations necessary before the planned surgi-
cal procedure:
—  24-hour blood glucose profile (7 measurements 
during 24 hours, with an additional measurement 
at 3 AM in insulin-treated patients);
—  HbA1c level;
—  Complete blood count;
—  Serum creatinine, electrolytes (Na+, K+), amino-
transferases (AST, ALT);
—  International normalized ratio (INR), bleeding 
time, activated partial thromboplastin time (APTT);
—  Acid-base balance (blood gases), if disorders are 
suspected;
—  Urinalysis;
—  Fundoscopy (current examination result);
—  Resting ECG (see Remark 1);
—  Chest radiograph.
Remark 1: Complete non-invasive diagnostic work-up 
(exercise testing, echocardiography, ECG Holter monitor-
ing) should be performed in patients at high or very high 
cardiovascular risk, and those scheduled for an extensive 
procedure (e.g. abdominal or iliac vascular surgery).
Remark 2: One-day surgery may be performed in dia-
betic patients with good metabolic control treated with 
intensive insulin therapy, and in patients with type 2 dia-
betes who do not require temporary insulin treatment in 
the postoperative period, because withholding the antihy-
perglycemic drug on the day of surgery will not result in 
an increase in blood glucose of > 180 mg/dL (10 mmol/L).
II. Preoperative management
 1.  Diabetic patients requiring intermittent insulin ther-
apy should be admitted 2 days before the planned 
surgery.
 2.  Elective surgery should be delayed in patients with in-
adequate metabolic control [persisting blood glucose 
values > 250 mg/dL (13.9 mmol/L), HbA1c > 8.5% and/ 
/or the presence of glucosuria with acetonuria].
 3. If a patient with type 2 diabetes treated with two 
or three antihyperglycemic drugs will not eat their 
meals on the day of the procedure, or will undergo 
major surgery with an increased risk of hemodynamic 
instability, it is recommended to temporarily suspend 
current therapy and use insulin instead.
 4.  For temporary insulin therapy, a multiple injection 
model (basal-bolus) is recommended.
 5.  Daily insulin dose — 0.3–0.7 unit/kg body weight;
— 50–60% of the daily dose — a short-acting insulin 
or rapid-acting insulin analog administered 15–30 
minutes before main meals according to the fol-
lowing regimen: 50–20–30% of the daily dose of 
short-acting insulin/rapid-acting insulin analog;
— 40–50% of the daily dose — a long-acting insu-
lin (NPH) administered in two doses — at 7–8 
AM (40%) and 10–11 PM (60%), or a long-acting 
analog given once daily, most commonly in the 
evening. A well-trained diabetic patient with 
good metabolic control is able to self-adjust 
insulin doses to his/her current needs and thus 
this practice should be allowed to be continued 
in the hospital instead of initiating treatment 
with	fixed,	unmodifiable	insulin	doses.
Individuals using personal insulin pump should main-
tain the current treatment by the day of the surgery.
 6.  If preparation for the surgery requires a nil-by-mouth 
regimen during the day(s) before the surgery, intrave-
nous infusion of 500 mL dextrose 10% with 12 units 
of short-acting (rapid-acting) insulin and 10 mmol of 
KCl is recommended instead of meal.
 7.  Blood glucose control: in the perioperative period, 
blood glucose levels should be kept within the safe 
range of 100–180 mg/dL (5.6–10.0 mmol/L).
 8.  The surgical and anesthetic team should be informed 
about complications that increase the operative risk 
(cardiac and renal disease, neuropathy, proliferative 
retinopathy).
25. Preparing a diabetic patient for a surgical procedure
Developed in cooperation with Prof. Wojciech Szczeklik
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Remark 3: Temporary insulin therapy is not required 
in patients undergoing minor procedures (tooth extrac-
tion, abscess incision, small amputation performed in the 
outpatient settings, cataract surgery) but only if prepa-
ration for the surgery does not require any change in 
nutrition. If 1 or 2 meals need to be omitted due to the 
surgery, intravenous glucose, insulin, and potassium infu-
sion is recommended (500 ml of 10% dextrose with 12 
units of a short-acting (rapid-acting) insulin and 10 mmol 
KCl), administered at the rate of 100–150 ml/hour. Insulin 
and potassium doses may need to be modified according 
to blood glucose and serum potassium levels.
III. Management on the day of the surgery
 1.  Use intravenous glucose, insulin, and potassium infu-
sion with blood glucose monitoring:
—  Algorithm 1: In patients with absolute insulin 
deficiency, separate continuous intravenous in-
fusions of insulin (1 unit of short-acting human 
insulin in 1 mL 0.9% saline) and dextrose (5– 
–10%) using infusion pumps are recommended. 
For each 1 g of exogenous dextrose, 0.2–0.3 unit 
of insulin is needed (Table 25.1). If blood glucose 
during the procedure increases by 30–50 mg/dL 
over 180 mg/dL, the rate of insulin infusion should 
be increased by 1–2 units/hour. If blood glucose in-
creases above 250 mg/dL (13.9 mmol/L), dextrose 
infusion should be stopped and resumed only af-
ter blood glucose decreases below 180 mg/dL (10 
mmol/L). At the same time, it is also recommended 
to increase the rate of insulin infusion. This treat-
ment should be continued until resumption of 
oral feeding. During intravenous insulin infusion, 
blood glucose should be monitored every 1 hour, 
followed by every 2 hours after blood glucose is 
stabilized in three subsequent readings;
—  Algorithm 2: In patients with diabetes type 2 and 
preserved insulin secretion, an optional approach 
is to administer glucose, insulin, and potassium 
(500 mL 10% dextrose with 8–16 units of short-
acting insulin and 10–20 mmol of KCl).
• A larger insulin dose (≥ 16 units) should be 
considered in obese patients, with severe infec-
tion, during cardiac or lung surgery, in patients 
operated under hypothermia, and if baseline 
blood glucose is > 180 mg/dL (10.0 mmol/L),
• A smaller insulin dose (< 12 units) should be 
considered in lean patients and in those re-
ceiving small insulin doses or oral antidiabetic 
agents before the surgery.
 2.  Intravenous glucose, insulin, and potassium infusion 
should be initiated at 8 AM and continued at the rate 
of 80 mL/hour until resumption of normal oral feeding.
 3.  During intravenous glucose, insulin, and potassium 
infusion, blood glucose should be kept at 100–180 
mg/dL (5.6–10.0 mmol/L):
—  If plasma glucose level decreases or is close to the 
lower limit of the recommended range, insulin 
dose should be reduced by 2–4 units;
—  It is recommended to increase the insulin dose by 2 
units per each 30 mg/dL (1.6 mmol/L) rise of plasma 
glucose level over > 180 mg/dL (> 10 mmol/L).
 4.  If continued surveillance over the operated patient is 
possible, the algorithm 1 should be preferred.
IV. Postoperative management
 1.  Insulin treatment with multiple subcutaneous insulin 
injections or using a personal insulin pump should be 
initiated upon resumption of oral nutrition and contin-
ued (in case of temporary insulin therapy) until surgical 
wound healing. Depending on blood glucose levels, in-
sulin should be administered subcutaneously 1–3 hours 
before termination of the intravenous infusion.
  For patients with type 2 diabetes who have been on 
non-insulin medications and had good glycemic con-
trol prior to surgery, previous therapy can be resumed 
when starting normal nutrition, provided there are no 
clinical contraindications.
Remark 4: In diabetic patients previously treated 
with insulin, operated due to an acute or chronic inflam-
matory condition, a possibility of a reduction of daily 
insulin requirement should be taken into consideration.
V. Perioperative management in children
Insulin dosing algorithm in case of major procedures 
and those requiring intravenous insulin therapy (Table 25.2).
In case of non-major procedures (< 2 hours) under gen-
eral anesthesia or conscious sedation, patients with good 
metabolic control may be admitted in the morning on the 
day of the procedure or in the afternoon on the preceding 
day. Subcutaneous insulin therapy may be continued, or the 
algorithm for major procedures may be used (Table 25.3).
Table 25.1. Dosing of 10% and 5% dextrose and insulin infusion in relation to blood glucose levels
Blood glucose 10% dextrose  
[mL\hour]
5%	dextrose*	 
[mL\hour]
Insulin  
[units\hour]
< 90 mg/dL (< 5.0 mmol/L) 50 100 Stop infusion for 15–30 minutes 
90–120 mg/dL (5.0–6.7 mmol/L) 50 100 0.5–2 
120–180 mg/dL (6.7–10 mmol/L) 50 100 2–3 
*5% dextrose is preferred with greater fluid deficit and/or higher plasma osmolality
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Table 25.2. Perioperative management in children. An algorithm for intravenous insulin dosing in relation to blood  
glucose levels
Infusion of a 1 unit of insulin/1 mL solution  
(add 50 units of insulin to 50 mL 0.9% saline) using a syringe pump
Blood glucose [mg/dL]/[mmol/L] Insulin infusion rate Hydration
< 90/5.0 Stop infusion for 10–15 minutes Type	of	fluid:
90–109/5–6.1 0.02 mL/kg/hour • blood glucose > 250 mg/dL: 0.9% saline
110–126/6.1–7.0 0.025 mL/kg/hour (basal infusion rate) • blood glucose < 250 mg/dL: 10% dextrose
127–143/7.0–8.0 0.035 mL/kg/hour Rate:
144–216/8.0–12.1 0.05 mL/kg/hour • 4 mL/kg/hour (for body weight up to 10 kg)
217–271/12.1–15.1 0.075 mL/kg/hour • add 2 mL/hour per each kg of body weight  
between 11–20 kg
> 271/> 15.1 0.1 mL/kg/hour • add 1 mL/hour per each kg of body weight > 20 kg
Maximum rate 2000–2500 mL/day
VI. Urgent surgery
Diabetic patients may sometimes require an urgent 
surgery.
In these cases, it is necessary to exclude ketoacidosis 
associated with poor metabolic control of diabetes as 
the cause of peritonism. Thus, if an acute abdomen is 
thought to be present in a patient with diabetic acidosis 
(acetonuria and metabolic acidosis as indicated by blood 
gases), correction of acid-base abnormalities should be 
attempted immediately.
 1.  Ketoacidosis (base excess < –12; pH < 7.3) and hy-
perglycemic hyperosmolar state should be corrected 
according to the general management principles. If 
surgery cannot be postponed, treatment of meta-
bolic disorders should be carried out simultaneously 
with surgical procedures.
 2.  If acute diabetes complications are nor present and 
the patient took his/her morning insulin dose, intra-
venous insulin infusion should be administered dur-
ing the procedure, as described above.
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Table 25.3. Subcutaneous insulin therapy in case of non-major procedures under general anesthesia or conscious  
sedation
Basal–bolus  
therapy
Basal insulin: NPH insulin — 50% of the morning dose, long-acting insulin analog — 100% of the morning 
dose
Initiate intravenous fluids; in patients with normal blood glucose levels, non-glucose-containing fluids may 
be used initially, followed by 5% or 10% dextrose in amounts appropriate to prevent hypoglycemia.
Morning procedure:
Bolus — only as a correction dose
Initiate intravenous fluids
Afternoon procedure:
Bolus — if the child is allowed to have a breakfast — the usual dose of a rapid-acting insulin analog or 50% 
of the usual dose of a short-acting insulin; a correction dose may be added
Initiate intravenous fluids 2 hours before the procedure or no later than at noon
Therapy using  
personal insulin 
pump
It may be continued only if the anesthesiologist accepts this form of therapy and is able to manage it
Continue insulin therapy using a previously programmed basal dose for a given period during the day  
(modification of the basal dose is usually not required)
Hypoglycemia: withhold basal dose administration (for up to 30 minutes)
Hyperglycemia: a correction bolus
Initiate intravenous fluids 2 hours before the procedure
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Every child with diabetes should undergo all current-
ly recommended vaccinations. According to the immu-
nization schedule for Poland, compulsory immunization 
includes vaccination against Streptococcus pneumoniae 
at 2–5 years of age (using 10- or 13-valent pneumococ-
cal vaccine), and 13-valent pneumococcal vaccine is 
recommended from 6 years of age until the elderly age. 
Annual influenza vaccination is recommended in chil-
dren > 6 years of age and adults. Non-immune patients 
should be vaccinated against chickenpox (varicella) 
(2 doses 6 weeks apart) rubella, mumps and measles as 
these diseases may result in serious decompensation of 
diabetes.
Since 1996, all infants are vaccinated against hepatitis 
B virus, and since 2000 this vaccination is also offered to 
14-year-olds. Vaccination is recommended in all patients. 
Unvaccinated subjects at any age should be actively iden-
tified and offered vaccination according to the 0, 1, 6 
months regimen. If the anti-HBs antibody titer in previ-
ously vaccinated subjects is < 10 IU/L, revaccination using 
1–3 doses is recommended. If a protective antibody titer 
(> 10 U/mL) is not achieved after 3 doses of the vaccine 
(4–12 weeks after the last vaccination), further vaccina-
tion is not attempted. Mandatory and recommended 
vaccinations should be done before traveling to endemic 
areas in accordance with the epidemiological recom-
mendations of the destination country. Each vaccination 
should be preceded by a physician examination.
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Most important recommendations
• Every child with diabetes should undergo all currently recommended vaccinations. [C]
• Annual influenza vaccination is recommended in children > 6 months of age and adults. [C]
• Vaccination against hepatitis B virus is recommended in all patients with diabetes. [C]
26. Vaccinations in diabetic patients
27. Recommendations regarding professional activity of diabetic patients
Developed in cooperation with Dr Andrzej Marcinkiewicz and Prof. Jolanta Walusiak-Skorupa from the Institute 
of Occupational Medicine in Łódź
 1.  The sole fact of suffering from diabetes should never 
be a basis for discrimination or unequal treatment. 
Any professional limitations should be imposed after 
a careful analysis of the individual patient status and 
health condition.
 2.  In addition to providing effective therapy, the role of 
diabetologist in maintaining professional activity of 
diabetic patients includes:
—  Health education targeted at the development of 
health awareness and understanding of limitations 
arising from potential diabetes complications;
—  Help with producing an objective opinion regard-
ing patient’s health predispositions to professional 
activity by presenting information to the physician 
authorized for medical review and opining.
 3.  The patient’s attitude should be the key factor taken 
into account when evaluating the health status for the 
purpose of professional activities. Each diabetic patient, 
regardless of the diabetes type and the management 
approach, must actively participate in the treatment.
 4.  Patient’s health predispositions to professional activi-
ties or driving are evaluated and opined by a physi-
cian authorized to perform preventive health exami-
nations or medically certify drivers. Due to an inci-
dental nature of contacts with patients (often dur-
ing a single consultation) leading to opining on the 
individual health status, it is advisable that a diabetic 
patient produce an opinion of the treating physician.
 5.  During the consultation for the purpose of medical 
review and opining, a diabetes specialist should:
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—  Evaluate patient knowledge regarding the disease, 
its treatment, and possible complications, rating it 
as extensive, satisfactory, or not satisfactory;
—  Evaluate blood glucose self-management ability, 
rating it as high, acceptable, or low;
—  Evaluate hypoglycemia awareness and the pa-
tient’s ability to prevent and counteract hypogly-
cemia, rating it as good or not satisfactory;
—  Confirm the presence or absence of hypoglycemia 
prodromes;
—  Categorize the risk of hypoglycemia as low, ac-
ceptable, or high;
—  Determine the presence of chronic diabetes com-
plications involving the eye, nervous system, and 
cardiovascular system;
—  Provide additional comments regarding chronic 
diabetes complications and the health condition 
of the patient which are important for the assess-
ment of the risk for public safety.
 6.  Justification of professional activity limitations in dia-
betic patients is twofold and results from:
—  A risk of a hypoglycemic episode and associated 
impaired consciousness;
—  A risk of late diabetes complications which reduce the 
ability to engage in specific professional activities.
Contraindications to driving for holders of various 
categories of driving license and contraindications to 
work at specific workplaces are given in Appendix 2. 
 7.  Patients with advanced chronic diabetes complica-
tions should not engage in professional activities in 
which organ damage resulting from diabetes might 
affect work safety. However, this should not refrain 
them from undertaking other activities for which 
a given diabetes complication is not an issue. At 
the same time, the nature of professional activities 
and related nuisances should not hinder metabolic 
control of diabetes, and thus patient protection from 
the development and acceleration of chronic diabetes 
complications.
 8.  A diabetes consultation for the purpose of examin-
ing drivers and workers should conclude with issuing 
a clear opinion on a standardized diabetes consultation 
card, using a template provided in the Appendix 2.
 9.  Health requirements for diabetic patients should be 
divided into two categories depending on patient’s 
professional activities or workplace.
 10. The first (higher) category includes professional activi-
ties and workplaces requiring unaffected psychomotor 
skills and related to exposure to adverse psychosocial 
factors, when performing professional duties might 
have an effect on the safety of the worker and his/her 
environment (collaborators and other persons who 
are not directly involved in these professional activities 
but are present in the immediate vicinity or are poten-
tially affected by these activities, e.g. road traffic par-
ticipants, big-box store clients, etc.). More restrictive 
health requirements should be viewed in the context 
of the risk of impaired consciousness, which may be an 
effect of severe hypoglycemia in diabetic patients. 
 11. Professions requiring a higher category health re-
quirements, and thus particularly requiring consider-
ation of the fact that a worker suffers from diabetes, 
are those related to public safety, including:
—  Professional driving (passenger transport drivers, 
truck drivers, train and underground drivers, taxi 
drivers);
—  Uniformed and emergency services: armed forces 
(army, navy, airforce), police, fire services, munici-
pal police, paramedic services, shipping, peniten-
tiary service, security guards;
—  Civil aviation: pilots and aviation engineers, flight 
deck personnel, air traffic controllers;
—  Other professions associated with particular 
dangers (working at a height, operating moving 
equipment, work at furnaces, in high ambient 
temperatures, incineration plants, ironworks, min-
ing, places with high traffic and other places with 
high risk of accidents).
 12. The second (lower) category of health requirements 
involves professional activities and workplaces with 
noxious factors and nuisances which may have 
a negative effect on the course of diabetes. In case 
of this lower category of health requirements, some 
professions and workplaces should be viewed as not 
recommended rather than absolutely contraindicat-
ed. Thus, addition attention should be paid to, and 
individual evaluation of health predispositions of 
a diabetic patient is required when making a decision 
regarding initiation or continuation of work at the 
following workplaces:
—  requiring increased physical effort, particularly of 
a static nature (e.g. miner, ironworker);
—  involving shift or night work;
—  involving exposure to carbon disulfide and pes-
ticides — 2-chlorophenoxyacetic acid derivatives 
(e.g. dichlorprop, mecoprop).
13. Diabetologist should serve as an advisor to young 
patients, in whom particular attention should be paid 
to the choice of profession. In these cases, the natural 
history of diabetes should be taken into consideration 
in addition to the current health status, as future 
health limitations may prevent not only vocational 
training but also, in the longer term, work itself.
14. Appendix 3 includes the Charter of Employer and Em-
ployee Rights and Duties, serving to increase patient 
responsibility and their position as employees on one 
hand, and on the other hand to counteract exclusion 
of the diabetic patients from the labor market.
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Metabolic surgery is an effective approach to man-
age obesity and concomitant conditions, in particular 
diabetes type 2. Multidisciplinary approach allows proper 
patient selection for metabolic surgery and choice of an 
appropriate surgical technique.
I. Patient selection for metabolic surgery
 1.  Metabolic surgery should be considered in all patients 
with diabetes type 2 and BMI > 35 kg/m2, especially 
if concomitant conditions are present, such as hyper-
tension and lipid disorders. In particular, metabolic 
surgery should be considered if drug treatment and 
lifestyle modifications do not allow adequate control 
of diabetes type 2 and obesity.
 2.  Referral for metabolic surgery is recommended in all 
patients with diabetes type 2 and BMI > 40 kg/m2.
 3.  Metabolic surgery is indicated in patients with diabe-
tes type 2 between 18 and 65 years of age. The upper 
age limit may be in some cases extended to 70 years 
if the individually assessed operative risk is lower than 
the potential benefits of surgery.
 4.  Patient selection for bariatric surgery should be per-
formed by a physician team that at least comprises 
a diabetologist and a surgeon with a large experience in 
metabolic surgery. It is also recommended that the mul-
tidisciplinary team involved in patient selection include 
a cardiologist, respiratory medicine specialist, psycholo-
gist or psychiatrist, anesthesiologist, and dietician.
II. Types of surgical procedures
 1.  It is recommended that patients be referred for mini-
mally invasive (laparoscopic) surgery.
 2.  Based on the available study results, patients with 
diabetes type 2 should be primarily referred for lapa-
roscopic Roux-en-Y gastric bypass, laparoscopic mini 
gastric by-pass, laparoscopic sleeve gastrectomy, 
laparoscopic biliopancreatic diversion or single anas-
tomosis duodeno-ileal by-pass (SADI).
 3.  The decision regarding the type of surgery should 
be made after a surgical consultation and individual 
consideration of the advantages and disadvantages 
of all surgical techniques listed above.
 4.  Before making the decision regarding metabolic sur-
gery, patients are recommended to become acquaint-
ed with the informed consent forms prepared by the 
Metabolic and Bariatric Surgery Section of the Polish 
Society of Surgeons.
III.  Complications of surgical treatment of diabetes 
type 2
Thirty-day mortality after metabolic surgery has been 
estimated at 0.1–0.3%, which is identical with the mortal-
ity risk associated with laparoscopic cholecystectomy and 
may be categorized as low risk. The most common compli-
cations of metabolic surgery include suture line dehiscence 
(3.1%), surgical suite infection (2.3%), pulmonary compli-
cations (2.3%), and gastrointestinal bleeding (1.7%).
IV.   Evaluating outcomes of surgical treatment of dia-
betes type 2
Diabetes type 2 resolves in 40–95% of patients, de-
pending on its duration, severity of obesity, and the type 
of surgical procedure.
The following approach to evaluating outcomes of 
surgical treatment of diabetes type 2 is recommended:
 1.  Resolution of diabetes and concomitant conditions
The disease may be considered resolved if after cessa-
tion of drug therapy:
Most important recommendations
• Metabolic surgery should be recommended in patients with diabetes type 2 and BMI > 35 kg/m2, especially if 
concomitant conditions are present and lifestyle modifications combined with antidiabetic medications do not 
allow adequate blood glucose control. [A]
• Each patient after surgical treatment of diabetes should remain under the care of a diabetologist and a general 
surgeon and receive continued vitamin and mineral supplementation to prevent their deficiencies. [C]
28. Diabetes care in penitentiary institutions
Subjects detained in penitentiary institutions (prisons, 
remand centers, juvenile detention centers) should be of-
fered access to the same level of medical care, including 
diabetes care, as in the general population.
The penitentiary institution personnel should be in-
formed about the diagnosis of diabetes in a detained 
subject, and should be trained how to recognize hyper- 
and hypoglycemia and intervene in such situations as 
well as in other emergencies.
29. Metabolic surgery
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—  HbA1c level is < 6.5%;
—  No hypoglycemia episodes occur in the patient;
—  Total cholesterol is < 4 mmol/L, and LDL choles-
terol is < 2 mmol/L;
—  Triglyceride level is < 2.2 mmol/L;
—  Blood pressure is < 140/90 mm Hg;
—  Body weight decreased by > 15% compared to 
baseline, i.e. preoperative body weight.
 2.  Clinical improvement
The disease may be considered improved following 
metabolic surgery if after reduction of drug treatment 
used before the surgery:
—  HbA1c level decreased by > 20%;
—  LDL cholesterol is < 100 mg/dL (< 2.6 mmol/L);
—  Blood pressure is < 140/90 mm Hg.
V.   Recommendations following surgical treatment 
of diabetes type 2
 1.  Each patient after surgical treatment of diabetes 
should remain under the care of a diabetologist and 
a general surgeon.
 2.  Continued vitamin and mineral supplementation is 
needed to prevent their deficiencies.
VI. Pregnancy and metabolic surgery
 1.  Pregnancy is allowed (i.e., becomes not contraindi-
cated) 24 months after metabolic surgery.
 2.  Continued contact with the treating diabetologist is 
recommended before conception and throughout 
the pregnancy.
VII.  Contraindications to metabolic surgery in pa-
tients with diabetes type 2
Absolute contraindications:
 1.  No patient acceptance for surgical treatment of dia-
betes type 2.
 2.  Alcohol or drug dependence (Qualification for surgi-
cal treatment of obesity may be considered in pa-
tients who fulfil the requirement of documented ab-
stinence for preceding 12 months or longer).
 3.  Mental conditions that cannot be controlled despite 
non-pharmacological and pharmacological therapy.
 4.  High cardiovascular risk associated with the procedure.
 5.  Endocrine diseases promoting obesity (e.g. Cushing's 
syndrome).
 6.  Lack of possibility to participate in permanent long-
term control after surgical treatment.
 7.  The period of 12 months preceding the planned preg-
nancy, pregnancy and feeding
Relative contraindications:
 1.  Increase in body weight in the period immediately 
preceding the surgery, indicating poor compliance;
 2.  Active peptic ulcer — it requires treatment before 
surgery; in patients with asymptomatic H. pylori in-
fection eradication before surgery is recommended, 
but not strictly necessary.
 3.  Patients who have been treated for cancer require an 
oncology consultation confirming that the cancer is 
cured.
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30. Selected special situations and diseases in diabetic patients
Developed in cooperation with Prof. Renata Górska
I. Shift work
Shift work may be associated with both an increased 
risk of diabetes and its worse control. Hours of adminis-
tration of oral hypoglycemic drugs or insulin may need 
to be modified.
 1. Intensive self-monitoring is required in patients work-
ing in shifts, particularly during working hours.
 2. Antidiabetic drugs associated with low risk of hypo-
glycemia and allowing greater dosing flexibility (both 
oral and injected, including insulin) are preferred in 
patients working in shifts.
 3. Patients treated with insulin, particularly those with 
diabetes type 1, should be able to modify insulin 
doses during intensive insulin therapy.
II. Time zone change
Travel is not contraindicated in diabetes. Diabetic 
patients, particularly those with diabetes type 1 or 2 
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treated with insulin, should prepare for the travel, taking 
into account such factors as travel duration, means of 
transportation, time zone change (the direction of travel 
should also be considered, i.e., eastbound or westbound) 
and the climate of the destination country. Particular 
problems may be posed by a rapid change of the time 
zone (airplane travel).
 1. Diabetic patients treated with insulin, particularly 
those with diabetes type 1, should be particularly 
alert during the period of adaptation to the new time 
zone (its duration in days equals the time difference 
in hours). Frequent blood glucose monitoring is nec-
essary during this period.
 2. Patients treated with basal-bolus insulin therapy fly-
ing westbound (i.e., with prolongation of the day) 
should administer a previously used long-acting in-
sulin dose in the evening (new time). Possible hy-
perglycemia resulting from, e.g., meals consumed 
onboard, may be corrected with additional doses 
of a short-acting insulin/rapid-acting insulin analog. 
When travelling eastbound (i.e., with shortening of 
the day), it may be necessary to reduce the evening 
dose of long-acting insulin.
 3. Patients treated with personal insulin pump do not 
need to adjust the pump clock or modify insulin 
doses when the time zone change does not exceed 
2 hours. With a greater change of the time zone and 
a longer planned duration of stay in the new time 
zone, it is recommended to gradually shift basal in-
sulin infusion by 2 hours per day.
III. Glucocorticosteroid therapy
 Multiple drugs have a diabetogenic effect. One par-
ticularly important class of diabetogenic drugs are glu-
cocorticosteroids, both due to the magnitude of their 
diabetogenic effect and the frequency of their use. Glu-
cocorticosteroids mostly increase postprandial glycemia.
 1. Substitution doses of glucocorticosteroids (hydrocor-
tisone up to 20 mg/day) and inhaled glucocortico-
steroids have no significant effect on carbohydrate 
metabolism.
 2. An increased risk of steroid-induced diabetes is af-
fected by the following factors: older age, obesity, 
impaired glucose tolerance, use of a high glucocorti-
costeroid dose, and simultaneous use of other diabe-
togenic medications.
 3. The preferred approach to the treatment of gluco-
corticosteroid-induced diabetes is intensive insulin 
therapy (or only administration of short-/rapid-acting 
insulin preparations before meals, if fasting and pre-
prandial glycemia is acceptable). No superiority of 
any insulin or insulin analog preparation over the 
others has been shown in steroid-induced diabetes.
 4. In patients with diabetes type 2 treated with oral 
hypoglycemic drugs who require temporary glucocor-
ticosteroid use, particularly in high doses, intensive 
insulin therapy is recommended.
 5. In patients with diabetes type 2 receiving combined 
therapy with basal insulin (NPH insulin or a long- 
-acting insulin analog), it is usually necessary to add 
short-acting insulin before meals.
 6. In diabetic patients treated with insulin, glucocorti-
costeroid use is associated with an increased insulin 
requirement, particularly during the day.
IV. Periodontal disease
Periodontal disease and other oral diseases are more 
common in patients with diabetes. Periodontal disease 
negatively affects the metabolic control of diabetes and 
increases the risk of its complications. Treatment of perio-
dontal disease improves the metabolic control of diabetes.
 1. Patients with diabetes should be interviewed and un-
dergo dental physical examination for oral diseases.
 2. Every patient with diabetes should have a dental ex-
amination once a year.
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Appendix 1
Recommendations regarding transition of patients with diabetes type 1 
from pediatric to adult diabetes care
Transition from pediatric to adult diabetes care is 
a special period in the life of a young patient with diabe-
tes type 1. The basic principle of this transition should be 
to provide continuity of care without any significant gap 
between termination of pediatric care and initiation of 
adult care. To make the transition smooth, the following 
recommendations should be adhered to:
 1.  The moment of transition from pediatric to adult 
diabetes care should be set individually so as not to 
interfere with the therapeutic process. Depending on 
the emotional development, family and educational 
situation, and other factors, the optimal age for tran-
sition of care is 16–21 years.
 2.  The patient should be prepared for the transition 
by his/her pediatrician over the period of at least 
one year. It is recommended that during this time, 
examinations for chronic disease complications and 
comorbidities are performed.
 3.  At the last visit in the pediatric diabetes clinic, which 
should take place at least 6 months before the tran-
sition, the patient should be referred to an adult 
diabetes clinic in a coordinated effort, which should 
include in particular:
— setting the date of first visit in the adult clinic by 
contacting in advance the clinic, its coordinator, or 
optimally the future treating physician;
— providing the patient with the pediatric care dis-
charge summary (see an attached template on 
pages 79–80) which includes all relevant informa-
tion regarding previous pediatric diabetic care.
 4.  Adult care should begin within 6 months after termi-
nation of the pediatric care.
 5.  It is recommended to create regional networks of coop-
erating pediatric and adult clinics that would develop 
the policy of continuous contact and patient transfer.
 6.  If the transition of care involves a large number of 
patients, it is recommended to appoint, both in pe-
diatric and adult clinics, transition care coordinators 
who would manage the process of patient referral 
and care transition by scheduling visits, providing ef-
ficient flow of information, etc.
 7.  Devoting separate days for new arrivals of transitioned 
pediatric patients to adult clinics is not necessary but 
may be helpful in terms of organizing care, as these 
visits are much more time-consuming, particularly in 
patients treated with personal insulin pumps.
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PEDIATRIC DIABETES CARE DISCHARGE SUMMARY
PATIENT DATA
Name and surname:    PESEL: 
Diagnosis: Type 1 diabetes   Date of diagnosis (MM/YYYY): 
CURRENT THERAPY:
Multiple insulin injections  
Type(s) of insulin: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Daily dose: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Basal dose: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Meal boluses: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Correction dose:   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Continuous glucose monitoring  
Type of insulin: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pump report attached   * or:
Daily dose:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Basal dose:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Carb-to-insulin ratios: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Correction dose: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other antihyperglycemic drugs:
Glycemic control:   Glucometer      CGM      FGM 
HbA1c range during therapy: 
Recent value: (date-value): 
The number of visits to diabetes clinic during the previous 12 months 
PREVIOUS HOSPITALIZATIONS FOR ACUTE COMPLICATIONS
Cause Number
Diabetic ketoacidosis
Severe hypoglycemia
Episodes of severe hypoglycemia during the previous 12 months (dates): 
Chronic complications of diabetes: GRADE/COMMENTS 
Retnopathy YES/NO 
Diabetc kidney disease YES/NO 
Somatic neuropathy YES/NO 
Autonomic neuropathy YES/NO 
Concomitant conditions:
Diagnosis Date of diagnosis Current treatment 
Autoimmune thyroid disease YES/NO 
Celiac disease YES/NO 
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Hypertension YES/NO 
Hyperlipidemia YES/NO 
Diabetes education:     needs correction:        satisfactory        very good
Documents attached
Hospital Discharge Summary Report:    YES  /    NO
Results of examinations performed dring the last 12 months:    YES  /    NO
Date          Physician’s signature 
PATIENT’S STATEMENT: 
I, the undersigned, hereby declare that I have received a Pediatric Diabetes Care Discharge Summary:
Date: 
Patient’s signature: 
Parent’s signature: 
ADDITIONAL INFORMATION FOR A DIABETES SPECIALIST IN THE ADULT DIABETES CLINIC PROVIDED VOLUNTARY BY THE PATIENT: 
I would like to improve the treatment of diabetes in the following areas: 
  Frequency of blood glucose measurements
  Regular administration of insulin before meals and to correct hyperglycemia 
  Healthier nutriton, e.g. limitng sweets
  Carbohydrate counting 
  Knowing the glycemic index and glycemic load
  Knowing the impact of protein and fat on glycemia
  Knowing my energy demand 
  Regular physical actvity 
Patients using insulin pumps 
  Regular replacement of infusion sets
  Using the bolus calculator
  More frequent use of the temporary basal rate 
Patients using contnuous glucose monitoring systems
  Checking more frequently glycemic levels and trends
  Taking into account glycemic trends when modifying insulin doses and glucose intake 
  System calibration
  Alarm programming
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Appendix 2
Medical review and opining in drivers  
and workers with dysglycemia or diabetes
I.   Medical review and opining in drivers
 1. Medical review and opining in drivers with dysglyce-
mia or diabetes is regulated by the Appendix No. 6 to 
the ordinance of the Minister of Health of August 29, 
2019 on medical examinations of driving license ap-
plicants and drivers (Journal of Laws 2019, item 1659), 
entitled “Detailed conditions of the medical examina-
tions related to diabetes”.
 2. Based on the results of a medical examination, labora-
tory tests, and specialist consultations, a physician au-
thorized to medically certify drivers evaluates the risk 
for traffic safety and includes it in the medical opinion.
 3. According to the section 3a and 4 of the above men-
tioned Appendix to the ordinance of the Minister of 
Health, an opinion of a diabetes specialist or anoth-
er physician engaged in treating diabetes, including 
a statement of no other medical contraindications to 
driving related to diabetes, is obligatory in subjects:
— Applying for or holding a category C1, C1+E, C, 
C+E, D1, D1+E, D, D+E driving license, or a tram 
driving permit;
— Working as road carriage drivers, within the mean-
ing of the Road Transport Act; 
— Working as drivers of emergency vehicles or ar-
mored transportation service vehicles;
— Driving license instructors and examiners;
—  Applying for or holding a category AM, A1, A2, A, 
B1, B, B + E or T driving license — in patients with 
recurrent severe hypoglycemia.
 4. In case of diagnostic or medical opining uncertainties, 
a physician authorized to examine drivers may also 
order a diabetes consultation.
 5. To be considered by a physician authorized to medi-
cally certify drivers, a diabetes consultation for the 
purpose of medical review and opining in drivers 
must conclude with issuing a diabetes consultation 
card using a template provided in the Appendix No. 6 
to the above cited ordinance of the Minister of Health 
of August 29, 2019 (see page 84).
 6. The consulting diabetes specialist, or other physician 
engaged in treating diabetes, should also assess the 
patient’s ability to drive and enter the relevant infor-
mation in the consultation card, which may have the 
following effect of the final medical opinion:
— No medical contraindications to driving:
• Without time constraints resulting from the 
investigations for dysglycemia,
• With time constraints resulting from the iden-
tified dysglycemia (consistent with a low or in-
creased risk for traffic safety);
— Medical contraindications to driving resulting from 
the identified dysglycemia:
• Relative, with indication of a 6-month period 
after which the patient may undergo a repeat-
ed medical assessment (consistent with a high 
risk for traffic safety, and an option of reassess-
ment),
• Absolute medical contraindications to driving 
(consistent with a high risk for traffic safety and 
no indication of the timing of a repeated medi-
cal assessment).
 7. In patients applying for or holding a category AM, A1, 
A2, B1, B, B+E, or T driving license:
—  An absolute contraindication to driving vehicles is 
insufficient hypoglycemia awareness, meaning that 
the patient, when awake, does not feel pathologi-
cally low blood glucose levels or does not respond 
to them, despite alerts generated by an external 
continuous glucose monitoring (CGM) device, 
which may lead to severe hypoglycemia and impai-
red consciousness.
— A relative contraindication is recurrent severe hypo-
glycemia (at least two episodes of severe hypogly-
cemia during the last 12 months),
 8.  In patients using CGM, a statement of no contraindi-
cations to driving vehicles of category AM, A1, A2, B1, 
B, B+E, or T may be issued by a physician authorized 
to medically certify drivers upon obtaining the opinion 
of a diabetologist indicating that:
— The patient constantly uses a CGM system for self- 
monitoring;
— The patient has at least sufficient knowledge about 
self-monitoring in diabetes, including CGM;
— The patient adequately responds to alerts generated 
by a CGM device;
— Regular diabetes care (minimum 3 visits a year in 
diabetic clinic, at regular intervals of 3–4-months).
 9.  In patients with a history of recurrent severe hypo-
glycemia who are applying for or holding a category 
AM, A1, A2, A, B1, B, B + E or T driving license, a sta-
Developed in collaboration with Andrzej Marcinkiewicz, MD, and Prof. Jolanta Walusiak-Skorupa 
from the Institute of Occupational Medicine in Łódź
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tement of no medical contraindications to driving can 
be issued by a physician authorized to medically certify 
drivers upon obtaining the opinion of a diabetologist 
indicating that:
— At least 3 months have passed since the last episode 
of severe hypoglycemia during the waking hours;
— The level of diabetes control ensures traffic safety;
— The patient constantly uses a CGM system for self-
monitoring, including mandatory use of CGM while 
driving;
— The patient has at least sufficient knowledge about 
self-monitoring in diabetes, including CGM;
— The patient adequately responds to alerts generated 
by a CGM device;
— The patient has regular medical check-ups — at least 
3 times a year, at regular intervals of 3–4-months 
(subject to point 13).
10. In patients applying for or holding a category C1, 
C1+E, C, C+E, D1, D1+E, D, D+E driving license, or 
tram driving permit, road transport drivers, emergency 
vehicle or armored transportation service drivers, and 
driving license instructors and examiners:
—  Absolute contraindications to driving vehicles are:
• Any history of severe hypoglycemia during the 
waking hours;
• Hypoglycemia unawareness during the wak-
ing hours, defined in Appendix No. 6 to the 
above-mentioned ordinance of the Minister of 
Health of August 29, 2019 as not being aware 
of pathologically low (< 70 mg/dL or < 3.9 
mmol/L) blood glucose levels, which is an impor-
tant complication of the frequent occurrence of 
hypoglycemic episodes;
• Other diabetes-related complications that pre-
clude driving.
— A positive opinion on the ability to drive can be 
issued if the following conditions are met:
• Regular monitoring of blood glucose, i.e. at least 
four times a day in patients taking more than 
one insulin injection daily, and once a day and at 
times relevant to driving vehicles in patients us-
ing other treatment models, with glucose read-
ings recorded in a way that allows assessment of 
the course of diabetes;
• Documentation of diabetes control by treating 
physician;
• Full awareness of the risk of hypoglycemia dur-
ing the waking hours.
11. The consultation card is handed by the diabetes spe-
cialist, or other physician engaged in treating diabetes, 
to the patient who presents it to the physician autho-
rized to medically certify drivers. In case of a negative 
opinion regarding the ability to drive, it is recommend-
ed that the opining physician who referred a patient 
for a diabetes consultation is informed directly by the 
consulting specialist.
12. During the consultation, the driver must be informed 
that in the event of an episode of severe hypoglycemia 
during the waking hours, also unrelated to driving, he 
or she is strictly obliged to have his/her ability to drive 
reassessed.
13. Diabetes consultation should be performed by a physi-
cian certified in diabetology or a physician with other 
board certification who manages diabetes in the con-
sulted patient.
14. In the following cases, information about the need 
of repeated medical assessment in order to verify the 
patient’s fittness to drive should be sent to the ter-
ritorially competent transport department or local 
government unit using a form referring to Article 75, 
paragraph 1, item 5 of the Act of January 5, 2011 on 
drivers of vehicles (Journal of Laws of 2019, item 341 
as amended) (see page 86).
—  When there are reasonable indications that the pa-
tient is driving the vehicle less than 3 months after 
the last episode of severe hypoglycemia;
—  When the patient does not attend the scheduled 
medical examinations (especially if he or she has 
severe hypoglycemic episodes during the waking 
hours) and when all available forms of effective no-
tification to the patient about the need for follow-
-up examinations have been ineffective;
—  Obligatory after each episode of severe hypoglycemia.
15. Any insulin-treated patient who has been considered as 
having no diabetic contraindications to driving vehicles 
should be adviced to monitor blood glucose (gluco-
meter/scanning system/CGM) each time before driving. 
The patient should not start driving with blood glucose 
below 100 mg/dL, unless the diabetologist individually 
sets a different blood glucose threshold for driving.
16. While driving, blood glucose should be measured at 
least every 2 hours, and in the case of a decrease in 
blood glucose below 100 mg/dL, the patient should stop 
driving and eat an appropriate amount of carbohydrate.
II.   Medical review and opining in workers
 1. Medical review and opining in workers and persons 
taking up work is regulated by the ordinance of the 
Minister of Health of May 30, 1996 on medical ex-
aminations of workers, the extent of preventive care 
for workers, and issuing medical opinions for the pur-
poses provided for in the Labor Code (Journal of Laws 
2016, item 2067 with amendments).
 2. A physician performing a preventive examination may 
extend it with a diabetes consultation and additional 
tests if these are considered necessary for proper eval-
uation of the health status of a worker or a person 
taking up work.
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 3. To serve as a useful opinion allowing an objective 
decision to be made based on individual patient as-
sessment, diabetes consultation for the purpose of 
preventive examination should include key infor-
mation for the evaluation of health predispositions 
to	work	 in	 specific	 conditions	 and	 in	 accordance	
with	specific	requirements. For this purpose, it is rec-
ommended to use a diabetes consultation card based 
on the template provided (see page 86). 
 4. Based on the results of a medical examination, labora-
tory tests, and specialist consultations, a physician au-
thorized to perform preventive examinations and medi-
cally certify workers issues a medical opinion regarding 
the absence or presence of medical contraindications 
to perform or take up work at a specific workplace.
 5. Absolute contraindications to perform work at 
workplaces associated with higher health require-
ments include: 
— Recurrent severe hypoglycemia or even a single 
previous episode of medically unexplained severe 
hypoglycemia during the waking hours (a fall in 
blood glucose level leading to impaired conscious-
ness and the need for medical intervention); 
— Hypoglycemia unawareness during the waking 
hours without prospects for an improvement, re-
sulting from a chronic diabetes complication of 
vegetative neuropathy which impairs patient’s abil-
ity to detect an increasing severity of hypoglycemia, 
and thus is not associated with an appropriate 
patient response to decreased blood glucose levels; 
— Advanced eye complications, mostly diabetic reti-
nopathy or cataract with vision impairment; 
— Other advanced chronic diabetes complications; 
— An opinion of a diabetologist or a treating primary 
care physician which states a high risk of hypogly-
cemia and/or unawareness of hypoglycemia pro-
dromes during the waking hours. 
 6. Relative contraindications to perform work at 
workplaces associated with higher health require-
ments exist in conditions with a potential to im-
prove, including: 
— Lack of metabolic control of the disease (HbA1c  ≥ 8%); 
— Lacking or low blood glucose self-management 
ability; 
— Inadequate patient knowledge regarding diabe-
tes, hypoglycemia, and the approaches to prevent 
hypo glycemia; 
— Non-compliance to physician recommendations. 
 In such cases, reassessment should be scheduled 
within 1–3 months.
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Diabetes consultation card for examining driving license 
applicants and drivers (Appendix No. 6 to the ordinance of 
the Minister of Health of on medical 
examinations of driving license applicants and drivers —
Journal of Laws 2019, item  1659)
Patients data
Name and surname
PESEL Personal identity card details and number in non-PESEL holders
Address: City/town Postal code
Street House/apartment number
Diabetes: Date of diagnosis Type: Treating physician:
Entity performing
medical activities
Diabetes clinic
Patient knowledge regarding the disease, its treatment, and 
complications:
Extensive Satisfactory Not satisfactory
Blood glucose self-management ability: High Acceptable Low
Hypoglycemia awareness, ability to prevent and counteract 
hypoglycemia:
Good Not satisfactory
Occurrence of hypoglycemia prodromes Yes No
Risk of hypoglycemia: Low Acceptable High
Presence of chronic diabetes complications y No chronic diabetes complications
Eye Nervous system Cardiovascular system
Comments regarding other diabetes complications:
----------------------
----------------------
Assessment of the ability to drive:
-----------------------
----------------------
In patients using continuous glucose monitoring, the following three questions should be answered:
1. Constant use of CGM:   ☐ Yes   ☐ No                     2. Good knowledge of and adequate response to CGM:     ☐ Yes   ☐ No
3. Regular visits in diabetes clinic (minimum every 3–4 months) with data retrieval from pump and CGM memory:    ☐ Yes   ☐ No
Other remarks:
----------------------
----------------------
........................................ ...........................................................
(Date) (Signature and stamp of the diabetes specialist
        or another physician engaged in treating diabetes)
Stamp of the healthcare unit or physician’s practice
August 29, 2019
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Diabetes consultation card for preventive examinations
— documentation of diabetes control by the treating physician 
for the purpose of evaluation of patient’s health 
predispositions to professional activity
(developed by A. Marcinkiewicz and D. Szosland)
Patient data
Name and surname
PESEL Personal identity card details and number in non-PESEL holders
Diabetes Date of diagnosis: Type: Treating physician: Primary care Diabetes clinic
Patient knowledge regarding the disease, its treatment, and 
complications:
Extensive Satisfactory Not satisfactory
Blood glucose self-management ability: High Acceptable Low
Hypoglycemia awareness, ability to prevent and counteract hypoglycemia: Good Not satisfactory
Occurrence of hypoglycemia prodromes Yes No
Risk of hypoglycemia: Low Acceptable High
Presence of chronic diabetes complications No chronic diabetes complications
Eye Nervous system Cardiovascular system
Comments regarding chronic diabetes complications:
Other remarks:
In patients using continuous glucose monitoring, the following three questions should be answered:
1. Constant use of CGM:   ☐ Yes   ☐ No                     2. Good knowledge of and adequate response to CGM:     ☐ Yes   ☐ No
3. Regular visits in diabetes clinic (minimum every 3–4 months) with data retrieval from pump and CGM memory:    ☐ Yes   ☐ No
Other remarks:
----------------------
----------------------
........................................ ...........................................................
(Date) (Signature and stamp of the diabetes specialist
or another physician engaged in treating diabetes)
Stamp of the healthcare unit or physician’s practice
86
Clinical Diabetology 2020, Vol. 9, No. 1
..............................................., (Date)
................................
                        (City/town)
Name and address of the referring center:
...............................................................
...............................................................
...............................................................
...............................................................
Name, surname, address, 
identification data of the person 
whom the notification concerns:
...............................................................
...............................................................
...............................................................
...............................................................
The name of the territorially competent transport
department or local government unit*:
............................................................................................
............................................................................................
............................................................................................
............................................................................................
Notification
Pursuant to Article 75, paragraph 1 item 5 of the Act of 5 January 2011 on drivers of vehicles (Journal of Laws 
of 2019, item 341 as amended), we inform that there are reasonable and serious concerns regarding the 
health status of:
Mr./Ms......................................................................................................................,
which, if he or she has a driving license or a tram driving permit, require a necessary and urgent 
assessment of the ability to drive the above-mentioned vehicles and verification of the medical certificate.
………………………………………………………………
Signature of the person making the notification
Note:
*territorial competence concerns the person being reported
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Appendix 3
Charter of Employer and Employee Rights and Duties
Diabetes is a chronic metabolic disease that affects an 
increasing number of patients. It has been estimated that 
the number of subjects with diabetes in Poland is about 
2.6 million people, and the disease has been identified and 
treated in 60% of them. The current scope of this problem 
and an increasing incidence of both diabetes type 1 and 
type 2 have very significant medical and socioeconomic 
consequences, and issues related to the prevention and 
effective treatment of diabetes and its complications are 
beyond the responsibility of the medical community and 
patients themselves.
According to the World Bank estimates, the economic 
burden of diabetes is second only to that of ischemic heart 
disease. This economic toll results not only from the costs 
of diagnosing and treating diabetes but also from the 
costs of premature termination of professional activity, 
including inability to work and related social benefits, as 
well as unemployment which is a particular problem in 
diabetic subjects.
Due to the fact that:
• unemployment rates among diabetic subjects 
are more than twice increased compared to the 
healthy population, and the resulting worse eco-
nomic status may hinder appropriate diabetes 
control;
• the place of work is an important link in the pro-
cess of preventing civilization disorders;
and also due to our belief that:
• drugs currently used in the treatment of diabetes, 
along with increasing patient awareness regarding 
self-management, lead to a longer and more effec-
tive preservation of a good health condition and 
the ability to remain professionally active;
• the sole fact of having diabetes does not automa-
tically make the employee inferior
Building on numerous European initiatives target-
ed at the prevention, early detection, and appropriate 
treatment of diabetes, and improvement of the qual-
ity of life of diabetic patients, including the European 
Parliament resolution of March 13, 2012 on addressing 
the diabetes epidemic in the European Union and the 
Copenhagen roadmap developed during the European 
Diabetes Leadership Forum on April 25–26, 2012.
On the eve of the 2012 World Diabetes Day, the 
signatories of the present document, representing the 
medical community, diabetes patient community, and 
the employers’ community, postulate to write down 
the rights and duties of diabetic patients and their 
potential employers to increase patient responsibility 
and their position as employees on one hand, and on 
the other hand to counteract exclusion of the diabetic 
patients from the labor market.
Rights and duties of an employee suffering 
from diabetes
1. Each diabetic patient should be aware of the fact 
that effective diabetes control must take place both 
at home and at work.
2. At work, an employee suffering from diabetes should 
conform to the same principles of diabetes control 
as at home, i.e. periodic blood glucose monitoring, 
taking medications as prescribed by a physician, and 
adhering to the recommended meal timing and diet.
3. An employee suffering from diabetes should inform 
the employer about the disease and if possible, in-
dividually adjust the nature and timing of the work 
to allow disease control.
4. Diabetic patients should be aware of the contrain-
dications to engage in some professions (e.g., pi-
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lot, public transport driver, working at height, work 
requiring extremely strenuous exercise) and should 
inform their employers if their professional respon-
sibilities entail such activities.
5. An employee suffering from diabetes should inform 
his/her closest collaborators about the disease so as 
they are able to provide appropriate help in case of 
an episode of hyper- or hypoglycemia, and main-
tain continuity of work.
Rights and duties of an employer
1. Each employer should be aware that diabetes does 
not disqualify subjects with this disease from un-
dertaking professional activities, and any employee 
discrimination due to incident or prevalent diabetes 
is unacceptable. Acquirement of the basic knowl-
edge about the disease by the employer is the key 
to understand the situation of a diabetic patient.
2. Carrying out employer’s duties, including the ob-
ligation to create safe and hygienic work environ-
ment, requires that the employer has the right to 
On behalf of the signatories
Prof. Leszek Czupryniak
President of Diabetes Poland
Warsaw, November 13, 2012
and should know which of his/her employees suffer 
from diabetes.
3. The employer should allow the employee suffering 
from diabetes to conform to the principles of con-
trolling the disease at work and motivate him/her to 
a responsible behavior that guarantees the safety of 
the patient him-/herself and his/her collaborators.
4. If possible, the employer should provide the employ-
ee suffering from diabetes with a workplace that al-
lows optimal disease control (e.g., option to discon-
tinue shift work, short breaks for additional meals).
5. If possible, the employer should allow transfer of 
an employee with newly diagnosed diabetes to an-
other/equivalent workplace if continuing work at 
the previous workplace might be associated with 
work safety hazards or would make controlling the 
disease difficult for the employee.
6. If possible, the employer should promote the healthy 
lifestyle at work by encouraging employees to en-
gage in physical activity, adhere to a balanced nutri-
tion, and undergo preventive examinations.
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Appendix 4
Recommendations of the Polish Endocrine Society  
and Diabetes Poland  
on screening for thyroid dysfunction  
in diabetes type 1 and 2
Diabetes type 1
1.  During each patient visit to a diabetes specialist, it is 
necessary to perform clinical examination targeted at 
thyroid disease. If thyroid dysfunction is suspected, 
thyroid-stimulating hormone (TSH) level should be 
measured.
2.  It is recommended to determine TSH level and thyroid 
peroxidase autoantibody (TPOAb) titer in all patients 
with newly diagnosed diabetes type 1 and in patients 
with established diabetes type 1 in whom thyroid 
function was not evaluated previously.
3.   In patients with anti-TPO antibody titer above the re-
ference range and TSH level ≥ 2 mIU/L, free thyroxine 
(fT4) should be measured and TSH level measurement 
should be repeated annually.
4.   In patients with anti-TPO antibody titer within the refe-
rence range and TSH level ≥ 2 mIU/L, TSH level should 
be measured every 2 years.
5.  In patients with TPOAb titer within the reference range 
and TSH level < 2.0 mIU/L, TSH level should be deter-
mined every 5 years.
6.  In patients with a positive family history of hypothy-
roidism due to chronic autoimmune thyroiditis, TSH 
level should be determined annually.
7.  TSH level should be determined in diabetic patients 
with uncontrolled lipid parameters.
8.  TSH level and TPOAb titer should be determined in 
any patient planning pregnancy (particularly with an 
adverse obstetric history).
9.  TSH level and TPOAb titer should be determined in all 
patients at 4–8 weeks of gestation (initial obstetric 
visit).
10. In all patients with a history of Graves disease, TSH 
level and thyrotropin receptor antibody (TRAb) titer 
should be determined at 4–8 weeks of gestation (initial 
obstetric visit). In addition, TRAb titer should reevalu-
ated at the end of the second trimester (before 22 
weeks of gestation).
Diabetes type 2
1.  During each patient visit to a diabetes specialist, it is 
necessary to perform clinical examination targeted at 
thyroid disease. If thyroid examination is abnormal, 
TSH level should be measured.
2.  It is recommended to determine TSH level in all pa-
tients with newly diagnosed diabetes type 2 and in 
patients with established diabetes type 2 in whom 
thyroid function was not evaluated previously.
3.  TPOAb titer should be determined in patients with TSH 
level ≥ 2.0 mIU/L.
4.  If TPOAb titer is above the reference range, the dia-
betes type should be verified, primarily by measuring 
anti-glutamic acid decarboxylase (anti-GAD) autoanti-
bodies.
5.  In patients with TPOAb titer above the reference range 
and TSH level ≥ 2.0 mIU/L, fT4 level should be mea-
sured, and TSH level should be determined annually.
6.  In patients with TPOAb titer within the reference range 
and TSH level ≥ 2.0 mIU/L, and TSH level should be 
determined every 2 years.
7.  In patients with TPOAb titer within the reference range 
and TSH level < 2.0 mIU/L, TSH level should be deter-
mined every 5 years.
8.  TSH level should be determined in diabetic patients 
with uncontrolled lipid parameters.
9.  TSH level should be determined in any patient plan-
ning pregnancy.
10. TSH level and TPOAb titer should be determined in all 
patients at 4–8 weeks of gestation (initial obstetric 
visit).
11. In all patients with a history of Graves disease, TSH 
level and thyrotropin receptor antibody (TRAb) titer 
should be determined at 4–8 weeks of gestation (initial 
obstetric visit). In addition, TRAb titer should reevalu-
ated at the end of the second trimester (before 22 
weeks of gestation).
Source: Sowiński J, Czupryniak L, Milewicz A, Hu-
balewska-Dydejczyk A, Szelachowska M, Ruchała M, 
Lewiński A, Górska M, Siewko K, Wender-Ożegowska E, 
Zozulińska-Ziółkiewicz D, Junik R, Sawicka N, Gutaj P. 
Recommendations of the Polish Endocrine Society and Diabe-
tes Poland for the diagnosis and management of thyroid 
dysfunction in diabetes type 1 and 2
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Appendix 5
Position of the Polish Society of Obesity Research and Diabetes Poland  
on the use of low-calorie sweeteners
An increasing prevalence of overweight and obesity 
along with their complications, primarily diabetes type 2 
and cardiovascular disease, is one of the major challenges 
of modern medicine. Obesity has been considered a 21st 
century epidemic by the World Health Organization. The 
epidemic of obesity is caused by lifestyle changes such 
as lack of physical activity and excessive consumption 
of highly processed high-energy-dense foods, leading to 
a positive energy balance.
Effective prevention and treatment of overweight and 
obesity together with their complications requires perma-
nent lifestyle changes which are difficult due to numer-
ous intrinsic and extrinsic factors that tend to decrease 
the motivation of a person forced to stop consuming 
favorite foods. A reduction of the energy density of the 
available foods by changing their production technol-
ogy and composition is an important component of 
prevention efforts at the societal level. However, intro-
duction of such changes requires consumer acceptance 
regarding the choice of low-calorie products, which in 
turn requires preservation of an attractive taste by the 
food industry. In humans, sweet taste preferences develop 
already in childhood, as human milk contains lactose and 
has a mildly sweet taste. To satisfy consumer preference 
for sweet taste and at the same time reduce the calorie 
content of foods and beverages, low-calorie sweeteners 
are used by the food industry.
Low-calorie sweeteners are substances with a sweet 
taste and the energy content of zero to few calories. As 
their sweet taste is very intensive, they may be added to 
foods in very low quantities. Currently, sweeteners are 
used in the production of non-alcoholic beverages, sweets, 
frozen desserts, yoghurts and puddings, as well as many 
medications.
A natural low-calorie sweetener, stevia, may be used 
for baking and cooking, as it is resistant to temperatures 
up to 200°C.
Based on safety studies and positive opinions of the 
European Food Safety Authority and the Panel on Food 
Additives and Nutrient Sources Added to Food, eleven low- 
-calorie sweeteners are approved for use in the European 
Union: acesulfame K (E950), aspartame (E951), aspartame-
acesulfame salt (E962), cyclamate (E952), neohesperidine 
dihydrochalcone (DC) (E959), saccharin (E954), sucra-
lose (E955), thaumatin (E957), neotame (E961), eryth-
ritol (E968), and steviol glycosides (E960). According to 
the Regulation (EC) No. 1333/2008 on food additives, 
food products containing these substances should be la-
beled accordingly. In addition, the Regulation (EC) No. 
1333/2008 specifies the maximum content of specific low- 
-calorie sweeteners for different food product categories.
During the process of approving low-calorie sweeten-
ers, the acceptable daily intake (ADI) in mg/kg body weight 
per day is also determined, defined as the amount of the 
substance which may be safely taken daily on a long-term 
basis (throughout life) without any harmful effects on the 
health. ADI values for specific low-calorie sweeteners are 
shown in Table 1.
The remaining approved substances are very rarely 
used by the food industry and therefore respective ADI 
values have not been determined.
European studies indicate that the intake of all low- 
-calorie sweeteners is lower than their ADI.
Regarding reports of a purportedly increased risk 
of some neoplasms in experimental animals given sac-
charine, aspartame, and cyclamate, it should be em-
phasized that the results of recent human studies did 
not	confirm	these	suggestions.
Based on these data, the Polish Society of Obesity 
Research	 and	Diabetes	 Poland	 confirm	 the	 safety	 of	
Table	1.	Acceptable	daily	intake	(ADI)	of	specific	low-calorie	sweeteners
Substance Code ADI [mg/kg body weight/day]
Acesulfame K E950 0–15
Aspartame E951 0–40
Cyclamate E952 0–7
Saccharin E954 0–5
Sucralose E955 0–15
Neotame E961 0–2
Steviol glycosides E960 0–4
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low-calorie sweetener use in food products and rec-
ommend substituting these substances for saccharose 
by overweight and obese subjects, particularly if dys-
glycemia (impaired fasting glucose, impaired glucose 
tolerance, or diabetes type 2) is also present.
Of note, a beneficial effect of low-calorie sweeteners 
on body weight in children and adolescents has been re-
cently confirmed in randomized studies published in the 
New England Journal of Medicine.
A separate issue is the use of low-calorie sweeteners 
during pregnancy. While saccharine crosses the placenta 
and should not be used during pregnancy due to its un-
clear effects on the fetus, other low-calorie sweeteners are 
allowed during pregnancy.
The Polish Society of Obesity Research and the Diabe-
tes Poland would like to draw attention of patients and 
physicians to the need to evaluate the energy value of 
the products in which low-calorie sweeteners have been 
substituted for sugar and which are marketed as safe 
for diabetic patients due to the fact that they have no 
significant effect on postprandial glucose and insulin 
levels. Despite this modification, some of these products 
may still be characterized by a high energy value due 
to their fat content and may contribute to an increase 
in body weight, thus worsening blood glucose control. 
The best way to make sure that a product in which low-ca- 
lorie sweeteners were substituted for sugar is actually 
a low-calorie product is to compare its energy value 
with the energy value of a similar sugar-containing 
product, and to note its fat content.
The Polish Society of Obesity Research and Dia-
betes Poland emphasize that consumption of food 
products with a reduced energy value due to their 
low-calorie sweetener content may not be the sole 
lifestyle change introduced. This is only an approach 
to satisfy the need for sweet taste without consuming 
mono- and disaccharides, which may facilitate adher-
ence to the nutritional recommendations and blood 
glucose control. However, another factor that plays 
an important role in the development of overweight 
and obesity along with their complications is fat intake 
which also needs to be reduced. It should also be em-
phasized that decreasing food energy value alone leads 
to a reduction of not only adipose tissue mass but also 
muscle mass. Thus, regular physical activity is required 
to prevent muscle mass loss (30 minutes of aerobic 
exercises at least 5 times a week, e.g. walking, cycling, 
swimming).
Magdalena Olszanecka-Glinianowicz
President of the Polish Society of Obesity Research
Leszek Czupryniak
President of the Diabetes Poland
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I.   Requirements for centers initiating and/or providing 
treatment with a personal insulin pump. Therapy 
initiation includes patient education regarding con-
tinuous subcutaneous insulin infusion, setting up 
the insulin pump, and offering consultation services.
 1.  Initial training should include technical aspects of 
insulin pump handling and discussion of the fol-
lowing issues: principles of basal rate programming 
and modification, temporary changes of a basal rate, 
use of simple, extended, and complex boluses, use of 
bolus calculator function, principles of setting up an 
infusion set (including choice of the puncture site). Tra-
ining should continue until the patient is well versed 
with practical aspects of personal insulin pump use. If 
a pump with continuous glucose monitoring option is 
needed, the training should also include the principles 
of system functioning, its calibration, interpretation of 
messages and alerts, and placing a sensor.
 2.  Particular attention should be paid to the following 
issues: what to do in case of an insulin pump failure 
– return to treatment using insulin pens, management 
of initial symptoms of ketoacidosis, principles of wit-
hholding insulin infusion in special situations (e.g., 
following sport activities).
 3.  Organizational requirements: minimum duration of 
training 9 hours, split into minimum 3 sessions. Trai-
ning should be performed in groups not larger than 
6–8 persons. Parents or legal guardians should parti-
cipate in training of children and adolescents. Patients 
should be offered an opportunity to practice with 
infusion sets using phantoms. It is also recommended 
to practice subcutaneous insertion of an infusion set in 
the period before initiating treatment with continuous 
subcutaneous insulin infusion.
The center providing reimbursement bears responsi-
bility for appropriate training and initial insulin pump set-
tings. These settings should also include initiation of the 
bolus calculator function. The patient’s knowledge should 
be verified by the education team. It is recommended to 
develop a test based on own educational materials.
In case of insulin pumps with continuous glucose mo-
nitoring option, alarm presetting is recommended, taking 
into account the current level of metabolic control and 
patient capabilities. 
Regular use of the software for insulin pump and 
glucose meter/continuous glucose monitoring (CGM) data 
retrieval is required.
Appendix 6
Recommendations on the management of diabetes using  
a personal insulin pump
 II.  Requirements for insulin pumps to be used in centers 
providing treatment with a personal insulin pump 
are listed in a table in the Appendix 6. It is recommen-
ded that different types of insulin pumps should be 
available at the diabetes centers, enabling patients to 
choose the pump that best suits their needs.
 III.  Indications and contraindications for publicly fun-
ded insulin pump therapy are listed below.
A.  Indications for reimbursement by the National 
Health Fund of personal insulin pump purchase in 
diabetic children, adolescents and adults below 26 
years of age.
 1. Early morning hyperglycemia in patients with diabetes 
type 1 following the end of a remission period*.
 2. Frequent hypoglycemia episodes in patients with dia-
betes type 1 following the end of a remission period*:
—  Severe hypoglycemia episodes more frequently 
than once a year;
— Hypoglycemia < 70 mg/dL without the need for 
help of another person ≥ 4 times a week;
—  Inability to achieve target hemoglobin A1c (HbA1c) 
level without frequent hypoglycemia episodes, i.e. 
≥ 4 times a week;
— Impaired awareness of typical hypoglycemia symp-
toms.
 3. Persistently elevated HbA1c level > 6.5% but < 9.0% 
despite treatment intensification in a patient who is well 
educated regarding the principles of intensive insulin 
therapy, cooperates with the diabetes treatment team, 
and adheres to blood glucose self-monitoring recom-
mendations (≥ 6 blood glucose measurements per day).
 4. Subjects engaged in shift work, with irregular school 
or professional activity, or traveling frequently to other 
time zones, with HbA1c level < 9.0%.
 5. Subjects engaged in competitive sport or undertaking re-
gular intensive physical activity, with HbA1c level < 8.5%.
 6. Children below 10 years of age with diabetes type 1.
 7. Continuation of previous treatment with personal in-
sulin pump if no contraindications exist (e.g., personal 
insulin pump failure)**.
In selected cases, the decision on insulin pump pur-
chase reimbursement may be made by the voivodship 
diabetes consultant after reviewing the patient’s medical 
records and obtaining an opinion of the treating diabetes 
specialist (including such issues as concomitant condi-
tions and corticosteroid treatment).
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B.   Contraindications for reimbursement of personal 
insulin pump purchase in diabetic children, adole-
scents and adults below 26 years of age.
 1. HbA1c level ≥ 9.0% — an average value during the last 
year.
 2.  Mental disorders — psychosis and severe depression, 
also those affecting the parents of children below 10 
years of age.
 3.  Intellectual disorders, also those affecting the parents 
of children below 10 years of age, which prevent un-
derstanding the principles of intensive insulin therapy 
and personal insulin pump handling.
 4.  Eating disorders.
 5.  Addiction to alcohol and psychoactive substances also 
those affecting the parents of children below 10 years 
of age.
 6.  Unexplained missing visits to a diabetes clinic (atten-
dance at only one visit or no visits during a year).
 7.  Non-adherence to or non-comprehension of the prin-
ciples of intensive insulin therapy (no adequate blood 
glucose self-monitoring, failure to test for ketone bo-
dies in cases of prolonged hyperglycemia, imprecise 
estimation of prandial insulin doses).
 8.  More than one episode of ketoacidosis during a year.
 9.  Severe, rapidly progressing proliferative retinopathy 
before or during laser therapy.
 10. No disease acceptance despite full diabetes care and 
psychologic support (a written opinion of psychologist 
experienced in diabetes care).
 11. Poor personal hygiene.
 12. Regular exposure to strong magnetic fields.
C.  Contraindications to continuation of treatment with 
a personal insulin pump and equipment reimbur-
sement***	 in	 diabetic	 children,	 adolescents	 and	
adults below 26 years of age.
 1.  No improvement or worse metabolic control of diabe-
tes after one year of treatment using a personal insulin 
pump.
 2.  More than one episode of diabetic ketoacidosis during 
a year.
 3.  More episodes of severe hypoglycemia compared to 
during treatment with insulin pen devices.
 4.  Non-adherence to the principles of intensive insulin 
therapy.
 5.  Severe skin reactions at the site of infusion set implan-
tation despite an attempt to change the type of the 
infusion set.
 6.  Irregular exchanges of infusion sets (less frequently 
than every 3 days).
 7.  Unexplained missing visits to a diabetes clinic (atten-
dance at only one visit or no visits during a year).
 8.  Persisting HbA1c level ≥ 9.0% (two subsequent read-
ings).
A diabetes specialist applies for reimbursement of 
personal insulin pump purchase for the patient to a cen-
ter providing this service.
The patient presenting to a center offering the reimbursed 
service submits:
 • A reimbursement application filled in by the treating 
diabetes specialist;
 • A glucose meter or CGM report covering the last 4 
weeks — at least 6 measurements per day are required 
(glucose meter or CGM device may be read in the clinic);
 • In some patients with inadequate metabolic con-
trol, providing additional information regarding the 
amount of consumed carbohydrate equivalents and 
insulin doses is indicated before considering CSII 
therapy. This information may be provided using a 
self-control diary or appropriate application (electronic 
data).
*Remission criteria according to Schölin A et al. Diabet Med. 2011; 28: 156: normoglycemia in blood glucose profile with insulin requirement < 0.3 unit/kg 
body weight per day and peptide C level > 0.5 ng/mL.
**Patients previously treated with a personal insulin pump which failed or reached its end of service life date undergo the same selection process as new 
patients. Previous treatment with a personal insulin pump does not automatically lead to reimbursement of a new device.
***An order for personal insulin pump supplies may be issued only by a physician working in a diabetes clinic or a hospital unit.
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Appendix 1
Requirements for the computer software for pump memory data retrieval:
—  Current basal rates (all available at single data retrieval, with data on graphs or in tables, exact doses and time with 
accuracy of insulin administration at a given basal rate);
—  Used correction factors with time periods set in bolus calculators;
—  History of boluses (precise information on bolus type, dose, and timing of administration);
—  History of infusion set primings;
—  Daily graphs showing:
• Basal rate on a given day,
• Temporary changes of the basal rate,
• Timing of pump switching on and off,
• All administered boluses, with information on their types and timing of administration, included that of extended 
boluses,
• Blood glucose readings transmitted from a compatible glucose meter;
—  History of alarms;
—  Free provision of the software to the patients upon request;
—  Data retrieval software should also be able to retrieve data from a glucose meter and/or CGM and integrate both 
types of information.
Appendix 2
Required information available on the webpage:
—  Telephone number of a 24-hour helpline providing information to insulin pump users in case of technical problems 
associated with pump use;
—  Telephone numbers of local representatives with their working hours;
—  Data on pump supplies (types of needles, syringes, batteries along with their pricing etc.).
RECOMMENDED ADDITIONAL OPTIONS
 1.  Integration with a glucose meter: wireless communication with at least one type of a glucose meter, possibility to 
activate and deactivate the option of data transmission from the glucose meter to the pump, possibility of recording 
blood glucose values with the bolus calculator function switched on or off.
 2.  Insulin pumps that have a dedicated glucose meter should be distributed together with that glucose meter.
 3.  Alarms to remind about boluses or blood glucose measurements at times set by the user.
 4.  Price of infusion sets not exceeding the monthly reimbursement limit in persons < 26 years of age and 30% of that 
limit in persons > 26 years of age.
For a separate package for children/adults with recurrent hypoglycemia: personal insulin pump and a CGM 
system:
—  At least 1 transmitter for 5/10 pumps and 2 sensors for each transmitter.
ADDITIONAL NOTES
The ordering party may determine additional parameters in accordance with the needs of specific patient 
groups. In addition, the offer should include accessories necessary for therapy initiation and educations: ser-
ters, various types of infusion sets, insulin containers, batteries for the pump, protective cases.
When evaluating a pump during a tender, the pump price should count for 60%, and additional functions for 40% 
of the overall assessment.
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Patients with diabetes type 1 may be cleared by 
a sports medicine specialist for participation in any sport 
after obtaining a positive diabetologist opinion.
One prerequisite for such clearance for participation 
in sports is intensive insulin therapy with good understan-
ding of its principles. This may be undertaken with either 
a pen or a personal insulin pump. The latter approach is 
preferred in athletes as it allows more physiological ad-
ministration of insulin. A responsibility of an athlete with 
diabetes is to perform systematic blood glucose monito-
ring using a glucose meter, at least 6 times a day, with ad-
ditional measurements during training and competitions. 
It is also recommended to use continuous glucose measu-
rement (CGM) or flash glucose monitoring (FGM) systems 
to guide insulin therapy and increase its safety in athletes.
Diabetes type 1 should not be a contraindication to 
participation in sports classes at each level of education 
and in school sports competitions.
Optimal blood glucose levels at the onset and during 
sport activities are in the range of 126–180 mg/dL (7–10 
mmol/L) for aerobic activities and 90–180 mg/dL (5–10 
mmol/L) for anaerobic activities.
 I.  Contraindications to participation in sports by chil-
dren and adults with diabetes type 1 who require 
clearance by a sports medicine specialist:
 1. HbA1c — mean level over the last 12 months > 8.5% or 
current value ≥ 9%.
 2. More than one episode of ketoacidosis during the last 
12 months.
 3. More than one episode of severe hypoglycemia during 
the last 12 months.
 4. Blood glucose self-monitoring: < 6 measurements per 
day using a glucose meters in athletes not using CGM 
or FGM.
 5. Diabetology clinic visits: < 4/year in children, < 2/year 
in adults.
 6. Hypoglycemia unawareness when awake — a relative 
contraindication, may be overturned depending on 
Appendix 7
Recommendations of the Diabetes Poland and the Polish Society  
of Sports Medicine on obtaining a consent for participation  
in sports by patients with diabetes type 1
Developed by the experts of the Diabetes Poland: Leszek Czupryniak, Andrzej Gawrecki,  
Przemysława Jarosz-Chobot, Tomasz Klupa, Bartłomiej Matejko, Krzysztof Pawlaczyk, Agnieszka Szadkowska,  
Agnieszka Szypowska, Bogumił Wolnik, Dorota Zozulińska-Ziółkiewicz and the Polish Society of Sports Medicine:  
Grzegorz Biegański, Andrzej Bugajski, Anna Jegier, Jarosław Krzywański, Marek Pietruszewski,  
Katarzyna Szmigielska, Wiesław Tomaszewski, Andrzej Ziemba
sports discipline or when using CGM or FGM.
 7. Chronic complications of diabetes — depending on 
their severity and sports discipline:
—  Proliferative retinopathy until the end of laser the-
rapy — absolute contraindication to all sport activi-
ties;
—  Overt autonomic neuropathy — contraindication to 
high-intensity physical exercise;
—  Macrovascular complications — clearance following 
cardiac investigations including echocardiography, 
exercise test, and 24-hour Holter monitoring;
—  Proteinuria > 0.3–0.5 g/day (A3) — relative contra-
indication, follow-up necessary — reassessment of 
proteinuria every 3–6 months, regular evaluation of 
blood pressure and renal function*;
—  Proteinuria > 0.5 g/day — temporary disqualifica-
tion from sport activities;
—  eGFR 45–60 mL/min/1.73 m2 (G3a) — reassessment of 
serum creatinine and eGFR at least every 3 months;
—  eGFR 30–45 mL/min/1.73 m2 (G3b) — relative con-
traindication to competitive sports, temporary 
disqualification, reassessment of serum creatinine 
and eGFR every 4–6 weeks;
—  eGFR < 30 mL/min/1.73 m2 (G4) — absolute contra-
indication to sport activities.
 II.  Investigations required for the assessment of an 
athlete with diabetes type 1
Initial (preparticipation) assessment: current test 
results according to the Diabetes Poland guidelines.
HbA1c levels over the last 3 months, reports from a glu-
cose meter and/or CGM/FGM and from an insulin pump.
 III.  High-risk sport disciplines: motor, aquatic, air 
sports, climbing
Sport disciplines in which hypoglycemia poses parti-
cularly high risk for the safety of the patient and others 
*eGFR calculated using the Schwartz formula in subjects ≤ 15 years 
of age, using the CKD-EPI formula in subjects ≥ 16 years of age.
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nearby are not recommended for patients with diabetes 
type 1.
Participation is acceptable if the following conditions 
are met:
—  The patient is very well educated in regard to diabe-
tes treatment and meets the treatment goals;
—  Blood glucose measurement within 15 minutes be-
fore the onset of an activity yields a value of ≥ 120 
mg/dL (6.7 mmol/L), with further blood glucose 
monitoring by a glucose meter every 60 minutes or 
less frequently is CGM or FGM is used.
CGM is recommended when participating in high-risk 
sport disciplines.
 IV.  Contraindications to participation in sport training 
and competitions
 1. Severe hypoglycemia within the last 24 hours.
 2. Hyperglycemia > 250 mg/dL (13.9 mmol/L) with con-
comitant ketonemia/ketonuria due to insulin deficit 
and not carbohydrate excess.
 3. Ketonemia ≥ 1.5 mmol/L is an absolute contraindica-
tion to initiation and continuation of physical exercise.
 4. Hyperglycemia > 300 mg/dL (16.7 mmol/L) persisting 
for more than 2 hours.
 5. Any acute event requiring physician’s assistance, e.g. 
vision disturbances, chest pain, syncope/presyncope, 
acute infection etc.
Diabetes consultation card for participation in sports  
by	patients	with	diabetes	type	1*
...................................................................................................................................................................................................................................................
Patient name
PESEL number
Address: City/Town                                                                                                                                                    Postal (ZIP) code
Street                                                                                                                                                            House/apartment number
Initial assessment                                                             Follow-up assessment                                             Year of diabetes diagnosis 
Ability to adhere to intensive insulin therapy:
High                                               Acceptable                                               Need for education                                               
Ability to monitor blood glucose levels:   good                                                  acceptable                                           inadequate
Hypoglycemia:  ability to prevent and counteract                         good                                                                        unacceptable
Presence of hypoglycemia prodromes:                         YES                                  at blood glucose levels:                                   NO
Risk of hypoglycemia:  low                                              acceptable                                            unacceptable 
HbA1c levels over last 12 months: ...........................................................................................................................................................................
Severe hypoglycemia during last 12 months:        Absent                                            1                                  ≥ 2
Ketoacidosis during last 12 months:                      Absent                                            1                                  ≥ 2       
Chronic diabetes complications:                  Absent                                         Present   
Proliferative retinopathy                                                                        Overt autonomic neuropathy
Diabetes foot syndrome                                               Nephropathy                                                    Cardiovascular complications
Remarks                                         
Is participation in sports contraindicated due to chronic complications?    YES                                          NO
Further advice regarding treatment and control of chronic complications
Remarks regarding qualification: 
Remarks regarding sport discipline (blood glucose self-control, stopping insulin pump, insulin dose reduction etc.):
Approval for participation in sports:                                YES                                       NO 
Healthcare provider or physician’s office stamp                                                                                             Date and diabetes specialist’s stamp
Sport discipline  ............................................................................................
Items constituting  temporary  contra-
indications to  participations in sports
*Diabetes specialist consultation valid for 12 months
_____________________
Date, patient signature             *For athletes >16 years of age
**I have the ability to undertake intensive insulin therapy and blood glucose level monitoring in my child during participation in sports. I commit to educate the child sys-
tematically regarding diabetes treatment and responding to hypo- and hyperglycemia associated with participation in sports. I commit to inform the trainer regarding the 
disease present in my child.
_____________________
Date, parental signatures            **For athletes <18 years of age
I have been informed that the above mentioned athlete has diabetes type 1. I am aware of the risk associated with the occurrence of hypo- and hyperglycemia. I have basic 
knowledge regarding identification of symptoms of hypo- and hyperglycemia. I am aware of the need to respond should these circumstances occur.
_____________________
Date, trainer signature 
QUALIFICATION BY A SPORTS MEDICINE SPECIALIST:
Fit	/	Unfit	for	participation	in	sports
Healthcare provider or physician’s office stamp                        Date and sports medicine specialist’s stamp
*I declare to abide by the safety rules for participation in sports by patients with diabetes type 1. I have been educated regarding intensive insulin therapy and variable insulin dosing during 
participation in sports.
